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Abstract  
 
Loss of insulin-producing β-cells is central to the development of Type 1 diabetes (T1D). 
Currently, we lack diagnostic tools to quantitate this β-cell loss.  
Non-protein coding RNAs called microRNAs (miRNAs/miRs) play an important role in islet 
development and function. Recent detection of miRNAs in peripheral circulation, has renewed 
interest in microRNA biomarkers of diabetes.  Comparably, circulating insulin cell-free (cf)DNA 
has been proposed as a direct biomarker of β-cell death.  DNA methylation studies have 
identified specific sites within DNA that are unmethylated in β-cells but methylated in other 
cell types, thus providing a handle to discriminate between cfDNA from β-/non-β-cells.  
Previous research carried out in the Hardikar lab identified a signature of 20 miRNAs (the 
‘RAPID’ signature)  with potential as a biomarker of β-cell death. The RAPID signature was 
revised to accommodate other microRNAs finally constituting a panel of 50 microRNAs 
(PREDICT T1D panel).  An analysis of these 50 miRNAs, as well as insulin cfDNA in 
serum/plasma from individuals before, during and after clinical diagnosis of T1D is presented.  
Human islet cell death assays using sodium nitroprusside exposure identified a subset of 27 
miRNAs and insulin cfDNA associated with islet cell stress/death. Non-obese diabetic mice 
(N=32) were found to have elevated candidate miRNAs prior to immune infiltration and 
glycaemic dysfunction. This trend was also noted in the human progression to T1D; 26 miRNAs 
were elevated in (N=19) high-risk individuals and those at diagnosis (N=199) but decreased 
within 6-weeks after diagnosis. Furthermore, candidate miRNAs exhibited differential 
abundance with disease duration, residual C-peptide, and microvascular complications in 180 
subjects with prolonged T1D. At diagnosis, miRNAs and cfDNA associated with GAD 
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autoantibody titres (N=167 P-values range from 0.044 to <0.0001) and HbA1c levels (N=187, 
P-values range from 0.047 to 0.00095). 
Such biomarkers may inform medical researchers as to how to predict the development of 
T1D, monitor response to interventions such as islet transplantation, vaccines & drugs aiming 
to retard β-cell loss. In basic research, such an assay may help to select treatments to block β-
cell death and guide the development of new treatments to lessen the burden of diabetes. 
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Dedication 
This body of work is dedicated to my son, Lachlan. Born of a father with T1D, this thesis may 
end up being more than just a book on a dusty bookshelf. I hope that my small contribution 
can leave a better world for you. 
 
“Nothing in life is to be feared, it is only to be understood. Now is the time 
to understand more, so that we may fear less.”  
Marie Curie (1867-1934) 
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1. Introduction  
1.1. History of Type 1 Diabetes Mellitus (T1D) 
Type 1 diabetes mellitus (T1D) has captured the attention of physicians for more than three 
millennia. This condition presented with frequent  urination, weight loss, and excessive thirst, 
and was invariably fatal until the early 1920s. The earliest records of T1D can be traced back 
to 1500 B.C.E in ancient Egypt, where it is described in the Ebers Papyrus as a rare disorder 
that resulted in “too great emptying of the urine”. Indian physicians around the same time 
noted that the urine had a sweet taste that attracted flies and ants, and so they named the 
condition “madhumeha” or “honey urine”. The term diabetes has been used since 230 B.C.E. 
and was derived from the Greek “diabainein”, which means “to pass through”, a reference to 
the excessive urination of those afflicted. Aretaeus of Cappadocia, a Greek physician who lived 
between 80 and 130 B.C.E. distinguished diabetes mellitus (mellitus being Latin for “honeyed” 
or “sweet”) and the unrelated disorder diabetes insipidus, which also results in excessive 
urination, but not hyperglycaemia. He wrote: 
“Diabetes is a dreadful affliction, not very frequent among men, being a 
melting down of flesh and limbs to urine. The patients never stop making 
water and the flow is incessant, like the opening of the aqueducts. Life is 
short, unpleasant and painful, thirst unquenchable, drinking excessive and 
disproportionate to the large quantity of urine, for yet more urine is passed 
… If for a while they abstain from drinking their mouths become parched 
and their bodies dry; the viscera seem scorched up, the patients are 
affected by nausea, restlessness and a burning thirst, and within a short 
time they expire.” (1)   
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Sushruta and Charaka, two Indian physicians, were the first to note the differences between 
what is now considered Type 1 and 2 diabetes (fifth century C.E.). They observed that thinner 
individuals with diabetes developed the disorder at a younger age and subsequently survived 
for a shorter amount of time than heavier individuals with diabetes. It wasn’t until 1776 that 
British physiologist Matthew Dobson identified that the sweetness of diabetic urine was 
caused by elevations in sugar content. He further described the ‘sweetness of serum’ in 
patients with diabetes and thus identified hyperglycaemia (2). 
Despite the centuries of interest in T1D, the prognosis for individuals was universally bleak 
until the discovery of insulin in the early 20th century. Numerous important advances were 
made in the 19th century that subsequently led to this discovery. In 1889 Minkowski and von 
Mering found that complete pancreatectomy in dogs resulted in diabetes, while ligation of the 
pancreatic duct caused digestive issues in dogs but did not culminate in diabetes. 
Furthermore, in 1893 French scientist Edouard Hedon identified that grafting a small piece of 
the pancreas under the skin after pancreatectomy protected animals from developing 
diabetes. Upon the removal of the graft, symptomatic diabetes began immediately; a finding 
mirrored by Minkowski (1). This supported the idea that the pancreatic secretion within the 
body were central to the pathogenesis of T1D. A young Canadian surgeon, Frederick Banting, 
had the idea to isolate the internal pancreatic secretions by ligating the pancreatic ducts in 
dogs, and then waiting until the exocrine pancreas degenerated to minimise the 
contamination of digestive secretions. He approached John J.R. Mcleod, a professor at the 
University of Toronto, who gave him limited laboratory space, dogs, and a medical student 
research assistant (Charles Best) to conduct his investigations. In July 1921, Banting and Best 
were successful in harvesting the atrophied canine pancreases, grinding them up, and 
straining out the subsequent solution. They injected this extract into the vein of a 
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pancreatectomised dog and found that its condition greatly improved. Subsequent 
experiments yielded similar dramatic improvements in diabetic dogs, and so the pair then 
repeated these using different pancreatic extractions and administration routes (3). By 
January 1922, Banting and Best, with collaboration from biochemist Collip, were ready to 
inject this extract into patients with T1D. The first patient, Leonard Thompson, was a 14-year 
old then being treated at Toronto General Hospital. After injection, the patient’s blood glucose 
dropped from 520 to 120 mg/dl during the following 24 hours. Thompson continued to receive 
subcutaneous insulin treatment that enabled him to live until succumbing to pneumonia at 
age 27. The discovery of insulin, and the subsequent large-scale manufacture of the substance 
by the Eli Lilly Company, finally removed the death-sentence that had always come with the 
diagnosis of T1D. Ted Ryder, one of the first children to receive the treatment after Thompson, 
was the greatest example of this; he lived until 76 years of age, dying in 1993.    
Banting and McLeod were awarded the 1923 Nobel Prize for Medicine for the discovery of 
insulin and shared their prize with Best and Collip. Today, because of the availability of 
exogenous insulin therapy there are children and adults with T1D in every country, an 
estimated 40 million people.  With access to insulin and related diabetes care a long and full 
life is possible for many, albeit with daily challenges of balancing exogenous insulin doses, 
meals and exercise, monitoring glucose levels and the challenges of avoiding (or dealing with) 
the chronic complications of diabetes related to eye, renal, nerve and cardiovasculature (4).   
There is much recent and ongoing research to prevent or at least delay the onset of T1D (5) 
and to preserve as much β-cell function as possible.  Even low level residual C-peptide levels 
are associated with better glucose control, lower risk of diabetic ketoacidosis and severe 
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hypoglycaemia and lower risk of chronic complications (6).  This thesis explores and provides 
tools that can facilitate such research.   
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1.2. Current Impact of T1D 
Type 1 diabetes is a multi-faceted disorder characterised by immune-mediated destruction of 
insulin producing pancreatic β-cells thought to arise in genetically susceptible individuals 
following an ‘environmental’ trigger. Patients typically present acutely with days to weeks of 
hyperglycaemia, polyuria, polyphagia, and polydipsia, and require immediate intervention 
with exogenous insulin to maintain normal blood glucose levels and reverse or prevent life-
threatening diabetic ketoacidosis (DKA). This β-cell destruction culminates from a complex 
interplay between host genetics, immunity and environmental factors. Although T1D is often 
seen as a pancreas-specific disorder, the dysregulation of glucose homeostasis impacts upon 
a wide range of tissues. Individuals with T1D can develop numerous complications that stem 
from poor glucose control, including retinopathy, nephropathy, neuropathy and micro- and 
macrovascular events (4).  Indeed, studies have concluded that people with T1D are at least 
two-fold more likely to have a cardiovascular event (7), and experience less favourable 
outcomes following an acute coronary event (8). 
Type 1 diabetes is one of the most common chronic diseases in children, with a mean age of 
onset of approximately 12 years, although diabetes onset can occur at any age. In Australia, 
the incidence of T1D equates to 11 cases per 100,000, with slightly more males diagnosed 
than females (12 versus 9 per 100,000 respectively) (9). As of the 31st of March 2016, there 
were 117,319 people with T1D registered with the National Diabetes Services Scheme (NDSS), 
representing approximately 10% of Australian people with diabetes (10). Globally, both the 
incidence and prevalence of T1D is rising, although there is a large degree of heterogeneity in 
the incidence and prevalence of this currently incurable disease between countries (4). 
Regardless, T1D places an enormous physical, social and financial burden on the individual, 
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their family, the healthcare system and society.  The T1D-associated costs amount to 14.4-
14.9 billion annually in the U.S.A. alone (11; 12). In Australia, the annual cost of T1D to the 
healthcare system is 570 million dollars (13)., whilst that of the more common Type 2 diabetes 
(T2D) which affects over 1 million Australians is 6 billion dollars (14).  
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1.3. Progression of T1D 
Once T1D is clinically diagnosed, individuals have lost a substantial proportion of their insulin 
producing β-cells. It is often cited that 80-95% of β-cells are destroyed prior to clinical 
diagnosis; however, some studies have reported that this figure may be highly variable and 
dependent on other factors, such as age of onset (4; 15-17).  Post-mortem studies of people 
with Type 1 diabetes have demonstrated residual insulin producing cells (16; 17) even after 
many years of diabetes.  This β-cell death occurs gradually, over months to years, with no 
overt symptoms and apparent normoglycaemia (Figure 1-1). Research continues towards 
identifying a plethora of endogenous and exogenous factors that may affect the incidence of 
T1D (see 1.3.1 and 1.3.2). The natural history of T1D, first proposed by Eisenbarth in 1986 (18), 
has had several iterations to reflect this continuous increase in knowledge. Although the loss 
of β-cells, which may be due to cell death or to dormancy, appears to occur in a generally 
linear fashion, there is evidence that the pancreas is capable of regeneration and so an 
individual’s functional β-cell mass may show fluctuations over time (Figure 1-1).  Although 
pancreatic regeneration has been demonstrated in diabetic mouse models (19), we are yet to 
understand mechanisms that will enable/facilitate us to reverse the β-cell loss seen in humans 
after T1D diagnosis. 
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Figure 1-1. Natural history of Type 1 diabetes 
Schematic representation of β-cell loss during the progression to T1D. A precipitating event causes the gradual, and 
potentially fluctuating, loss of β-cell mass. The individual presents with no overt clinical symptoms, including normal glucose 
control, until the majority of the β-cell mass is lost. After the clinical diagnosis of T1D, C-peptide is often still detected.  
Atkinson et al (2014) (20).   
 
Recent studies have further shown that although individuals diagnosed with T1D have a 
marked reduction in insulin, they are not always completely devoid of the hormone. C-peptide 
is cleaved from the proinsulin molecule and secreted in equimolar amounts with mature 
insulin, and hence can be used as a marker of endogenously produced insulin (as C-peptide is 
absent in pharmacologically produced insulin).  Indeed, Davis and colleagues identified that 
almost one in three patients demonstrated detectable circulating C-peptide (21). This 
correlated with a subsequent finding that pancreatic tissue from people with T1D had residual 
insulin-containing islets, irrespective of disease duration (16).  
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1.3.1. Genetic Risk Factors 
As stated earlier, T1D is a complex disorder, and this is reflected in its polygenic and 
multifactorial nature. With reference to the genetic component, there are over 40 loci that 
have been associated with either susceptibility or resistance to the condition (22). The human 
leukocyte antigen (HLA) region, located on chromosome 6, stands out as having the greatest 
influence on T1D. This region spans approximately 4 megabases, contains over 200 genes, and 
is subject to extreme polymorphism (23). This association was initially identified in 1973 by 
Singal and Blajchman (24), with many subsequent studies attempting to tease out loci or 
haplotypes that exhibit the strongest association for progression to T1D (25). Intriguingly, not 
all haplotypes pose a high T1D risk, some are even seen to be protective (26), with reported 
odds ratios ranging from 0.02 to >11 (27). The principle of linkage disequilibrium (alleles that 
are inherited together more often than would be expected by random chance) underlies the 
observation that a given HLA allele is often found in a limited number of haplotype 
combinations (23). As the name suggests, the classical HLA genes encode for cell-surface 
proteins that are involved in the capture and presentation of antigens to the T-cell receptor. 
These proteins are also known as the major histocompatibility complexes (MHC). 
Furthermore, these molecules (especially MHC Class I) have an important involvement in the 
immune-mediated destruction of β-cells. 
Many of the other genes that have been identified with T1D risk also interact with various 
aspects of the immune system, including some that lie within the HLA region (these are often 
referred to as HLA class III, although they do not code for the classical HLA proteins). Tumour 
necrosis factor-α  (TFN-α) – in particular single nucleotide polymorphisms (SNPs) found in the 
promoter region – has been the subject of numerous investigations, often with conflicting 
conclusions (28; 29). TNF-α also demonstrates linkage disequilibrium with the HLA DR3 
Chapter 1  Introduction 
10 
 
haplotype, which may explain the genetic association with T1D (28). Furthermore, MHC class 
I chain-related gene A (MIC-A), cytotoxic T-lymphocyte-associated protein 4 (CTLA), protein 
tyrosine phosphatase non-receptor type 22 (PTPN22), and genes involved in the complement 
system have been investigated for T1D association (30-33).     
Early investigations also highlighted an association between T1D and polymorphisms in 
regions flanking the insulin gene (34). Three different classes were described, depending on 
the number of tandem repeats in the allele. Class I (associated with T1D susceptibility) was 
shown to result in a reduction of insulin transcription and translation within the thymus, which 
may lead to a reduction in central immune tolerance to insulin (35; 36). This hypothesis 
correlates with subsequent studies that highlighted insulin as the major autoantigen in 
precipitating T1D (37; 38).  
Genetic susceptibility is still seen as a predisposing factor for the development of T1D, 
however, it is no longer seen as the central pathogenic cause of the disease. This is due, in 
part, to the realisation that genetic influences, or even an increase of progeny from T1D 
mothers, cannot fully explain the global rise in T1D incidence (39). Intriguingly, the rise in T1D 
prevalence has been associated with greatest increases in people with low to moderate risk 
genotypes, not high risk genotypes (40).   
1.3.2. Environmental Risk Factors 
There are numerous environmental factors that have been linked with the incidence of T1D, 
with viruses, bacteria, diets (particularly during early childhood), and vitamin D deficiency /its 
associated pathways, receiving the most attention (41-43). A lower incidence of T1D in babies 
born by normal vaginal delivery (vs caesarean section) (44) and the hygiene hypothesis, which 
implicates a cleaner environment early in life and a less challenged immune system and 
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greater risk of autoimmune diseases (45), suggest important roles of body’s microbiome, 
which may modulate immune system development, in the first couple of years of life. So far 
these associations have been unsuccessful in confirming the underlying cause or precipitating 
events in the progression into T1D. As we currently lack tools needed to accurately quantify 
β-cell death, it is difficult to monitor the death of insulin-producing cells in response to any of 
the potential risk factors listed above. The characterisation of a biomarker signature of β-cell 
death would aid in the identification of factor(s) that could precipitate the loss of an 
individual’s β-cell mass and thus progress into clinical T1D. It would also help monitor the 
efficacy of potential therapeutic agents, such as in the many current (and likely future) trials, 
to prevent or retard T1D (as outlined at www.trialnet.org).  
1.3.3. Autoimmunity and T1D 
Type 1 diabetes results from the selective destruction of the insulin-producing β-cells by the 
host immune system.  CD8+ T cells are the main immune cells involved in directly killing β-cells 
via exocytosis of granules containing perforin and granzymes (46) as well as in a death 
receptor-dependent manner (47). Although T-cells are responsible for the majority of the 
immune-mediated cell death seen in the progression to T1D, additional leukocytes, such as 
CD20+ B-cells and antigen-presenting cells, also play a role (48).  
A recent study conducted by Leete and colleagues has highlighted the role of CD20+ B-cells in 
the development of insulitis (infiltration of immune cells into the pancreatic islets) in T1D 
patients (16). The investigators identified profound heterogeneity in the numbers of B-cells 
that infiltrated T1D islets. When they stratified the patients into CD20High and CD20Low groups, 
they found that individuals diagnosed before the age of 7 years were uniformly CD20High, while 
those diagnosed after 13 years of age were always CD20Low (16). This corresponded to an 
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increase in residual insulin containing islets (determined through insulin staining), and points 
to CD20+ B-cells as an indicator of differentially aggressive immune infiltration in T1D (16).   
A common characteristic of T1D is the presence of auto-antibodies against islet specific 
antigens. Greater than 90% of individuals with T1D are positive for one or more antibodies 
targeting insulin (insulin autoantibody, IAA), glutamic acid decarboxylase (GADA), islet 
autoantigen-2 (IA-2), or zinc transporter 8 (ZnT8A). These antibodies can appear during 
infancy (peaking between 9 months and 2 years of age) and are often present prior to clinical 
diagnosis of T1D (49).Heterogeneity of autoantibodies in people with T1D from different 
ethnic groups (50) is well known as well as the possible decline in their levels after T1D onset.  
1.3.4. Prediction of T1D Progression 
Currently, we lack the tools to accurately predict the progression into T1D. The lack of overt 
clinical symptoms prior to glycaemic dysfunction means that measurement of an individual’s 
blood glucose is the main tool used to identify and diagnose T1D. While this tool is incredibly 
important in the confirmation of T1D diagnosis and application of exogenous insulin, it only 
detects individuals at the tail end of T1D progression (Figure 1-1). Many potential therapies 
for T1D, such as immune suppression (51; 52), are unable to make a meaningful impact once 
clinical symptoms are present, reflecting the loss of more than 70 to 80% of functional islet β-
cell mass. Identification and monitoring of individuals currently undergoing non-symptomatic 
β-cell death is of utmost importance, as early interventions may delay the onset of clinical T1D 
and the often life-threatening complications that arise from it.  
There has been significant interest in other markers of T1D risk, however many other 
approaches have been unsuccessful in easily identifying and monitoring those individuals that 
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will progress into clinical T1D. Several approaches have estimated an individual’s risk for 
developing T1D, usually based upon genetic or immunological parameters.  
Genetic links based on family history. Previous studies have found that a child with a first 
degree relative affected by T1D has a higher risk of developing it themselves (~5% versus 0.4% 
in the normal population). Further stratification is possible depending on the relationship of 
the affected family member (3, 7 or 8% risk is their mother, father or sibling had T1D 
respectively). If the child has two affected first-degree relatives their risk increases 
significantly to 20%, and it increases even further to 36% if they have an identical twin with 
T1D (53; 54). Furthermore, an individual’s risk may be further affected by their underlying HLA 
genotype (55).  
Islet autoantibodies have also been scrutinised for their predictive value. The presence of a 
single antibody only confers a marginal increase in T1D risk, regardless of family T1D history. 
Indeed, only 5% of individuals positive for one islet autoantibody progress to clinical T1D (56). 
This may be a symptom of non-specific antibody binding, and so affinity testing may be 
required to increase the sensitivity of this test. The associated risk increases significantly if the 
individual undergoes seroconversion for two or more islet autoantibodies, but varies widely 
depending on the antibodies present (57). IAA and IA-2 are associated with the highest risk of 
T1D (57).  Interestingly, the age of seroconversion seems to associate with the rate of 
progression to T1D (58; 59). Both age of seroconversion and IAA antibody titres, but not GADA 
or IA-2 titres, have been shown to be determinants of the age of T1D diagnosis (59). 
Unfortunately, antibody positivity can be transient in individuals without a genetic risk, and 
this may obfuscate the findings interpreted from a single islet autoantibody result (60).    
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Glucose and insulin kinetics.  Other approaches, mainly used in a research setting, include the 
monitoring of glucose and insulin responses to an oral or IV glucose tolerance test as the 
normal phases of insulin release alter and subtle hyperglycaemia occurs prior to clinical T1D 
onset (61).  These changes are likely later in the progression to T1D.  
Currently, we lack the tools to accurately quantify the β-cell death that occurs after these 
precipitating factors. The development of a refined biomarker signature of β-cell death would 
allow us to 1) estimate the risk and timeframe of a child or adult progressing to T1D, 2) stratify 
individuals at risk of developing T1D,  3) monitor the rejection of islet transplants, which are 
now available for clinical use in a subset of T1D adults (62) and 4) monitor responses to 
interventions in trials, such as related to vaccines, immunomodulatory therapy and 
diet/lifestyle interventions.   
  
Chapter 1  Introduction 
15 
 
1.4. MicroRNAs (miRNAs) 
It was once thought that as organisms became increasingly complex, the number of protein-
coding genes increase accordingly. People theorised that if yeast had genomes containing 
approximately 6,000 protein-coding genes, then humans must have significantly more, with 
estimates as high as 2 million (63). In recent years, due largely to the Human Genome Project, 
this figure has identified to just over 20,000 protein-coding genes, intriguingly around half the 
number of genes in the rice plant genome. Conversely, it has been demonstrated that the 
amount of non-coding DNA increases with an organism’s complexity (64), indicating that 
regulatory agents produced from the non-coding part of the genome contribute largely to an 
organisms developmental and functional processes. 
Non-coding (nc)RNAs were first found to regulate gene expression in 1993 by Lee and 
colleagues (65); since then varying classes of these molecules have been characterised, with 
many found to be highly conserved among different species. MicroRNAs (miRNAs/miRs) are 
one such subset of ncRNAs and are the most abundant small RNAs in animals, with 2588 
mature sequences described in humans (miRBase release 21, June 2014) (66). These 18-22 
nucleotide molecules post-transcriptionally regulate endogenous gene expression, and as 
each miRNA is predicted to have multiple potential target messenger RNAs (mRNAs), they 
could potentially regulate up to 30% of the protein-coding genes within the human genome 
(67).  The expression of a single gene can be modulated by multiple miRNAs and a single 
microRNA can target multiple genes (68) thereby increasing the complexity in understanding 
the mechanisms through which microRNAs can fine-tune gene expression.  
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1.4.1. Biogenesis and Function 
The biogenesis of miRNAs involves multistage post-transcriptional processing of primary 
miRNA (pri-miRNA) transcripts, which are large polycistronic precursor molecules with 
multiple stem-loop structures connected via single stranded RNA segments (69). Pri-miRNAs 
are transcribed by RNA polymerase II or III and contain poly(A) tails and cap structures (70). 
Within the nucleus, these molecules are processed by the Microprocessor complex, which 
includes the RNAse III enzyme Drosha and the RNA binding protein Pasha (or DiGeorge 
syndrome critical region gene 8, DGCR8), to produce stem-loop precursor miRNAs 
(pre-miRNAs) approximately 70 nucleotides in length (71). Pasha first interacts with the ssRNA 
segments of the pri-miRNA and guides Drosha to a stem-loop structure. Drosha then cleaves 
the dsRNA ~11bp from the ssRNA-dsRNA junction, leaving a short 3’ overhang (72).  Additional 
proteins, such as the helicases p68 and p72, have also been shown assist the Microprocessor 
complex cleave pri-miRNAs (73). 
The subsequent pre-miRNA molecule is exported out of the nucleus by exportin 5, which 
recognises the dsRNA stem (minihelix structure) and the 3’ overhang (74). Once in the 
cytoplasm, Dicer, another RNAse III enzyme, cleaves the pre-miRNA near the terminal hairpin 
loop, generating mature dsRNA miRNAs (75). Dicer is a highly conserved protein, found in 
almost all eukaryotes; indeed, many organisms contain more than one Dicer homologue that 
each perform distinct roles. Dicer also associates with additional proteins, including Trbp (TAR 
RNA binding protein), PRKRA (protein activator of interferon induced protein kinase EIF2AK2) 
and Hsp90 (heat shock protein 90), which aid in forming the RNA-induced Silencing Complex 
(RISC) (76). RISC is a ribonucleoprotein complex that carries out the post-transcriptional 
silencing of the mRNA identified by the miRNA (76). Hsp90 is particularly important for RISC 
formation as it is predicted to mediate the conformation change required to allow entry of 
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the miRNA into RISC (76). Once incorporated into RISC, one strand of the miRNA is retained 
(active strand), while the other is removed (passenger strand). This strand selection is thought 
to be based on the thermodynamic characteristics of the miRNA; the strand with the weakest 
binding at the 5’ terminal often becomes the active strand (76). It was initially thought that 
the passenger strand was degraded and did not participate in mRNA silencing; however, 
recent reports have confirmed that both of the strands are often detected at comparable 
levels and that the passenger strand may also be incorporated into a different RISC with 
distinct or overlapping targets (77). Therefore, the nomenclature has been changed from 
miR/miR*, where * designated the passenger strand, to -3p/-5p, reflecting which arm of the 
pre-miRNA contains the sequence (3’or 5’) (66).  
After strand selection, RISC uses the active miRNA strand to identify the target mRNA, usually 
through complementarity to the 3’ untranslated region (UTR) of the mRNA. Although the first 
miRNA described, lin-4, demonstrated extensive complementarity with its target mRNA (78), 
many of the subsequent metazoan miRNA targets only show clear complementarity with the 
miRNA seed sequence (79). The seed sequence is comprised of 6-8 nucleotides on the 5’ end 
of the miRNA (usually nucleotides 2-7 of the miRNA sequence) and is thought to guide the 
miRNA-mRNA interaction (79). However, some of these canonical sites (regions 
complementary to the miRNA seed site) have no apparent effect on mRNA abundance, 
increasing the difficulty in predicting miRNA target sites. Non-canonical sites (sites effective in 
downregulating gene expression but with non-perfect complementarity to the seed sequence) 
have been described but are considered relatively rare (79). If the target mRNA has perfect 
complementarity to the miRNA seed region, the slicer activity of Ago2 cleaves the target 
between nucleotides 10 and 11 (relative to the active strand) and initiates rapid degradation 
of the transcript (80). If the target is only partially complementary, as the majority of animal 
Chapter 1  Introduction 
18 
 
miRNA targets seem to be, then RISC can either induce translational repression or guide the 
target to the 5’-to-3’ mRNA decay pathway, where the transcript is deadenylated, decapped, 
and then ultimately degraded by the endogenous 5’-to-3’ exonuclease 1 (Xrn1, reviewed in 
(81)).    
 
Figure 1-2. Biogenesis and function of microRNAs  
A schematic depicting synthesis and function of miRNA. Mature miRNAs are synthesized in the nucleus as primary miRNAs 
and processed to precursor miRNAs by Drosha. These precursors are then transported outside the nucleus, where they are 
further truncated by Dicer into double stranded mature miRNAs. Single strands of mature miRs are incorporated into RISC, 
which then targets the gene transcripts. Based on the complementarity of the mRNA:miRNA, the target mRNA is either 
destroyed or translationally repressed.  
Farr et al 2013 (82).   
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1.5. Role of MicroRNAs in Glucose Homeostasis and T1D 
MicroRNAs are essential for normal cellular development and function. A plethora of studies 
(83-109) have identified numerous miRNAs that regulate several aspects of glucose 
homeostasis, including the development of the pancreas, insulin production and secretion, as 
well as insulin utilisation in peripheral tissues. The following sections discuss the currently 
known miRNAs that are critically involved in these processes.  Table 1-A summarises the 
important miRNAs and their site specific roles.  
 
Table 1-A. Important miRNAs involved in glucose homeostasis and T1D  
MicroRNA Site Role Reference/s 
miR-375 Pancreatic islets Pancreatic development, insulin 
secretion, glucose homeostasis 
(96; 101; 102) 
miR-7 Pancreatic islets Pancreatic development, -cell 
mass, insulin production 
(83; 84; 96; 
100) 
miR-9 Pancreas Pancreatic development (96) 
miR-376 Pancreas Pancreatic development (96) 
miR-1 Skeletal muscle Glucose homeostasis (86; 89; 108) 
miR-133a Skeletal and 
cardiac muscle 
Glucose homeostasis (89; 93; 95; 
106) 
miR-206 Skeletal muscle Glucose homeostasis (89) 
miR-222, -27a, -195, 
-103 
Skeletal muscle T2D (Goto Kakizaki rats) (91; 92; 94) 
miR-106b Myotubes Insulin resistance (109) 
miR-143 Adipocytes Adipocyte differentiation, obesity, 
insulin resistance 
(88; 97; 107) 
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miR-103 Adipocytes Obesity, insulin resistance (107) 
miR-29a/b/c Skeletal muscle, 
adipocytes, liver 
Insulin resistance, T2D (Goto 
Kakizaki rats), gluconeogenesis 
(91; 98) 
miR-122 Liver Hepatic glucose homeostasis, 
fatty acid and cholesterol 
synthesis 
(87; 105) 
miR-148a Liver Hepatic glucose homeostasis (105) 
miR-192 Liver Hepatic glucose homeostasis (105) 
miR-194 Liver Hepatic glucose homeostasis (105) 
miR-33a/b Liver Insulin signaling (85) 
miR-126 Liver Insulin signaling (104) 
miR-223 Cardiac muscle Glucose homeostasis (99) 
miR-208a Cardiac muscle Insulin sensitivity, glucose 
tolerance 
(90) 
miR-21 Pancreatic islets Inflammation (103) 
miR-34a Pancreatic islets Inflammation, cytokine-mediated 
cell death 
(103) 
miR-146a Pancreatic islets Inflammation, cytokine-mediated 
cell death 
(103) 
 
1.5.1. Pancreas Development and Function 
1.5.1.1. MicroRNA Regulation of Pancreas Development 
Early studies attempted to investigate the role of miRNA-induced gene regulation upon 
embryonic development by creating Dicer-deficient mice models. As Dicer is crucial for the 
maturation of miRNAs, its removal caused an ablation of all miRNA functions. Unfortunately, 
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the results were inconclusive, as this loss of function appears to be lethal at e7.5 (110), 
however it underscored the importance of miRNAs in embryonic development. Lynn et al then 
conditionally deleted Dicer1 from the developing mouse pancreas via pancreatic and 
duodenal homeobox 1:Cre-recombinase (Pdx1:Cre)-mediated ablation, demonstrating that 
knockout mice suffered severe pancreatic agenesis and neonatal death (111). The authors 
noted that the gross endocrine defect was associated with increased levels of hairy enhancer 
of split 1 (Hes1) and a reduction is Hes1’s target gene neurogenin3 (Ngn3). This association 
suggests that Hes1, and possibly other notch signalling genes could be actively targeted by 
miRNAs during early pancreatic development. A more recent study, utilising a Ngn3:Cre 
knockdown of Dicer, found morphological defects within the islets and noted a loss of 
hormone production (112). Once the mutant mice were born they quickly (within 2 weeks) 
developed diabetes.  
Intriguingly, when Dicer is conditionally knocked out of β-cells, using a Cre-lox system under 
the control of the rat insulin promoter (RIP:Cre), no disruption of foetal or neonatal β-cell 
development was observed (113). The Dicer knockout mice did, however, demonstrate 
impaired insulin secretion, progressive hyperglycaemia and spontaneous development of 
diabetes later in life (113). Although the removal of Dicer indicates a general role for miRNAs 
in pancreatic development, several studies have implicated individual miRNAs in the 
regulation of important transcription factors (for a comprehensive review, please see (114)). 
As yet there are no known clinical case reports of defects in human pancreas development 
caused as a result of mutations/deletion in specific microRNAs 
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1.5.1.2. MicroRNA-375 
MicroRNA-375 is central to the development and function of the endocrine pancreas. It was 
one of the first islet-specific miRNAs to be characterised (101) and has been the subject of 
numerous subsequent investigations. Initial experiments in zebrafish confirmed the central 
role of this miRNA in pancreatic development. Knockdown of miR-375 during embryological 
development, using morpholino oligonucleotides, caused abnormal migration and 
morphology of pancreatic islets (115). Interestingly, the zebrafish islets are intact for 24 hours 
post-fertilisation before developing overt abnormalities. This observation may indicate that 
miR-375 helps to maintain cellular identity. A subsequent study by Joglekar and colleagues 
found miR-375 to be robustly expressed during the development of human islets (96). The 
expression of pri-miR-375 was found to be within both β-cells and non-β-cells in the islet, and 
coincided with augmented insulin production and β-cell proliferation. Interestingly, using 
immune-FISH and single cell PCR technologies, Joglekar et al demonstrated that the 
expression of mature miR-375 was more restrictive to non-β-islet cells indicating that 
microRNA processing may be differentially regulated in β-cells versus non-β-cells.  
A miR-375 knockout (375KO) mouse model has also been described (102). This deletion was 
shown to decrease the β-cell fraction, while increasing α-cells, circulating glucagon and 
gluconeogenesis. Indeed, the 375KO resulted in a 38% and 31% decrease in β-cell area at 3 
and 10 weeks of age, respectively. Further investigation demonstrated that a number of genes 
involved in cellular proliferation were increased in the 375KO model (102). A luciferase 
plasmid construct containing the partial or complete 3’ UTR of some of the cell proliferation 
genes found that apoptosis-inducing factor, mitochondrion-associated 1 (Aifm1), RAS, 
dexamethasone-induced 1 (Rasd1), eukaryotic translation elongation factor 1 epsilon 1 
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(Eef1e1), Hu Antigen D (HuD) and cell adhesion molecule 1 (Cadm1) demonstrate reduced 
reporter expression in the presence of miR-375, indicating direct targeting of these transcripts 
(102). All of these targets are involved in the negative regulation of cellular growth, and so 
post-transcriptional regulation via miR-375 may help to increase proliferation both during 
foetal development and during metabolic stress. Intriguingly, the expression of two other 
genes, tyrosine hydroxylase (Th) and neuronatin (Nnat), was up-regulated despite the lack of 
a miR-375 motif within their 3’ UTR (102). This suggests that miR-375 can indirectly regulate 
gene expression, widening its area of influence within the endocrine pancreas.  
A recent study used human embryonic stem cells to analyse the dynamic expression of 
miRNAs during differentiation into insulin-producing cells (116). It identified some prominent 
pancreatic transcription factors, such as hepatic nuclear factor 1 β (Hnf1β), SRY-box 17 
(Sox17), Gata binding protein 6 (Gata6) and paired box 6 (Pax6), had an inverse relationship 
with miR-375 expression, suggesting regulation by this miRNA. MicroRNA-375 overexpression 
experiments demonstrated a decrease in the pancreatic progenitor markers Hnf1β and Sox9 
(116). Additionally, a recent study has linked miR-375 with the regulation of yes-associated 
protein 1 (Yap1), a transcriptional co-activator of the Hippo signalling pathway involved in the 
proliferation of pancreatic progenitor cells (117). 
Another validated target of miR-375 is the protein kinase Pdk1 (118). Pdk1 is part of the PI 
3-kinase signalling cascade (119), a pathway that can phosphorylate Pdx1, a major pancreatic 
transcription factor (120). Exposure of INS-1E cells or isolated rat islets to high glucose reduced 
the transcript abundance of miR-375 (and increased Pdk1). MicroRNA-375 is also increased 
(and Pdk1 decreased) in the islets of neonatal rats from mothers on a low protein diet, which 
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also show reduced β-cell mass and function (121). Together, this highlights that nutritional 
stimuli may affect miRNA expression, which is particularly relevant for pancreatic islets. 
Islet specific expression of miR-375 is transcriptionally regulated by conserved promoter 
regions, cis-elements and enhancer boxes. The miR-375 gene is driven by an upstream TATA-
box containing promoter in both α- (122) and β-cells (123). This promoter region contains 
potential binding sites for several pancreatic transcription factors, including Hnf1, Hnf6, Ap1, 
Insm1, Xfd3 and Ptf1 (123). Additionally, the enhancer boxes are required for complete 
transcriptional activity of pre-miR-375, indicating that this miRNA may be regulated by basic 
helix-loop-helix transcription factors, such as Ngn3 and NeuroD1 (123). Chromatin 
immunoprecipitation experiments have also shown that Pdx1, along with NeuroD1, interact 
with conserved regions (labelled proximal promoter and distal enhancer binding regions) 
surrounding the miR-375 gene (124). Together, this data suggests that miR-375 is involved in 
a complex regulatory network throughout the development and function of the endocrine 
pancreas. 
1.5.1.3. MicroRNA-7 
MicroRNA-7, like miR-375 discussed above, has been identified as a major islet miRNA (83), 
and increases in expression during the development of the endocrine pancreas in humans (84; 
96). In situ hybridisation experiments identified that miR-7 expression during development 
was predominantly within the epithelial region of the pancreas (84). Moreover, the maximum 
expression of miR-7 seen during development (14-18 weeks of gestational age) coincides with 
the rapid increase of pancreatic endocrine hormones (84). Knockdown of miR-7 in early mouse 
embryos (e10.5) using an ultrasound-guided intrauterine injection of antisense miR-7 
morpholino oligonucleotides directly into the foetal heart reduced the number of β-cells, 
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down-regulated insulin production and caused glucose intolerance in the progeny (100). In 
vitro inhibition of miR-7 in isolated pancreatic buds causes the death of developing insulin 
producing cells, reinforcing the crucial role of this miRNA in the development of the endocrine 
pancreas (100). 
MicroRNA target prediction has identified that the pancreatic transcription factor Pax6 has 
three potential miR-7 target sites, two of which have been functionally validated (125). One 
of these is conserved among humans, pigs, rodents, frogs and fish, while the other is restricted 
to primates (125). Luciferase reporter assays containing the 3’ UTR of Pax6 have confirmed 
that it is indeed a target of miR-7 (125; 126). The interaction of miR-7 and Pax6 seems to affect 
the differentiation of endocrine precursors; overexpression of miR-7 reduces both α- and β-
cells but increases ε-cells, whereas inhibition results in the inverse (126).  
Due to the established importance of miR-7 within the endocrine pancreas, researchers have 
investigated its transcriptional regulation. There are two conserved E-box elements within the 
miR-7 promoter region, allowing transactivation via Ngn3 and its downstream transcription 
factor NeuroD1 (127).  
1.5.1.4. Other Important MicroRNAs During Pancreas Development 
Although the discovery of novel microRNAs continues at a brisk pace, the identification and 
validation of their targets remains a more arduous process. Additional miRNAs have 
demonstrated expression patterns during foetal pancreatic development but their specific 
targets during this process still elude us. Joglekar and colleagues have previously identified 
miR-7, miR-9, miR-375 and miR-376 expression during human pancreatic development (96). 
Further investigations into the miRNAs expressed during development and their specific roles 
will help to elucidate the intricate regulatory mechanism within this process. 
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1.5.2. Insulin Target Tissues 
Glucose homeostasis requires an appropriate balance between the release of insulin from 
pancreatic β-cells and the sensitivity of the target tissues to the action of insulin. Insulin 
sensitivity of peripheral tissues such as adipose tissue, skeletal muscle and liver is directly 
influenced by the expression of certain miRNAs.  
1.5.2.1. Skeletal muscle 
Muscle tissue, the primary site of glucose uptake, accounts for approximately 75% of insulin-
dependent glucose removal from the plasma (128). MicroRNA-1, -133 and -206, which are also 
called as myomiRs due to their muscle-specific expression, regulate muscle proliferation and 
differentiation (8; 9). Gene targets of miR-1 and miR-133a are involved in glucose 
homeostasis. MicroRNA-133 has been shown to alter expression of insulin like growth factor-1 
receptor (IGF-R1) in developing skeletal muscle (95) as well as the glucose transporter GLUT4 
by inhibiting expression of the Krüppel-like transcription factor KLF15 (93). MicroRNA-1 also 
targets insulin like growth factor 1 (IGF-1), blocking the capacity of glucose induced IGF-1 to 
cause mitochondrial dysfunction, cytochrome-c release and apoptosis in cardiomyocytes 
(108). Both IGF-1 and IGF-R1 were shown to be targets of miR-1 in c2c12 myoblasts; 
interestingly, this study also determined that IGF-1 is able to regulate the expression of miR-
1 via the transcription factor FoxO3a (86). 
Studies have examined the expression of miRNAs in skeletal muscle from Goto Kakizaki rats 
(91; 92; 94), a model of insulin resistance and diabetes (129). Different miRNAs, including miR-
222, miR-27a, miR-195, and miR-103 are altered in type 2 diabetes. A recent study also 
suggests a role of miR-106b in mitochondrial dysfunction and insulin resistance of c2c12 
myotubes (10; 109). MicroRNA-106b regulates mitochondrial function by targeting mitofusin-
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2 and also controls skeletal muscle insulin sensitivity. A study carried out in 2009 examined 
the expression levels of miRNA in the skeletal muscle of healthy individuals before and after a 
3 hour euglycemic-hyperinsulinemic clamp (89). Out of 216 miRNAs expressed in skeletal 
muscle, 39 were found to be down-regulated by insulin, including the muscle specific miRNAs 
miR-1, miR-133a and miR-206. This down-regulation of miR-1/miR-133a by insulin was shown 
to be mediated by the transcription factors sterol regulatory element binding protein (SREBP)-
1c and myocyte enhancer factor 2c (mEF2c). The effect of insulin on miR-1 and miR-133a was 
altered in the skeletal muscle of type 2 diabetic individuals; however, levels of these miRNAs 
in the absence of insulin were not altered compared to healthy individuals. Another study by 
Gallagher et al (130) examined mRNA and miRNA changes in skeletal muscle of healthy (non-
diabetic) individuals and those with impaired glucose tolerance or T2D. Of 172 miRNAs 
expressed in skeletal muscle, 61 were altered in individuals with T2D with a subset also found 
to be altered in individuals who had impaired glucose tolerance (130) suggesting that some 
expression changes occur before the onset of diabetes. 
1.5.2.2. Adipose tissue 
In adipose tissue, insulin stimulates lipogenesis, the conversion of blood glucose into fatty 
acids for efficient energy storage. MicroRNAs are demonstrated to be important in adipocyte 
lineage commitment, differentiation and proliferation. MicroRNA-143 has been shown to be 
involved in adipocyte differentiation both in vivo and in vitro (88; 107). Overexpression of miR-
143 and miR-103 in pre-adipocytes leads to an increase in the expression of adipogenesis 
markers and triglyceride accumulation. Interestingly, both miR-143 and miR-103 are 
downregulated in adipocytes from ob/ob mice which are insulin resistant and obese (107). 
MicroR-143 overexpressing mice demonstrate impaired insulin sensitivity, while miR-143 
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knock out animals do not develop obesity symptoms (21; 97). This indicates that miR-143 is 
one of the regulators of obesity and diabetes.  
The miR-29 family (miR-29a, b and c) have been shown to be upregulated in both the skeletal 
muscle and adipose tissue of diabetic Goto Kakizaki rats (91). The upregulation of miR-29a and 
miR-29b could be reproduced in vitro when 3T3-L1 adipocytes were incubated in the presence 
of high glucose and insulin. Indeed, overexpression of miR-29 in the same cell type decreased 
insulin-stimulated glucose uptake (91). These results suggest that miR-29 may be involved in 
mechanisms leading to insulin resistance in type 2 diabetes. 
1.5.2.3. Liver 
Selective deletion of the miRNA processing enzyme Dicer1 in the liver early after birth leads 
to mild hyperglycaemia in the fed state and in severe hypoglycaemia in the fasting state due 
to depletion of glycogen stores (105). The expression levels of four microRNAs that are highly 
enriched in the liver, miR-122, miR-148a, miR-192 and miR-194, were found to be decreased 
in Dicer null hepatocytes indicating that these miRNAs are important for hepatic glucose 
homeostasis. MicroRNA-122 is the most abundant miRNA in the liver, with copy numbers 
reaching 50,000-82,000 per average mouse liver cell, and 135,000 per primary human 
hepatocyte (131). In mice, inhibition of miR-122 leads to a decrease in hepatic fatty acid and 
cholesterol synthesis along with a reduction in plasma cholesterol (87). Inhibition of miR-122 
in a mouse model of diet-induced obesity also led to a reduction in plasma cholesterol 
concentrations. These results suggest that miR-122 inhibition may be of therapeutic benefit 
in lowering plasma cholesterol levels. The expression levels of miRNAs in liver have been 
examined in animal models of diabetes (92; 132-134), however, their precise role in regulation 
of liver function are not yet determined. In vitro, a number of microRNAs have been shown to 
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inhibit the expression of insulin receptor substrates (IRS). MicroRNA-33a/b inhibits the 
expression of IRS-2 in cultured hepatic cells reducing the activation of insulin signalling 
pathways including AKT and ERK (85). IRS-1 has been shown to be down-regulated by miR-126 
in the hepatic cancer cell line SK-Hep-1 (104). MicroRNA-145 has also been shown to down-
regulate IRS-1 in human colon cancer cells but it is unclear whether this is also the case in the 
liver (135). Recently, the effect of the miR-29 family on the liver of diabetic mice has been 
explored (98). Overexpression of these miRNAs, through adenovirus vectors, leads to 
improved fasting glucose and insulin tolerance in diet-induced obese mice. It is thought that 
this effect is a direct result of lowering hepatic gluconeogenesis via the decrease of PGc-1α 
and G6Pase protein levels.  
1.5.2.4. Cardiac Muscle  
Cardiac muscle, and muscle tissue in general, is a major site of glucose uptake. Therefore, 
many of the cardiac-specific miRNAs impact upon this process. MicroRNA-133, as discussed 
under the ‘skeletal muscle’ section (above), is seen to negatively regulate the expression of 
GLUT4, a major glucose transporter in cardiac muscle (106). Indeed, when miR-133 is 
overexpressed in cardiomyocytes it lowers GLUT4 expression and the associated insulin-
induced glucose uptake (93). Conversely, miR-223 has been shown to increase the levels of 
GLUT4 within cardiomyocytes (99). A cardiac-specific miRNA, miR-208a, has recently been 
demonstrated to impact upon energy homeostasis in mice by down regulating the expression 
of mED13, a component of the mediator complex (90). Inactivation of miR-208a, either by 
pharmacological means or the generation of miR-208a-/- mice, confers resistance to high-fat 
diet induced obesity and improves glucose tolerance and insulin sensitivity. Additionally, miR-
208a-/- mice are resistant to cardiac stress-induced remodelling (136). Further miRNAs, such 
Chapter 1  Introduction 
30 
 
as miR-378 (137), have been theorised to regulate energy homeostasis within cardiac cells, 
although more work is needed to validate the potential targets. 
1.5.3. MicroRNA Expression in Type 1 Diabetes 
In T1D, β-cells undergo immunologic-mediated destruction. Few studies have investigated the 
response of miRNA expression within islets during this cellular stress. When MIN6 cells and 
human pancreatic islets are exposed to proinflammatory cytokines, such as IL-1β and TNF-α, 
the expression of miR-21, miR-34a and miR-146a is increased within thse cells (103). This 
increase was also observed within the islets of NOD mice undergoing pre-diabetic insulitis 
(103). Knockdown of miR-34a and miR-146a conferred protection against cytokine-mediated 
apoptosis to MIN6 cells, indicating a role for these miRNAs in the immune destruction of β-
cells (103).  
  
Chapter 1  Introduction 
31 
 
1.6. Circulating MicroRNAs 
MicroRNAs have been extensively investigated as biomarkers in both research and clinical 
settings for a variety of diseases, including diabetes (82; 138; 139) and cancer (140). This is 
due to the fact that miRNAs are easily detected within the peripheral circulation and their 
abundance is seen to change with many pathophysiological states. It has also been reported 
that miRNA abundance does not vary significantly when challenged with multiple freeze-thaw 
cycles or exceedingly high or low pH levels (141), making them ideal biomarker candidates. 
Clinical usage of these molecules as indicators of disease status or stage would allow 
monitoring, early intervention and therapeutic stratification for patients. In terms of diabetes, 
miRNA biomarkers would provide multi-faceted benefits, such as in i) quantifying the level of 
islet cell death in type 1 diabetes (T1D) and islet transplant recepients; ii) identification of 
individuals at high-risk of developing diabetes prior to its clinical onset; and iii) allow 
monitoring of treatment efficacy for potential early intervention therapies for high-T1D-risk 
individuals; iv) monitoring the progression of established diabetes; and v) assessing systemic 
damage in tissues to predict progression of diabetic complications.  
How does one identify potential circulating miRNA biomarkers for diabetes progression? Due 
to the systemic nature of diabetes and its complications, miRNAs may be released from 
several tissues in response to cellular stress, injury, or death (Figure 1-3). Special attention 
should be placed on the pancreas due to its central role in this disease; however, it is 
important to note that in a dynamic in vivo system, other tissues may contribute to the overall 
biomarker signature. The death of β-cells during diabetes causes a release of the cellular 
contents, including β-cell enriched miRNAs, into the extracellular milieu, which may be 
detectable in circulation.  
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Figure 1-3. Theoretical model of a microRNA-based biomarker signature. 
 A) Cellular death of pancreatic islets release enriched miRNAs into circulation. B) Cellular stress or injury in blood vessels or 
other tissues may also release miRNAs into circulation. C) Released miRNAs are detectable within peripheral circulation via 
routine phlebotomy. Farr et al 2015. (114) 
 
1.6.1. Stability 
How miRNAs enter the circulation, and why they are not readily degraded by the abundant 
endogenous nucleases, is a point of much recent interest. Many investigations into circulating 
miRNAs utilise plasma as the sample of choice, however plasma contains a large number of 
endogenous RNases (142). Indeed, when naked miRNAs from Caenorhabditis elegans are 
spiked into plasma samples prior to protein denaturation they are quickly degraded (within 2 
mins), whereas endogenous miRNAs are unperturbed (140). This indicates that endogenous 
miRNAs are protected from degradation within circulation. 
There are at present multiple mechanisms to explain the presence and stability of miRNAs 
within circulation. Firstly, miRNAs could be passively leaked from damaged cells during tissue 
injury or oncogenesis (141). This possibility can neatly explain the presence of miRNAs within 
circulation, but not why they are robustly protected from degradation. Membranous vesicles, 
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such as microvesicles (143) or apoptotic bodies (144), have been found to harbour miRNAs 
and protect them from damage. Microvesicle-associated miRNAs have been demonstrated to 
comprise the majority of miRNAs found within plasma (145). Furthermore, data has shown 
that these miRNA microvesicles are a mediator of cell signalling (143; 144). MicroRNAs have 
also been found complexed with proteins (146) and lipoproteins (147), which may hide the 
miRNAs from endogenous nucleases. Figure 1-4 outlines the major forms of miRNA transfer. 
Figure 1-4. MicroRNA transfer 
A schematic representing the modes of miRNA transfer. Cellular miRNAs can travel via gap-junctions or exosome-mediated 
transfer to surrounding cells. MicroRNAs that are released from damaged cells (ruptured cell membrane above) can be 
detected in body fluids, including in the peripheral circulation, where they are known to be fairly stable due to their resistance 
to endogenous nucleases. 
Farr et al 2013  (138) 
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1.6.2. Circulating MicroRNAs in T1D 
MicroRNAs are intriguing transcripts; they are incredibly diverse and yet many are highly 
conserved across species. They represent the largest class of small RNAs within animals and 
impact upon a staggering amount of different cellular processes. Their discovery reshaped our 
knowledge of how varying genomes resulted in increased complexity without an ever-
increasing number of protein coding genes. In recent years, miRNAs have grown from post-
transcriptional regulators to biomarkers of disease (138-140). Their release and stability in 
peripheral circulation has created the potential to develop minimally-invasive tests (requiring 
a blood or other biofluid sample) to predict the onset of diabetes and track its progression 
within an individual. Although previous studies have identified some miRNAs that are 
differentially expressed in individuals with diabetes, there has not been a validated signature 
for the progression of diabetes and its complications. 
To date, there have been few investigations into the circulating miRNAs within individuals with 
T1D (148-154). So far most of the studies have had a candidate approach, identifying one or 
more miRNAs as increased or decreased within circulation (described below). To develop a 
biomarker signature that can accurately detect the progression of diabetes, there is a need to 
identify a combination of miRNAs that best reflect the natural progression of the disease. The 
sections below outline the miRNAs that have been found to be differentially expressed within 
T1D circulation and are summarised in Table 1-B. 
The first study, by Sebastiani and colleagues in 2011, identified an increase in the expression 
of miR-326 in the peripheral blood lymphocytes of patients with T1D currently undergoing 
islet autoimmunity (152). This implicates this miRNA as a marker or effector of the immune 
destruction seen in T1D, however, the study was quite small (19 individuals) and did not 
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compare levels with non-diabetic individuals. Another study that investigated miRNAs from 
peripheral blood mononuclear cells (PBMCs) in T1D patients found that miR-21a and miR-93 
were downregulated when compared to controls, however no associated with autoimmunity 
was found (150). Furthermore, a recently published small study found that miR-146a 
expression in PBMCs was decreased in individuals with T1D (154). Interestingly, the authors 
found that the decreased miR-146a expression significantly correlated with high serum GAD 
autoantibody titres, indicating that this miRNA may be a marker of ongoing islet autoimmunity 
(154). The changes seen in these studies, however, are not truly representative of circulating 
miRNAs, but rather mobile cell-associated miRNAs. 
In 2012, Nielsen and colleagues published a study that found 12 miRNAs (miR-152, 
miR-30a-5p, miR-181a, miR-24, miR-148a, miR-210, miR-27a, miR-29a, miR-26a, miR-27b, 
miR-25, and miR-200a) had a significantly increased abundance within the serum of two 
groups of individuals with T1D compared to matched controls (148). This was the first study 
that analysed cell-free circulating miRNAs in T1D patients. Interestingly, the authors found 
that miR-25 had a negative correlation with residual β-cell function as assessed by stimulated 
C-peptide, but a positive correlation with HbA1c levels (148). Another study found that T1D 
patients had increased levels of miR-21 and miR-210 within their plasma and urine, when 
compared to age and gender matched controls (149). Additionally, the study found that 
urinary miR-126 was decreased in T1D individuals and negatively correlated with the patient’s 
concurrent HbA1c level (149). A recent study has investigated select miRNAs in the circulation 
of subjects with pre-diabetes, T2D, T1D, and latent autoimmune diabetes in adults (LADA), 
and compared them with non-diabetic control subjects (153). LADA is a late onset form of 
T1D, which can often be mistaken for T2D initially, and whilst initially being able to be 
managed with lifestyle and oral glucose control agents, progresses to needing exogenous 
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insulin (155).  The investigators found that miR-148a, miR-21, miR-24, and miR-375 were 
elevated in the circulation of T1D individuals (153). Unfortunately, this study, like many before 
it, rely on investigating select candidates within small sample numbers (T1D; N=16) and so 
may possibly miss out on some of the key/important circulating miRNA biomarkers of diabetes 
progression. 
A recent study conducted by Samandari and colleagues assessed circulating miRNAs within 
123 individuals with newly-diagnosed T1D to identify whether they reflected measurements 
of -cell function (151).  Using a discovery approach, six miRNAs, miR-24-3p, miR-146a-5p, 
miR-194-5p, miR-197-3p, miR-301a-3p, and miR-375, at 3 months were found to correlate 
with residual -cell function at 6-12 months. Interestingly, an increase in the circulatory 
abundance of these miRNAs corresponded to higher stimulated C-peptide and lower insulin 
dose adjusted HbA1c. In the validation cohort, only miR-197-3p abundance at 3 months 
significantly predicted stimulated C-peptide at 12 months. These findings indicate that 
circulating miRNAs could also assist in the prediction of clinical outcomes after diagnosis. 
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Table 1-B. Circulating miRNAs in T1D  
Author (year) miRNA/s Observation Reference 
Sebastiani (2011) miR-326 Increased in PBMCs 
from T1D patients  
(152) 
Nielsen (2012) miR-152, -30a-5p,  
-181a, -24, -148a,  
-210, -27a, -29a,  
-26a, -27b, -25,  
-200a 
Increased in T1D 
circulation 
(148) 
Salaz-perez (2013) miR-21a, -93 Decreased in T1D 
PBMCs 
(150) 
Osipova (2014) miR-21, -210 Increased in T1D 
plasma and urine 
(149) 
Yang (2015) miR-146a Decreased in T1D 
PBMCs 
(154) 
Seyhan (2016) miR-148a, -21, -24, -
375 
Increased in T1D 
circulation 
(153) 
Samandari (2017) miR-24-3p,  
-146a-5p, -194-5p, -
197-3p, -301a-3p, -
375 
Correlated with 
-cell function 
(151) 
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The use of streptozotocin (STZ)-induced diabetic mice and non-obese diabetic (NOD) mice has 
enabled the identification of circulating miR-375 in these animals (156). One of the major 
advantages of these models is the high level of certainty that the majority of these animals 
will become diabetic and so the study was able to measure the circulating miR-375 level prior 
to the onset of the disease. It found that there was a marked increase in the levels of miR-375 
in the plasma of mice treated with STZ, prior to the onset of hyperglycaemia. To strengthen 
the use of miR-375 as a biomarker within these diabetic models, this miRNA was also found 
to be increased in the plasma of NOD mice roughly two weeks prior to the onset of diabetes 
(156). The increase of this miRNA in these models was associated with islet cell death, as 
isolated islets cultured with cell death inhibitors demonstrated a reduction in extracellular 
miR-375 levels (156). The finding that acute β-cell death resulted in a detectable rise of miR-
375 was supported by another recently published animal study; however, the authors noted 
that only a very small proportion of circulating miR-375 directly originated from β-cells (157). 
As they were using a model with -cell specific miR-375 expression, they could not conclude 
where the rest of the circulating miR-375 originated. This finding supports the use of this 
miRNA for the detection of β-cell death but not β-cell function. 
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1.7. Circulating Cell-free DNA (cfDNA) 
As seen with miRNAs, circulating cell free DNA (cfDNA) has been intensively investigated as a 
diagnostic and prognostic marker for various cancers (158-160). Again, this utilises a less 
invasive method of assessing an individual’s health status using liquid biopsy (e.g. blood, 
plasma, urine) samples (160). Unlike miRNAs, however, cfDNA has a shorter half-life (minutes 
to hours) within the peripheral circulation and highly pone to degradation by just two or more 
freeze-thaw cycles. Previous studies have identified rapid clearance of non-host DNA, mainly 
by the liver (161; 162). Indeed, a study evaluating the presence of foetal DNA within the 
circulation of expectant mothers has concluded that this cfDNA has an average half-life of 16.3 
mins after the delivery of the neonate (161). More recent investigations in both cancer and 
islet transplantation have identified a longer half-life of 114-117 mins (163; 164), however, 
the presence of continual DNA release inherent to these conditions would obfuscate the 
findings. In the progression to T1D it has been postulated that the β-cell mass of an individual 
undergoes periods of cell death and recuperation, yet the overall trend of β-cell death (Figure 
1-1) means that cfDNA has great potential as a biomarker of T1D progression.  
1.7.1. Methylated Insulin DNA   
Insulin cfDNA is the current frontrunner as a DNA-based biomarker of β-cell death. As all cell 
types contain genomic insulin DNA, how does one identify DNA that originates from the 
pancreatic β-cells? Despite having an identical genome, each cell type within the body 
contains DNA with a unique methylation pattern that correlates with its specific gene 
expression profile. The insulin gene, including the promoter region, is typically unmethylated 
within the pancreatic β-cells and methylated in almost all other cell types, and so researchers 
have developed assays to attempt to quantify methylated and unmethylated insulin DNA. 
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DNA methylation is an epigenetic mechanism whereby DNA methyltransferases (DMNTs) 
place a methyl group onto a cytosine base, converting it to 5-methylcytosine. The cytosine is 
usually placed next to a guanine, causing two 5-methylcytosines to be created diagonally from 
each other. These areas within the genome are commonly referred to as CpG sites. DNA 
methylation is generally regarded as negatively regulating gene expression, although the role 
of this epigenetic mechanism has not been fully elucidated. There are currently two main 
methods by which DNA methylation results in transcriptional suppression. Firstly, the addition 
of the methyl groups is thought to physically block the binding of transcription factors to the 
promoter regions of the gene of interest. Additionally, studies have found associations 
between certain DNA methylation sites and histone modifications, however it is uncertain 
whether the histone modification is required for DNA methylation or vice versa. 
The insulin gene, including the upstream promoter region, contains numerous methylation 
sites. Indeed, DNA methylation is a major factor in the regulation of insulin expression. Using 
a luciferase construct, Kuroda and colleagues found that methylation of the CpG sites within 
the insulin promotor resulted in a 90% reduction in expression (165). Intriguingly, subsequent 
studies have revealed that not all CpG sites show the expected methylation pattern within 
different tissues (unmethylated in β-cells, methylated in all other tissues). A recent study by 
Husseiny and colleagues concluded that intron 1, exon 2 and intron 2 do not show any tissue-
specific methylation pattern (166). Furthermore, only five of the nine known methylation sites 
in the promoter region demonstrated consistent methylation within the other non-pancreatic 
tissues analysed (166). To identify the death of the pancreatic β- cells in the presence of 
normal cellular turnover, the CpG sites of interest must display a highly unique methylation 
pattern. Some CpG sites, including those both upstream (-234, -206, -69 and -19 bases) and 
downstream (+63) of the transcription start site (TSS), not only have significantly different 
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levels of methylation between different tissues, but also between pancreatic α- and β-cells 
(167). This gives weight to the preposition that differentially methylated insulin DNA has the 
potential as a highly specific marker of islet β-cell death.   
Another consideration during such selection of the sites is the stability of the DNA 
methylation, especially during periods of cellular stress. Methylation analyses of islets from 
individuals with T2D, which are often undergoing extensive inflammatory stress, demonstrate 
that not all CpG sites are consistently methylated (167). CpG sites, including +63, -102 and -
180 (relative to the TSS), are more likely to be methylated within T2D islets, while -19, -69, -
135, and -206 show no difference in methylation (166). All of this previous data should be 
taken into account when selecting methylation sites for biomarker studies. 
1.7.2. Methylated and Unmethylated Insulin cfDNA in T1D 
Currently, there are three main groups, headed by Professors Mirmira (USA), Herold (USA), 
and Dor (Israel), investigating the use of methylated/unmethylated insulin cfDNA as a marker 
of β-cell death, each with their own approach.  
Professor Mirmira’s team have focused upon one particular CpG site located upstream of the 
TSS (-69), using both nested qPCR and digital droplet PCR approaches (168; 169). This 
particular site demonstrates consistent demethylation within the pancreatic β-cells, even 
while under cellular stress, and high levels of methylation in other tissues (166; 167).  The 
most recent paper from this group evaluated serum samples from paediatric patients within 
2-days from clinical diagnosis of T1D, and then 8-weeks and 1-year later (168). They identified 
that the levels of both methylated and unmethylated insulin DNA were increased in these 
individuals compared to non-diabetic control subjects, but that they decreased over time and 
returned to control levels by 1-year post-diagnosis (168). These findings support the notion 
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that the progression of T1D causes systemic stress on an individual, causing a release of 
methylated as well as unmethylated insulin DNA into peripheral circulation. Xeno-rejection of 
transplanted human islets resulted in a significant increase of unmethylated, but not 
methylated, insulin cfDNA, again suggesting that islets are not the source of the methylated 
copies (168). Furthermore, as the disease progresses post-diagnosis there is reduced β-cell 
mass to contribute to the circulating unmethylated insulin DNA levels.   
Professor Herold’s team has chosen to analyse two CpG sites located close to one another 
within the coding region (+396 and +399) of the insulin gene (170). They have also utilised a 
digital PCR approach to quantify the absolute copy numbers, however they have chosen to 
present their data as a ratio of unmethylated/methylated (UM/M) Ins DNA (163; 170). As the 
majority of investigations have focused upon the INS promoter region, there are little data on 
the specificity or stability of the two chosen methylation sites. A previous manuscript from 
this group identified that one of the CpG sites, +399, was unmethylated in β-cells and 
methylated in the majority of kidney cells (171), however the other site, +396, was not 
mentioned. A recent study from this group attempted to use their digital PCR assay to assess 
β-cell death within two longitudinal cohorts of at risk individuals from the TrialNet Pathway to 
Prevention study (163). A modest increase in the average UM/M Ins DNA ratio (P=0.048) was 
found in individuals that progressed to T1D, compared to healthy controls, however when all 
measurements were assessed independently this difference was abolished (163). 
Furthermore, this assay was not able to discriminate between high-risk individuals that 
progressed to T1D and those that did not. Individuals at high-risk of T1D (familial history and 
presence of islet autoantibodies) would benefit the most from an assay of β-cell death, as it 
would monitor progression toward T1D and allow early intervention if necessary. Therefore, 
a β-cell death assay must be sensitive enough to distinguish and stratify these individuals.  
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Professor Yuval Dor’s group has taken a much different platform; they have used a 
combination of Illumina 450K methylation arrays and next generation sequencing to identify 
a cluster of six CpG sites within the INS gene promoter region (172). These sites are in close 
proximity to one another. These sites are not able to distinguish patients with T1D from 
healthy controls when analysed individually, but when assessed in combination they 
demonstrate a signal within the circulation of T1D patients that is absent in healthy controls 
(172).  It is important to note, however, that bisulfite sequencing has previously identified 
differential methylation of CpG sites between β-cells and kidney that was later debunked by 
more extensive analysis (166). Additionally, bisulfite sequencing protocols are sample- and 
costs-prohibitive for many other research groups in utilising this approach on large biobank 
cohorts. The three main areas of DNA methylation can be seen in Figure 1.5. Table 1-B 
compares the two main technical approaches for quantitation of methylated and 
unmethylated insulin cfDNA. 
 
 
 
 
 
 
 
 
Figure 1-5. Methylation sites investigated as markers of β-cell death 
Nine CpG sites have been identified within the insulin gene, including the upstream promoter region. They are potential 
markers of β-cell death due to their differential methylation pattern. Diagrammatical representation of the insulin coding 
region, not drawn to scale. INS = insulin, TSS = transcriptional start site. 
TSS 
-69 
(153;154) 
+396 +399 
(148;155) 
Six CpG Sites 
(157) 
INS Promoter INS 
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Table 1-B. Approaches to Insulin cfDNA Quantitation 
Group 1 2 3 
Head of group 
Mirmira 
(168) 
Herold 
(163; 170) 
Dor 
(172) 
CpG site(s) -69 +396, +399 Six undisclosed sites 
Quantitation method 
Digital droplet PCR 
(Bio-Rad) 
Nested PCR/Digital 
droplet PCR (Bio-
Rad) 
Bisulfite sequencing 
(Illumina) 
Volume of plasma 
required (mL) 
0.03 – 0.05 0.2 0.2 – 1.0 
DNA extraction 
method 
QIAmp DNA Blood 
kit (Qiagen) with 
Poly(A) carrier 
(Sigma) 
QIAmp DNA Blood 
kit (Qiagen) 
QIAquick kit 
(Qiagen) 
Number of rxns/run† 8 – 96 8 – 96 
Up to 96, depending 
on use of barcodes 
Time required for 
quantitation and 
analysis 
+++ +++ + 
Costs‡ +++ +++ ++ 
 
 †Based on the possible reactions that can be assessed on each platform in a single run on a single instrument. ‡Based on 
inferred costs based on prices for studies in Sydney, Australia.  Rating scale = + poor, ++ good, +++ excellent.  
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1.8. Preliminary Data 
Prior to the commencement of this PhD project, the Hardikar laboratory invested significant 
effort in investigating the role of ncRNAs in the developing human pancreas and their potential 
application as T1D biomarkers. A summary of the findings of these experiments carried out by 
Dr. Mugdha Joglekar and A/Prof Anand Hardikar and their teams are detailed in the following 
sections, and form the basis on which this thesis is built.   
1.8.1. Non-coding RNAs in the Developing Human Pancreas 
In order to understand the microRNAs that are expressed during human pancreas 
development, the Hardikar lab obtained ethics and collected human fetal pancreatic samples 
from aborted human fetuses and assessed samples between 14-36 weeks of gestational age 
as well as adult pancreatic islets obtained from pancreatectomized samples using the SOLiD 
NGS platform. Following analysis and identification of miRNAs that increased in abundance 
during human pancreas development, the 300 most abundant microRNAs were then validated 
using TaqMan-based qPCR technology. Interestingly, a subset of these were found to increase 
in abundance during pancreatic development and remain highly expressed in adult islets 
(Figure 1-6a). To confirm that these ncRNAs are expressed within human islets in situ, these 
investigtors performed a combination of immunocytochemistry and fluorescent in situ 
hybridisation (FISH), or immune-FISH technique. This technique was used to confirm if the 
precursor microRNA molecule and/or the mature miRNA molecule were expressed within 
insulin-producing islet cells (Figure 1-6b). Interestingly, it was observed that some microRNAs, 
such as the pri-miR-375 was expressed in almost all of the human islet cells but the mature 
miR-375 appeared to be present only in a subset of these cells (Figure 1-6b) thereby 
demonstrating that yet unidentified microRNA processing mechanisms regulate the 
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expression of mature microRNA within islet cells.  Some of these findings were assessed using 
a technique of single cell PCR wherein these investigators confirmed that mature miR-375 
appears to be expressed in the non-β-islet cells than the β-cells within the pancreatic islets 
(96).  These studies led to identification of candidate microRNAs that are i) found to increase 
in abundance in developing human pancreas; ii) found to be present in adult human 
pancreatic islet cells; and iii) had mature microRNA gene transcripts expressed in relevant 
pancreatic cells.  Such candidate were selected for further evaluation/validation using in vitro 
and cross-sectional analyses discussed below.  
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Figure 1-6. Non-coding RNA expression in the developing human pancreas   
(a) Heat map of the 300 most abundant ncRNAs in the developing pancreas, identified by SOLiD NGS and validated by qPCR. 
(b) Confirmation of precursor and mature miRNA expression within adult islets using immuno-FISH. WGA = weeks of 
gestational age. Unpublished data from Hardikar Lab (credit: Joglekar MV et al.).  
 
 
a b 
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1.8.2. Circulating MicroRNA Signature in T1D 
To assess whether the RAPID signature had potential as circulating biomarkers of T1D, our 
laboratory quantified their abundance within Non-Obese Diabetic (NOD) mice, as well as 
clinical samples from human subjects with and without T1D. The NOD mouse model has been 
extensively utilised as a model of T1D due to their genetic predisposition for autoimmune 
diabetes (173) (discussed in more detail in Chapter 3). The RAPID miRNAs were found to be 
elevated in the circulation of female NOD mice, both before and after the confirmation of 
diabetes, compared to mice that are not genetically pre-disposed (female non-diabetic 
C57BL/6 mice) to diabetes (Figure 1-7). 
 
 
Figure 1-7. RAPID signature miRNAs in NOD mice  
Four representative RAPID signature miRNAs were elevated in the circulation of female pre-diabetic and diabetic NOD mice, 
compared to female non-diabetic C57BL/6 mice (dotted line). Mean ± SEM.  Unpublished data from Hardikar Lab (credit: 
Joglekar MV et al.). 
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The RAPID miRNAs were also found to be elevated in the circulating of human subjects with 
T1D (N=7), compared to age and gender matched controls (N=7) (Figure 1-8).  Interestingly, 
these miRNAs were observed at high levels even up to 50 years post T1D diagnosis.  
These data highlight the potential of miRNAs as circulating biomarkers of T1D. This thesis aims 
to extend existing findings to add to the RAPID signature miRNAs and validate a signature of 
candidate microRNAs as well as insulin cfDNA  as biomarkers of β-cell death and the 
progression to T1D. 
 
Figure 1-8. RAPID miRNAs in subjects with T1D 
(a) RAPID miRNAs were elevated in the circulation of 7 subjects with T1D (filled triangles), compared to 7 age and gender 
matched controls (open squares). (b) RAPID miRNAs remain highly expressed within T1D circulation up to 50 years post-
diagnosis, N=7. Black line = non-linear regression. Red line = abundance within control subjects. Mean ± SEM. * P<0.05, ** 
P<0.01, *** P<0.001. Unpublished data from Hardikar Lab (credit: Joglekar MV et al.). 
a 
b 
miR-30b 
miR-30b 
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1.9.  Identification of a Candidate MicroRNA Signature 
The miRNA signature investigated throughout this thesis was predominantly based upon the 
RAPID signature discussed in the previous section as well as Islet-specific microRNAs assessed 
through discovery analyses on over 500 different human tissues; including over 150 cadaveric 
human islets, (as part of the PhD thesis of Wilson Wong - Hardikar lab; supervisors: A/Prof. 
Anand Hardikar and Dr. Mugdha Joglekar). To ensure the inclusion of other microRNAs that 
are possibly reseased from non-pancreatic tissues, circulating miRNAs were also profiled in 
individuals with T1D and their age and gender matched controls (outlined in Chapter 4). 
Additionally, miRNAs previously identified within the literature as differentially abundant in 
T1D and its complications were also included.  This forms the PREDICT T1D study signature, 
which is validated through this thesis and continues to be confirmed in other individuals 
progressing to T1D in the Hardikar lab. 
This resulted in the generation of a signature of 50 candidate miRNAs, collectively known as 
the PREDICT T1D (Plasma RNA Evaluation and Diagnosis In Children progressing To Type 1 
Diabetes) Signature (Figure 1-9). Intriguingly, less than half of these 50 miRNAs have been 
previously identified in the development and function of the pancreas (Table 1-C), although 
further research may change this figure. This correlates with the hypothesis that cellular stress 
outside of the pancreas can contribute to the circulating miRNA signature.  
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Figure 1-9. Identification of the MicroRNA Signature Assessed Within this Thesis 
The miRNA signature investigated within this thesis was built upon the RAPID Signature, however additional miRNA 
candidates were identified through miRNA profiling of clinical samples and extensive literature searches of circulating miRNAs 
in T1D. The resulting signature of 50 miRNAs is known as the PREDICT T1D Signature. The RAPID Study from the Hardikar lab 
represents “RNA-based Analysis and Prediction of Islet Death”, while the PREDICT T1D study is the JDRF Australia-funded T1D 
CRN fellowship to A/Prof Hardikar and represents “Plasma RNA Evaluation for Diagnosis of β-cell death and vascular health 
In Children and adults progressing To Type 1 Diabetes”.  
 
Additionally, only 20 of these miRNAs have been previously reported in T1D circulation, 
indicating that the preliminary signature discussed here may provide up to 30 novel 
biomarkers. 
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Table 1-C Candidate miRNAs 
MicroRNA 
Islet Development, Function, 
or T1D Dysfunction 
T1D Circulation 
let-7e (174) - 
miR-103 - - 
miR-125a-5p - - 
miR-125b (175)  
miR-126 (176)a (153) 
miR-127 (177) - 
miR-145 (178) - 
miR-146a (116)b (154)c 
miR-148a (179) (148; 153) 
miR-152 - (148) 
miR-155 - - 
miR-15b (180) - 
miR-16 (180) - 
miR-181a - (148) 
miR-186 (181)b - 
miR-188 - - 
miR-199a-3p - - 
miR-200a (182)b (148) 
miR-20a - - 
miR-21 - (153) 
miR-210 - (148) 
miR-22-5p - - 
miR-220c - - 
miR-222 - (183)d 
miR-223 - - 
miR-24 (179) (148; 153) 
miR-25 - (148) 
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MicroRNA 
Islet Development, Function, 
or T1D Dysfunction 
T1D Circulation 
miR-26a (179) (148) 
miR-26b - - 
miR-27a - (148) 
miR-27b (176)a (184) (148) 
miR-29a (185)d (148) 
miR-301b - - 
miR-30a-5p (186) (148) 
miR-30b (186) - 
miR-30c (186) - 
miR-30e-3p (186) - 
miR-326 - 
 
(152) 
 
miR-340-3p - - 
miR-34a (116)b (153) 
miR-374 - - 
miR-375 (96; 101; 102; 115) (153; 187) 
miR-409-5p - - 
miR-558 - - 
miR-625 - - 
miR-7 (83; 84; 96; 100) - 
miR-9 (96) - 
miR-92a - - 
miR-93 - (150) 
miR-99b - - 
 
a Detected in islet extracellular vesicles. 
b Detected in insulin producing cells differentiated from hSCs. 
c Detected in PBMCs. 
d Rodent model. 
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1.10. Objectives and Significance 
This thesis intends to build upon the existing data on miRNA and cfDNA release during T1D 
progression. The studies discussed in the previous sections highlight the potential of both 
circulating miRNAs and insulin DNA as biomarkers of β-cell death. These studies, however, 
have yet to characterise and validate a clinically relevant molecular signature of β-cell death. 
A signature comprised of both circulating miRNAs and insulin cfDNA would provide clinicians 
with a minimally-invasive (blood) test to help identify, monitor and therapeutically manage 
those individuals undergoing immune-mediated β-cell destruction. The development of a 
biomarker signature to quantify islet cell loss would help in identifying children or adults at 
risk of developing T1D and allow preventative treatments, such as incretin drugs, anti-
inflammatory drugs, vaccinations and diets, to prevent islet loss and induce regeneration. This 
project has tremendous implications in diabetes research as early diagnosis can potentially 
delay the clinical onset of this disease, thereby delaying the onset of diabetic complications 
and enabling the retention of some endogenous insulin production, which is associated with 
better glycaemic control and lower risk of chronic complications (6). Severe hypoglycaemia 
(that requiring assistance from another person for recovery, such as by glucagon or glucose 
injection) and the end organ complications significantly impact upon an individual’s quality 
and duration of life and result in an increasingly large burden on the health care system.  
Furthermore, a molecular signature of β-cell death would allow clinicians to assess the insulin 
needs of individuals with LADA and with T2D, as well as the rejection of islet transplants. Basic 
researchers could also utilise such a signature to monitor the efficacy of novel drugs in 
preventing β-cell toxicityto therapeutic agents.  
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The hypothesis is that the cellular stress and mortality that occurs during the asymptomatic 
progression to clinical T1D results in the release of miRNAs (from both β-cells and non-β-cells) 
and insulin cfDNA (both methylated and unmethylated). Section 1.11 provides a graphical 
overview of this process and the approaches taken to quantify these circulating molecules. 
To test this hypothesis, several objectives must be met: 
1. Identify the most appropriate technology for the quantitation of a miRNA biomarker 
signature (chapter 2) 
1) Examine the release of miRNAs and INS cfDNA in in vitro and in vivo disease models 
(chapter 3) 
2) Profile circulating miRNAs in individuals with established or newly-diagnosed T1D 
compared to age and gender matched controls (chapter 4) 
3) Investigate the PREDICT T1D miRNA signature in the circulation of individuals with 
established T1D compared to age and gender matched non-diabetic controls 
(chapter 4) 
4) Examine the molecular (miRNA and cfDNA) signature within individuals at high risk of 
developing T1D, individuals at the point of T1D diagnosis, and individuals 
post-diagnosis (chapter 5) 
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1.11. Graphical Overview 
Figure 1-10. Graphical overview 
Simplified diagrammatical overview of this thesis. (a) This thesis hypothesises that islet enriched miRNAs and 
unmethylated insulin (INS) gene cfDNA are released into the circulation during βcell death, while other miRNAs and 
methylated Ins cfDNA could be released from other cell types undergoing cellular stress during the progression to 
T1D. (b) Two of the molecular techniques utilised in this manuscript are shown with blue dotted arrows. (c) Breakdown 
of the sample groups used to identify and validate this molecular signature of β-cell death. 
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2.  Assessing High-throughput qPCR Technologies for 
MicroRNA Signature Detection 
2.1. Published Manuscript 
Farr R.J., Januszewski A.J., Joglekar, M.V., Liang H., McAulley A.K., Hewitt A.W., Thomas H.E., 
Loudovaris T., Kay T.W., Jenkins A., and Hardikar, A.A., A comparative analysis of high-
throughput platforms for validation of a circulating microRNA signature in diabetic 
retinopathy. Scientific Reports, 2015. 5: p. 10375. 
2.2. Chapter Overview 
MicroRNAs are now increasingly recognised as biomarkers of disease progression. Several 
quantitative real-time PCR (qPCR) platforms have been developed to determine the relative 
levels of microRNAs in biological fluids. We systematically compared the detection of cellular 
and circulating microRNA using (a) a standard 96-well platform, (b) a high-content 
microfluidics platform and (c and d) two ultra-high content platforms. We used extensive 
technical and analytical tools to compute inter- and intra-run variability and concordance 
measured using fidelity scoring, coefficient of variation and cluster analyses. We also carried 
out unprejudiced next generation sequencing to identify a microRNA signature for Diabetic 
Retinopathy (DR), defined as late stage sight threatening DR requiring retinal laser treatment, 
and systematically assessed the validation of this signature on clinical samples using each of 
the above four qPCR platforms. The results indicate that sensitivity to measure low copy 
number microRNAs is inversely related to qPCR reaction volume and that the choice of 
platform for microRNA biomarker validation should be made based on the abundance of 
miRNAs of interest. 
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2.3. Chapter Aims 
The studies in this chapter aimed to: 
1. assess the reproducibility of micro- and nanofluidic high-throughput qPCR platforms 
in quantitating cellular and circulating microRNAs; 
2. compare the data generated from these platforms with the gold standard 96-well low-
throughput qPCR platform, and; 
3. validate a representative microRNA signature of diabetic retinopathy (DR), identified 
through unbiased next generation sequencing analyses, for recognition of the most 
reliable platform for microRNA profiling. 
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2.4. Methods 
2.4.1. Samples 
The study was approved by the University of Sydney Ethics Committee and all samples were 
collected following written informed consent Total RNA was isolated from human islets 
(Australian Islet Transplant Consortium) and from serum samples, collected from individuals 
with or without diabetes. Cellular RNA was isolated as outlined in Appendix A, while serum 
RNA was isolated as per the protocol in Appendix B. The study was carried out in accordance 
with the approved guidelines. Samples were tested for a total of 48 miRNAs, selected based 
upon their expression in small RNA sequencing, their relevance to islet biology or diabetes, or 
their suitability as housekeeping transcripts. However, six of these 48 miRNAs were identified 
to be incompatible on the Fluidigm system (see discussion) and therefore all of the analysis 
for the two platforms is based on comparison of the expression of these 42 miRNAs on all the 
platforms tested. The 42 miRNAs include the three most commonly used “housekeeping” 
miRNAs (U6, RNU44 and RNU48). Each PCR reaction was undertaken at least in duplicate. 
Technical replicates were also included within the same run as well as in different runs, and 
repeated by upto three users (Ryan J Farr, Mugdha V. Joglekar and Anandwardhan A. 
Hardikar). No statistically significant variation was seen in data obtained by the three users. 
2.4.2. ViiA7 
To aid comparison with the pre-amplified samples run on the high-throughput technologies, 
samples were pre-amplified and run in the 96-well format using 5 μl reaction volumes. Reverse 
transcription (RT) and pre-amplification (PA) was completed using the Megaplex RT/PA Primer 
Pools (Life Technologies) using the manufacturer’s protocol, with minor changes. Briefly, each 
sample had an RNA input of 100 ng (measured by Nanodrop), went through 12 cycles of PA 
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and was diluted 1:40 in nuclease-free water. qPCR was undertaken in 0.1 ml optically clear 96-
well plates using TaqMan MicroRNA Primer/Probe mixes and TaqMan Fast Universal PCR 
Master Mix (2X), No AmpErase UNG (Life Technologies) as described elsewhere (188). 
2.4.3. TaqMan Low Density Arrays (TLDA) 
RT and pre-amp were undertaken with Megaplex RT/PA Primer Pools using the 
manufacturer’s protocol. Each sample had 80-100 ng RNA input (as measured by Nanodrop), 
12 cycles of pre-amplification and was diluted 1:4 with 0.1 x TE pH 8.0. qPCR was completed 
using TaqMan® Low Density Array human microRNA Panel as previously published (188). 
2.4.4. OpenArray (OA) 
RT and PA were undertaken with Megaplex RT/PA Primer Pools using the manufacturer’s 
OpenArray microRNA Panel protocol as described elsewhere (188). Briefly, each sample (100 
ng input), underwent 12 PA cycles, then was diluted 1:40 in 0.1X TE (pH 8.0), combined with 
TaqMan OpenArray PCR Master Mix and loaded onto TaqMan OpenArray Human MicroRNA 
Panel (AccuFill™ system). qPCR was completed using the QuantStudio 12K Flex (Life 
Technologies). 
2.4.5. Dynamic Array (DA) 
RT and PA were undertaken with Megaplex RT/PA Primer Pools using the protocol supplied by 
Fluidigm Corporation. Each sample (input 100 ng), underwent 16 PA cycles (recommended by 
the manufacturer), then was diluted 1:10 in nuclease-free water, combined with TaqMan 
MicroRNA Primer/Probe mixes and TaqMan Fast Universal PCR Master Mix (2X), No AmpErase 
UNG, and loaded onto a 48 × 48 Dynamic Array IFC (Integrated Fluidic Circuit) using the IFC 
Controller MX. qPCR was performed on the BioMark system (Fluidigm Corporation). 
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2.4.6. Next Generation Sequencing 
RNA was isolated from plasma samples using protocol described earlier (189). SmallRNA 
libraries generated using the Ion Total RNA-Seq Kit v2 were processed through emulsion PCR 
using OneTouch 2 (Life Technologies) and the Ion PGM™ Template OT2-200 Kit, then enriched 
using the OneTouch ES (all Life Technologies). One sample was loaded per Ion-318™ chip and 
sequenced on Ion PGM using the Ion PGM™ Sequencing 200 Kit v2 (all Life Technologies). The 
aligned BAM files were analysed using Strand NGS (Strand Life Sciences) and differential 
miRNA expression was determined by a two-fold change in normalised read number. 
2.4.7. Statistical Analysis 
The data were analysed using Statistica for Windows analytical software (ver. 12.0, StatSoft, 
Tulsa, OK). For intra-platform reproducibility analysis, the coefficient of variation (CV%) was 
calculated between replicate measurements. Data were obtained from the multiple 
measurements (lowest number of replicates = 2, highest = 8) of 40 transcripts in four samples. 
miR-140 and miR-320 were excluded due to the lack of results on TLDA and DA platforms 
respectively. 
CT/CRT values could not be compared directly so they were transformed into Z-scores within 
each platform. Pearson correlation and linear fits were calculated. Level of compression or 
expansion of data measured on the different platforms were evaluated by comparing the 
slope of the best fitted line of a least square linear regression of the Z-scores between pairs 
to the “ideal” slope of 1. Ward’s linkage method and Euclidean distances were used for cluster 
analysis. Separate dendrograms were generated for each analytical platform. Number of 
clusters was based on Mojena rule for distances between the dendrogram knots. In each 
analytical method four clusters were observed. The miRNAs of each cluster were then 
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calculated using k-means method. MicroRNAs with >15% missing data (across all platforms) 
were excluded from the calculations; otherwise missing data were replaced by mean. Clusters 
concordance was estimated by comparing the clusters generated by other platforms with the 
ViiA7 (“gold standard”). The assignment was declared in concordance if at least two miRNAs 
were placed in the same cluster by different methods. 
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2.5. Results 
2.5.1. Platform Overview 
An overview of the different platforms (Figure 2-1) compared within this chapter can be found 
in Table 2-A. The ease of workflow and cost analysis was computed considering a study size of 
> 100 samples and 48 miRNAs to be screened. The ease of the workflow is also a reflection of 
the time and experience needed to create the cDNA, pre-amplify it and load it onto the 
respective platform. All software was supplied by the manufacturer and utilised with default 
recommended parameters. 
The raw cycle threshold (CT/CRT) values generated on each platform are plotted in Figure 
2-1b. A distinct decrease in CT values is seen in the Dynamic Array, most likely due to the 
increase in the number of pre-amplification cycles and lower dilution factor (1:10 versus 1:40 
for the OpenArray), as recommended for the DA platform. The median CT/CRT value for the 
entire miRNA dataset analysed is 18.09 for the ViiA7, 15.79 for OA and 12.76 for DA. 
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Figure 2-1. qPCR platform overview 
(a) Representative pictures of the four platforms. (b) CT/CRT values from all samples. 
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Table 2-A. Comparison of qPCR platforms 
 
Platform 
96-rxns/run 
(ViiA7) 
384 rxns/run 
(TLDA) 
12,228 rxns/run 
(OpenArray) 
2304 rxns/run 
(Dynamic Array) 
RNA Input (ng) 100 100 100 100 
RT cycles 40 40 40 40 
Pre-amplification 
(Pre-amp) 
Yes Yes Yes Yes 
Pre-amp cycles 12 12 12 16 
Pre-amp dilution 1:40 1:4 1:40 1:10 
PCR volume/rxn 5 μl 1 μl 33 nl 15 nl 
Primer/probe° Individual Pre-printed Pre-printed Pre-printed 
Number of 
rxns/run† 
1–96 384 3,072–12,228 2,304–9,216 
Ease of workflow ++ +++ +++ ++ 
Costs‡ + ++ +++ ++ 
Ease of analysis§ +++ +++ +++ ++ 
 
°The use of individually available TaqMan primer/probe assays or pre-printed TaqMan primer/probe assays. Note: we 
recommend using the individual TaqMan assays for the panel of microRNAs proposed as there may be compatibility issues 
between off-the-shelf Megaplex primer pools and the individual microRNA TaqMan assay. †Based on the possible reactions 
that can be assessed on each platform in a single run on a single instrument. ‡Based on actual total costs involved in Sydney, 
Australia. §Based on our analysis of software capabilities, robustness and ease of use of the software supplied by the 
manufacturer and ranked by three independent users. Rating scale = + poor, ++ good, +++ excellent. 
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2.5.2. Platform Variability 
To assess the variability of each platform, the co-efficient of variation (CV) was calculated for 
each microRNA assay (Figure 2-2). The median CV of the replicates was lowest in the 5 µl 
96-well platform (0.6%), ranging from 0.1 to 1.9%, then OA at 2.1% (range 0.7–4.6%), TLDA at 
8.3% (range 0.3–19.1%) and DA at 9.5% (range 2.2–27.6%). 
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Figure 2-2. Platform co-efficient of variation analysis 
Lines indicate median and IQR. Boxplots (median, 10–90th percentile) of the CV distribution for (a) ViiA7, (b) 
TLDA, (c) OA and (d) DA.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
b 
a 
c 
d 
ViiA7 
TLDA 
OA 
DA 
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As an indicator of overall reproducibility, the fidelity of each platform was assessed. Fidelity 
was calculated as the percentage of replicates that differed by less than 1, 2 or 3 CT values 
and is presented as deviation from fidelity in Figure 2-3a-c and Figure 2-4. The standard 96-
well format attained 99.23% fidelity for both 1 and 2 CT values, and 100% fidelity for the 3 CT 
cut-off. Both OpenArray and Dynamic Array platforms performed capably; 88.1% (OA) and 
77.78% (DA) of replicates differed by less than 1 CT, 96.29% (OA) and 91.27% (DA) less than 2 
CTs, and 98.41% (OA) and 94.44% (DA) less than 3 CTs. Neither of the high-throughput 
technologies were able to attain 100% fidelity using these CT cut-off points. This variation of 
the CT values would effectively translate to ~8-fold difference in transcript abundance. It is 
worth noting that even if an 8-fold variation between replicates is considered acceptable, 
1.59% (OA) and 5.56% (DA) of replicates may still show greater than 8-fold variability. The 
TLDA platform was able to attain 92.68% fidelity using the 1CT cut-off, and 100% using a 2 or 
3 CT cut-off. However, due to a limited number of replicates run on this platform, it is not 
appropriate to compare this data to the other technologies, and so it is plotted on its own 
(Figure 2-4). CT values were then segregated into expression levels and the replicate variation 
plotted (Figure 2-3d-g, 2-4). Ultra-high expression was considered to be CT values less than 
10, high expression defined to be a CT value between 10.01 and 20.00, moderate expression 
between 20.01 and 30.00, and low expression above 30.01. Replicate variability increased 
across all platforms as the transcript abundance decreased. This was especially apparent in 
the high-throughput platforms, where replicate variability increased substantially when the 
transcript was present at moderate or low expression (Figure 2-3d–g). The 96-well plate 
platform (ViiA7) maintained a CT variation of less than 1 cycle until the target transcript was 
expressed at low levels (> 30.01 CT; Figure 2-3g).  
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Figure 2-3. Platform variability 
(a–c) Fidelity scoring using (a) 1 CT/CRT, (b) 2 CT/CRT or (c) 3 CT/CRT cut-off. Data is presented as deviation from fidelity 
(100%) and plotted as mean + SEM. (d–g) Tukey boxplots (median + IQR) of variation between replicates (maximum CT/CRT—
the minimum CT/CRT) for the f our expression levels, (d) ultra-high (CT/CRT < 10), (e) high (CT/CRT 10-20), (f) moderate 
(CT/CRT 20-30) and (g) low (CT/CRT > 30). Dotted line is 1, 2 or 3 CT/CRT cut-off used in fidelity scoring.  
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Figure 2-4. TLDA variability 
(a) Fidelity scoring using 1 CT/CRT, 2 CT/CRT or 3 CT/CRT cut-off. Data is presented as deviation from fidelity (100%) 
and plotted as mean + SEM. (b) Spread of variation between replicates (measured as the maximum CT – the minimum 
CT) for the four expression levels, ultra-high (CT<10), high (CT 10-20), moderate (CT 20-30) and low (CT>30). 
a 
b 
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The ViiA7 platform thus truly represents the “gold standard” amongst these qPCR platforms 
as any variation seen for such low level transcripts is potentially due to the Poisson distribution 
(190). When dealing with low copy transcripts, the Poisson distribution predicts that in a large 
number of replicates containing an average of one copy of starting template per reaction (rxn), 
approximately 37% rxns should actually have no copies, only 37% rxns should contain one 
copy, and 18% rxns should contain two copies (190). Therefore, reliable detection of single 
copy transcripts in any sample calls for a large number of replicates to assess statistical 
significance and overcome the limitations of Poisson distribution. 
2.5.3. Reproducibility 
To determine how reproducible the high-throughput technologies are, RNA extracted from 
human islet cells and serum was run twice on each of the high-throughput platforms by two 
different users. The average difference between the two sets of replicates is plotted in Figure 
2-5e,f. The OpenArray system produced reproducible results, with the greatest variation being 
2.06 cycles, whilst the Dynamic Array system demonstrated larger variation (up to 8.17 cycles). 
Interestingly, the second repeat on the Dynamic Array system produced consistently lower CT 
values. This may reflect an increased susceptibility of this platform to user variation. 
Calibrations performed between the two runs may also have impacted on the results.  
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Figure 2-5. High-throughput platform reproducibility 
 (a-d) RNA from islet cells and human serum was run twice on the (a,c) OA and (b,d) DA (same batch/lot). Data are median ± 
range. The average difference (boxplots, median and 25th – 75th percentile, whiskers min/max) between runs for each miRNA 
tested for cellular miRNAs is plotted in (e) and for serum miRNAs in (f). 
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2.5.4. MicroRNA Signature Detection  
One of the ultimate goals of most miRNA expression studies is to determine a biomarker 
signature related to particular pathology. To assess a biomarker signature for diabetic 
retinopathy (DR), we used unbiased small RNA sequencing of plasma samples from diabetic 
individuals with or without retinopathy. While analysing samples from subjects with (DR) and 
without (No DR; NDR) diabetic retinopathy (Figure 2.6a–d) we selected five miRNAs based on 
consistent differences between DR and NDR subjects and assessed the detection of such a 
“fingerprint” (Figure 2.6e) using the four different qPCR platforms. Furthermore, these five 
miRNAs were detected on all platforms tested. Although other miRNAs displayed a greater 
differential expression, they were unable to be detected using all of the platforms tested, 
usually due to the absence of the respective assays. We carried out rigorous analyses (Figure 
2.7) to compare differences in expression of this microRNA signature amongst DR and NDR 
subjects. Interestingly, these analyses demonstrate that the features of miRNA expression 
(denoted by shaded areas in Figure 2.7) retain their profile across three qPCR platforms - ViiA7 
(96-well), TLDA and OA platforms - whilst these same features appear skewed for the DA 
platform. As expected, the area and feature properties are different for the sequencing 
platform and vary between the DR and NDR groups amongst the sequencing profile. 
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Figure 2-6. A circulating microRNA signature for diabetic retinopathy (DR) 
Fundus photographs showing the clinical spectrum of DR: (a) a normal retina—no DR; (b) mild non-proliferative DR, with 
haemorrhages, microaneurysms and hard exudates; (c) non-proliferative DR; (d) proliferative DR (PDR), at the optic disc 
(white arrow) and pre-retinal haemorrhage in the inferior retina. (e) MicroRNAs consistently identified in plasma of age and 
gender matched diabetic individuals with or without severe DR (PDR) following analysis of small RNA sequencing (see text). 
The miRs that constitute part of the DR biomarker signature are displayed in red. 
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Figure 2-7. NDR and DR microRNA signature profiles 
Radar plots of miRNAs signature profiles from small RNA sequencing of two age and gender matched subjects (with (DR) and 
without (NDR) DR). Based on DR/NDR difference 5 miRNAs were chosen as a “DR biomarker signature”. Radar plots were 
generated using the CT/CRTs for these miRNAs on the four platforms. The results show the profile of the miRNA signature 
plot differs between NDR and DR in all platforms. The DA delivers a different miRNA signature profiles for DR and NDR. Radar 
plot axes are normalised reads for small RNA-Seq and CT/CRT for 96-well, TLDA, OA and DA.  
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2.5.5. Correlation and Cluster Analysis 
To determine intra-platform consistency, the correlation between platforms was analysed. 
We assessed 42 miRNAs (including the DR signature miRs) in four human subject samples (two 
islet cell samples and two serum samples; a total of 168 matched measurement pairs) and 
plotted these as pair-wise comparisons against ViiA7 (“gold standard”) platform for OA and 
DA (Figure 2.8). All platforms show good correlations with ViiA7, with the R2 values 0.88 and 
0.66 for OA and DA respectively. The TLDA platform had an R2 value of 0.91. The lowest 
compression was observed in OA platform (slope: 0.98) and TLDA (slope: 0.94) whereas DA 
platform showed the moderate compression with slope 0.81. 
Cluster analysis was implemented to determine the ability of these qPCR platforms in 
allocating miRNAs into distinct clusters. Each platform grouped the microRNAs into four 
distinct clusters (Figure 2.9). Again, the 96-well ViiA7 platform was used as the benchmark; 
clusters produced by the other platforms were directly compared to this “gold standard” 
(Figure 2.10). Comparison of all of the platforms (qPCR and small RNA-Seq) reveal that 
approximately 8% of miRNAs were assigned to different clusters by OA, 17% by TLDA, 28% by 
small RNA-Seq, and 39% by DA (Figure 2.10). 
Chapter 2  High-throughput qPCR technologies 
77 
 
 
Figure 2-8. Platform correlation 
Correlation of Z-scored transformed results between ViiA7 and either (a)TLDA, (b) OA or (c) DA. The hypothetical trend line 
of slope = 1 (dashed line) represents complete concordance, with the actual trend plotted as a solid line. The slope of the 
trend line (upper left corner) shows the deviation from 1. 
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Figure 2-9. Cluster analysis dendrograms   
Dotted line represents the cut-off value for the number of 
clusters (as determined by the Mojena rule). 
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Figure 2-10. MicroRNA cluster classification 
(a) MicroRNA clusters as classified by the ViiA7, OA, DA, and RNA-Seq. Highlighted miRNAs represent members 
belonging to the same cluster as those in the ViiA7 cluster analysis. (b) Percentage dot plot of miRNA cluster 
classification.  indicates the percentage of miRNAs that have been correctly classified as compared to the cluster 
analysis from the ViiA7 platform, while  indicates those that are misclassified. 8.33% of microRNAs were assigned 
to different clusters by OA, 16.66% by TLDA, 27.77% by RNA-Seq, and 38.88% by DA. 
O A
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R N A -S e q
27 .8%
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38 .9%
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2.6. Discussion 
The appeal of high-throughput technologies is readily apparent; they provide a significant 
decrease in sample processing time and reagents consumed, with a substantial increase in the 
volume of data generated in the same time. For researchers within the burgeoning field of 
miRNA biomarker research, such a tool is immensely desirable, especially when dealing with 
a multitude of clinical samples from large trials. Such assay performance would also be 
required should a miRNA profile related to diabetes reach clinical practice. It is imperative that 
technologies used for quantitative research or in clinical practice be accurate, sensitive and 
reproducible, and high-throughput platforms must present a similar (if not greater) level of 
reproducibility offered by current high sensitivity/low-throughput platforms. 
The two high-throughput technologies discussed here represent the two most contemporary 
high-throughput qPCR platforms. The Dynamic Array platform offers a finely crafted plate with 
a set of individually pressure-tested valves that control the flow of reagents into the 
microfluidic plate. The OpenArray platform provides a high density PCR plate/slide that allows 
automated sample loading using a specially designed robotic device (Accufill™). The major 
difference is that the OpenArray comes with pre-printed miRNA assays while the Dynamic 
Array provides flexibility to choose the miRNA assays just before setting up the plate. The DA 
platform thus provides only the “hardware” for users to perform qPCR. Although this flexibility 
is an advantage, the limitation of the DA is that it heavily depends on the compatibility of the 
pooled RT primers with the TaqMan real-time PCR assays. Of the 48 miRNAs selected from the 
TaqMan primer pool A (Life Technologies, CA) six of these assays could not be read on the DA 
due to incompatibility between the RT and PCR primers. Since the proprietary primer pools 
are compatible with the primers printed in TaqMan Low Density Arrays (TLDAs) or OpenArray 
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plates only, the individual assays available from Life Technologies may not be compatible with 
the multiplex RT pools. Of course, users can avoid this by ordering customised primer pools 
from Life Technologies to assess a specific set of miRNAs. 
In our analysis, the OpenArray system was the most reproducible high-throughput platform 
tested, with less inter- and intra-run variation than the Dynamic Array. This conclusion 
correlates with a recent study comparing these platforms for screening genomic mutations in 
the Ashkenazi Jewish community (191). The OA platform also proffers a simple, cost-effective 
workflow, with user-friendly software for further analyses. 
Our data demonstrate that replicate variability was exacerbated when quantifying low 
abundance transcripts on any of the platforms. As shown in Figure 2-3, this variability is 
especially apparent in the high-throughput platforms, highlighting a limitation of these 
systems. Screening low abundance transcripts on these platforms should be avoided, as even 
the implementation of a pre-amplification step was insufficient to reduce CT variability. 
Increasing the number of pre-amplification cycles is not recommended as it would amplify any 
bias that is introduced in the process. Users of Dynamic Arrays could expect 5.6% of their 
assays to demonstrate more than 8-fold variability. Any data obtained using DAs with 
differences less than or around 8-fold need to be re-validated using a high sensitive PCR 
technology, such as the 96-well platform described herein. For miRNAs detected around a CT 
value of 30, the standard qPCR format proves more reliable. 
For medium-throughput studies, researchers can utilise the TLDA platform. We found a 
comparable level of reproducibility on this platform when using cards from the same lot, but 
have observed considerable (13.9%) lot-to-lot variation (188). 
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Correlation between technologies is required to translate relative gene expression data on 
different qPCR platforms. Since CT values cannot be directly compared across platforms due 
to the differences in sample preparation, reaction volume and detection technologies, 
correlation between z-scored transformed data (Figure 2.8) is a reliable method to compare 
the data obtained from multiple qPCR technologies. All of the technologies assessed 
correlated well with the standard 96-well platform, however the OpenArray platform deviated 
the least from the theoretical ideal value of 1, demonstrating that it correlates extremely well 
with the staple 96-well format. As such, up or down scaling miRNA qPCR reactions between 
the ViiA7 and OA platforms will produce parallel data. 
Segregation of miRNAs based upon their expression profile is useful for biomarker 
identification. Our cluster analysis (Figures 2.9 and 2.10) demonstrated that data obtained 
from all platforms were able to create four distinct miRNA clusters; however, the members of 
these clusters differed between the platforms. The Dynamic Array generated fundamentally 
different clusters, making it difficult to identify our test DR miRNA signature (generated 
through smallRNA sequencing). The OpenArray platform generated the most similar clusters 
(compared to 96-well), with similar segregation of miRNA DR signature members into clusters 
giving confidence in validating disease-related microRNA signatures. Although quantitative 
real time PCR platforms have different sensitivities and efficacies for reproducing the miRNA 
DR signature we assessed the similarity in data obtained from qPCR versus our sequencing 
platform. Interestingly, the small RNA-Seq data also generated four distinct clusters, with 27% 
of the miRNAs misassigned to the four clusters. This may be due to the fact that qPCR and 
next generation sequencing employ vastly different chemistries to quantitate miRNAs and 
that the outcome of such comparisons would be largely impacted by the depth of sequencing 
achieved. 
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The miRNA signature profile generated by our small RNA sequencing, although representative, 
demonstrates the importance of rigorously analysing new technologies, especially those that 
may become routine for biomarker discovery and validation and potentially be used in clinical 
practice. Figure 2.7 demonstrates the differences in miRNA signature profile detected by 
multiple platforms. 
This report demonstrates the importance of multiple technical factors that can influence the 
conclusions derived from miRNA qPCR data. Although there are differences in the respective 
detection systems (QuantStudio for OpenArrays, Biomark HD for Dynamic Arrays), the size of 
the reaction may also affect the reproducibility of these high-throughput systems. Although 
both platforms have a reaction volume in nanoliters, the OpenArray reaction volume is 2.2-
fold more than the Dynamic Arrays. During the optimisation of our standard (96-well) qPCR 
analysis for detection of low-copy miRNA/mRNA transcripts, the amplification curves differed 
by 0.5 cycles when the reaction volume was reduced from 10 µl to 5 µl (not shown here. 
Considering the Poisson distribution of miRNA templates, this difference can be significant 
when more than two-fold difference is factored in, even at the nanoliter range.  
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2.7. Conclusions 
The data presented within this chapter demonstrate that the OpenArray system provides the 
greatest reproducibility of the micro- and nano-fluidic platforms assessed, and this is evident 
when quantitating both cellular and circulating miRNAs. When compared to the gold-standard 
96-well plate system, however, all platforms demonstrated increased variability. This was 
especially apparent when attempting to quantify low abundance transcripts – a probable 
consequence of increased throughput and decreased reaction volume. Interestingly, these 
studies also highlighted the impact of technology on the characterisation of a circulating 
miRNA signature. The representative DR signature, obtained from NGS studies, displayed a 
markedly different profile when quantitated on the DA platform.  
Although each of the platforms discussed have their own advantages/disadvantages, users 
need to consider all aspects before choosing an analytical platform, and ideally should test 
their data across another high-sensitivity platform such as the 96-well platform. These 
observations provide a useful guide for researchers planning to switch to high-throughput 
qPCR technologies for quantitative assessment of gene transcripts in large number of 
research/clinical trial samples. Furthermore, the development of a sensitive, reliable and 
minimally invasive test with high predictive power for clinical stratification of DR will provide 
a surrogate marker for clinical trials, improve prognosis information and guide development 
of future therapies aimed towards preventing the vascular complications of diabetes. 
Similar studies as performed herein are likely merited in the future with the refinement of 
existent systems and likely development of novel systems.  
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3. In Vitro and In Vivo Models of β-cell Death 
3.1. Chapter Overview 
Pancreatic β-cell death and immune cell infiltration are characteristic of the progression to 
T1D. To understand if these processes result in a significant and detectable release of miRNAs 
and cfDNA, two models of β-cell death were employed. The first (in vitro) model exposed 
primary human islets cultured in a defined (serum-free) medium to sodium nitroprusside 
(SNP), a compound known to initiate apoptosis through the generation of nitric oxide (NO) 
(192) or hydrogen peroxide (193). Exposure to SNP for 24 hours resulted in an increase in islet 
cell death (measured by DNA fragmentation). The two highest concentrations (1 and 10 mM) 
caused some miRNAs, but not others, to be significantly released into the surrounding 
supernatant. This affirms our hypothesis that only select miRNAs are released in response to 
islet cell stress/death, leading to a circulating miRNA signature. A 1 mM SNP concentration 
also caused a significant release of both unmethylated and methylated Ins cfDNA into the 
defined culture medium, however 10 mM did not demonstrate a dose-dependent increase, 
indicating that the cfDNA may have been either rapidly degraded or reached a saturation level 
for release into the surrounding cellular environment.   
To emulate the progression to T1D in an in vivo model system, non-obese diabetic (NOD) mice 
were assessed at 4 to 18 weeks of age. NOD mice demonstrate immune cell infiltration of the 
pancreatic islets, β-cell destruction and a significant increase in blood glucose levels (BGLs), all 
of which are confirmed within this chapter. Circulating candidate miRNAs were elevated prior 
to immune cell infiltration and the dysfunction of glucose homeostasis, and demonstrate 
significant correlation with fasting BGLs. In contrast, other miRNAs are stable within the NOD 
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circulation. These data highlight important miRNAs that are released in response to β-cell 
stress/death using in vitro (human) as well as in vivo (mouse) model systems.   
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3.2. Chapter Aims 
Studies in this chapter aimed to: 
1. assess the miRNA and cfDNA release in response to SNP-mediated human islet cell 
death. 
2. quantitate circulating miRNA abundance in NOD mice during diabetes progression. 
3. identify any associations between circulating miRNAs and measures of β-cell function. 
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3.3. Methods 
3.3.1. Cadaveric Islets 
Cadaveric human islets were kindly provided by Associate Professor Wayne Hawthorne and 
his surgical team at the Westmead Institute, Sydney Australia and Professor Tom Kay and his 
surgical team at the St Vincent’s Institute, Melbourne Australia.  Islets were generally obtained 
from cadaveric pancreas harvested from brain dead donors.  The best islet quality/numbers 
were from pancreas of younger and heavier donors with minimal intensive care stay period 
and with short cold/warm ischaemic times (61; 194).  Islets that were consented for research 
and were not of the desired quantity/quality to progress into clinical islet transplantation were 
made available to the Hardikar Lab within 24-48 hours of isolation.  Islets from Melbourne and 
Sydney isolation centers were delivered on wet ice and used for the in vitro experiments 
discussed herein.  
3.3.2. Sodium Nitroprusside (SNP) Exposure 
Primary cadaveric human islets were exposed to SNP for 24 hours as per the protocol outlined 
in Appendix G. SNP exposure was conducted at 1 µM, 10 µM, 100 µM, 1 mM and 10 mM. 
3.3.3. Flow Cytometry 
SNP-induced islet cell death was assessed using flow cytometry as outlined in Appendix L. 
Briefly, cell death was analysed by separating islets into a single cell suspension and then 
placing them into a hypotonic buffer containing propidium iodide (PI) to lyse the cells and 
stain the nuclei. Flow cytometry was then used to assess the size of the nuclei – dying/dead 
cells have fragmented nuclei, resulting in hypodiploid DNA.   
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3.3.4. Non-Obese Diabetic (NOD) Mice  
Female NOD mice (N=32) were received in two groups of 16; one group was received at 3 
weeks of age and studied from 4 weeks of age to 10 weeks of age, while the other group was 
received at 11 weeks of age and was studied from 12 weeks of age to 18 weeks of age. Four 
mice were randomly placed into each cage at the beginning of the study; all mice were fed on 
an ad libitum chow diet with unrestricted access to food and water. Each cage was placed in 
the same room in the middle rack and were exposed to the same day/night schedule. Every 
two weeks, one cage was fasted overnight for 12-14 hours and all four mice then had plasma, 
pancreas, liver (and other tissues) collected as per the protocol outlined in Appendix G. Fasting 
blood glucose concentration (BGL) was recorded as blood was collected via cardiac puncture. 
Sufficient plasma was unable to be collected from one mouse at week 4 so miRNA results were 
not obtained. Pancreas and liver samples were stored in 4% paraformaldehyde then given to 
the Royal Prince Alfred Hospital Pathology Department for paraffin embedding, sectioning, 
and Haematoxylin and Eosin (H&E) staining. Liver sections were used as negative controls for 
both H&E staining and immunohistochemistry.  All tissues from a mouse were incorporated in 
a single block to assess the immunostaining and histochemistry for pancreatic as well as non-
pancreatic tissues in a single section. 
3.3.5. Immunohistochemistry 
Pancreas and liver paraffin sections were stained for insulin and glucagon expression using the 
protocol outline in Appendix K. Insulin was detected using primary polyclonal guinea pig anti-
insulin antibodies (Dako) at 1:100 dilution, and secondary anti-guinea pig Alexafluor 488 
antibodies (Invitrogen) at 1:100 dilution. Glucagon was detected using mouse polyclonal anti-
glucagon antibodies (Sigma) at 1:400 dilution, and secondary anti-mouse Alexafluor 546 
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antibodies (Invitrogen) at 1:100 dilution. Stained slides were visualised using the Zeiss 510 
Meta scanning laser confocal microscope. All thresholds were set below saturation, and all 
other parameters (including laser power) were identical for all samples. Dye swaps for 
secondary antibodies were carried out to confirm specificity and staining on a subset of these 
samples. 
3.3.6. RNA Isolation 
RNA was isolated from NOD mice EDTA-plasma using the protocol outlined in Appendix B. RNA 
from cell culture media was isolated using the protocol outline in Appendix B or C. Cellular 
RNA was isolated using the protocol outlined in Appendix A. RNA was quantitated using a 
spectrophotometer.  
3.3.7. MicroRNA Quantitation 
Candidate miRNAs were identified through previous work from the Hardikar lab (discussed in 
Section 1.7) and through literature searches. MicroRNA abundance was measured using the 
custom high throughput qPCR protocol outlined in Appendix D.  To remove non-specific 
amplification, results with an AMP score of <1.24 and/or a Cq confidence score of <0.6 were 
omitted. Results were normalised to the RNA isolation and RT ath-miR spike-in miRNAs (see 
Supplementary Chapter 1 for optimisation). Transcript abundance was calculated using the 
fold over detectable method (limit of detection = 39) described earlier (190). 
3.3.8. Cell-free DNA Isolation and Bisulfite Conversion 
Cell-free DNA was isolated from the cell culture media after islet SNP exposure as per the 
protocol outlined in Appendix E. All samples underwent one freeze-thaw prior to cfDNA 
isolation. Bisulfite conversion was completed as per the protocol outlined in Appendix I.  
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3.3.9. Insulin cfDNA Quantitation 
Methylated and unmethylated insulin cfDNA were quantified using the digital droplet PCR 
protocol outlined in Appendix J. Each plate contained a positive control, which consisted of a 
mixture of control plasmids (10% unmethylated, 90% methylated plasmid, 1 ng total per 
reaction), and a no template control (nuclease-free water). Control plasmids, kindly provided 
by Professor Raghu Mirmira (Indiana University, Indianapolis, Indiana, USA) as part of an 
existing collaboration with A/Prof. Hardikar, were amplified using the transformation protocol 
outlined in Appendix H. FAM and VIC thresholds were identified based on the positive control 
and then applied to the entire plate.   
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3.4. Results 
3.4.1. SNP Exposure Causes Cell Death in Primary Human Islets 
Primary human islets were allowed to recuperate in serum-free media for atleast 14 hours 
prior to culture in the presence of increasing concentrations of SNP for 24 hours. After this 
time, the islets demonstrated consistent morphological changes indicative of cell death, 
including blebbing and fragmentation, which is particularly evident in the higher 
concentrations. The highest concentration of SNP, 10 mM, resulted in striking morphological 
changes, indicating that this concentration is highly cytotoxic and may also cause necrosis. 
Figure 3-1 contains representative photographs of human islets prior to exposure and after 24 
hours of SNP exposure.  
To confirm the apoptotic and/or necrotic effect of SNP, the nuclei of the islet cells were 
assessed using flow cytometry (Figure 3-2). During such apoptotic cell death, the genomic DNA 
is fragmented, causing a decrease in PI staining. Normal diploid nuclei in the control islets 
cultured in media without SNP (Control, Figure 3-2a) have the highest percent of live cells. 
Hyperdiploid nuclei are seen to the right (increasing PI fluorescence) of the diploid nuclei, 
indicating cells that were within or had completed the S-phase of the cell cycle prior to mitosis. 
Hypodiploid (fragmented or degraded) nuclei show reduced PI fluorescence. Reflecting the 
images seen in Figure 3-1, 10 mM SNP results in extensive cell death and fragmented DNA 
(Figure 3-2f). 
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Figure 3-1. Human islets during SNP exposure  
Representative images of human primary islets prior to SNP exposure (Pre-exposure) and after 24 hours cultured with serum-
free media only (0µM) or serum-free media containing differing concentrations of SNP as indicating above each panel. All 
images were taken from a single experiment using islets from a single donor. Bar=50μm (all panels except insets).  
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Figure 3-2. SNP causes an increase in DNA fragmentation 
(a) Representative flow cytometry results showing an increase cell death with exposure to SNP. (b) Combined results showing 
a significant increase in cell death at 10 mM SNP. Mean ± SEM. ** P<0.01 (unpaired t-test). All comparisons were made with 
reference to 0 µM. N = 2-3 independent experiments. 
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3.4.2. Islet Cell Death Causes a Release of MicroRNAs and Cell-Free DNA 
A significant increase in the abundance of 27 miRNAs was found within the supernatant of 
human islets cultured in the presence of 1 and 10 mM SNP (Figure 3-3). As shown in the 
previous section, these concentrations result in increased cell death, leading to the release of 
these miRNAs. When the abundance of these 27 miRNAs was quantified within the cellular 
fraction, a significant decrease was found in the islets exposed to 10 mM only (Figure 3-4). 
This suggests that 1 mM SNP results in an active release of these candidate miRNAs in 
response to the cellular stress. Meanwhile, 10 mM indicates a significant release of the cellular 
miRNAs due to membrane rupture, a hallmark of necrosis.  
Not all miRNAs that were measured demonstrated an increased or dose-dependent release 
during SNP exposure (Figure 3-5). Intriguingly, two of these miRNAs are commonly utilised 
“housekeeping” small nucleolar RNAs, U6 and RNU44.   
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 Figure 3-3. Islet SNP exposure causes a release of miRNAs 
27 miRNAs were increased in the cell supernatant following a 24-hour exposure to SNP.  Mean ± SEM. * P<0.05 ** P<0.01 
*** P<0.001 (t-test, deviation from 100%). N = 6-7 islet preps for all concentrations apart from 10 mM (N = 3 islet preps). 
Each islet preparation was conducted in multiple technical replicates.  
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 Figure 3-4. Islet SNP exposure causes a decrease in cellular miRNAs 
The same 27 miRNAs (as shown in Figure 3-3) were found to be reduced in the cells exposed to 10 mM SNP. Mean ± SEM. ** 
P<0.01 **** P<0.0001 (t-test, deviation from 100%). N = 6-7 islet preps for all concentrations apart from 10 mM (N = 3 islet 
preps). Each islet preparation was conducted in multiple technical replicates.  
m iR -7 le t -7 e m iR -1 0 3 m iR -1 2 5 a -5 p m iR -1 2 5 b m iR -1 2 7
1
1 0
1 0 0
1 ,0 0 0
P
e
r
c
e
n
t 
(%
)
o
f 
C
o
n
tr
o
l 
(L
o
g
1
0
)
1  M 10  M 1 0 0  M 1  m M 1 0  m M
**** **** **** **** **** ****
m iR -1 4 6 a m iR -1 5 b m iR -1 6 m iR -1 8 6 m iR -2 0 0 a m iR -2 0 a
1
1 0
1 0 0
1 ,0 0 0
P
e
r
c
e
n
t 
(%
)
o
f 
C
o
n
tr
o
l 
(L
o
g
1
0
)
** **** **** **** **** ****
m iR -2 2 2 m iR -2 4 m iR -2 5 m iR -2 6 a m iR -2 6 b m iR -2 7 b
1
1 0
1 0 0
1 ,0 0 0
P
e
r
c
e
n
t 
(%
)
o
f 
C
o
n
tr
o
l 
(L
o
g
1
0
)
**** **** **** **** ********
m iR -2 9 a m iR -3 0 a -5 p m iR -3 0 b m iR -3 0 c m iR -3 7 4 m iR -3 7 5
1
1 0
1 0 0
1 ,0 0 0
P
e
r
c
e
n
t 
(%
)
o
f 
C
o
n
tr
o
l 
(L
o
g
1
0
)
**** **** **** **** **** ****
m iR -9 2 a m iR -9 9 b m iR -9 3
1
1 0
1 0 0
1 ,0 0 0
M ic ro R N A
P
e
r
c
e
n
t 
(%
)
o
f 
C
o
n
tr
o
l 
(L
o
g
1
0
)
**** **** ****
In t r a -c e llu la r
1 μM 10 μM 00 μM 1 mM 10 mM 
 
Chapter 3  In vitro and in vivo models 
98 
 
 
 Figure 3-5. Other miRNAs are not released in response to SNP exposure 
SNP mediated islet cell death does not cause a significant, or dose-dependent, release of some miRNAs into the cell culture 
supernatant. Mean ± SEM. * P<0 .05 ** P<0.01 (t-test, deviation from 100%).  N = 6-7 islet preps for all concentrations apart 
from 10 mM (N = 3 islet preps). Each islet preparation was conducted in multiple technical replicates.  
 
Both unmethylated and methylated Ins cfDNA was significantly released by islets cultured in 
the presence of 1 mM SNP (Figure 3-6), mirroring the miRNA release seen in Figure 3-3. When 
exposed to 10 mM, however, the unmethylated cfDNA did not demonstrate a dose dependent 
increase. Methylated Ins DNA copies were not significantly increased in response to 10 mM 
SNP. The increase cytotoxic effect of 10 mM SNP, and the associated DNA fragmentation 
(Figure 3-2), is likely to result in the reduction in detectable cfDNA copies.  
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Figure 3-6. Cell-free DNA release due to SNP exposure 
N = 6-7 islet preps for all concentrations apart from 10 mM (N = 3 islet preps). Each islet preparation was conducted in multiple 
technical replicates. Mean ± SEM. * P<0.05 ** P<0.01 (t-test, deviation from 100%). 
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3.4.3. NOD Mice Demonstrate Immune Infiltration and Loss of Glucose 
Homeostasis 
To model the progression of T1D, NOD mice were housed between 4 to 18 weeks of age, with 
four mice euthanised every two weeks and samples taken as per Figure 3-7. Due to the volume 
of plasma needed for RNA isolation and miRNA quantitation, the blood had to be collected via 
terminal cardiac puncture and so the study was cross-sectional in nature. The mice developed 
normally, with consistent total and pancreas weight gain over time (Figure 3-8). Fasting BGLs 
started to rise around 10 weeks of age and became significantly higher at 12 weeks of age 
(Figure 3-9), consistent with previous reports. The fasting BGLs of the mice at 16 and 18 weeks 
of age were lower, albeit not significantly so, than those at 12 and 14 weeks of age. All mice 
were housed and treated identically, however, as the study was cross-sectional and consisted 
of two groups of animals, inter-animal differences may be observed. Furthermore, changes in 
stress levels, possibly due to unavoidable construction noise at the Medical Foundation 
Building during the later time points in the study, unintentional changes in diet manufacturer 
and the use of non-sterile water provided by the facility to these mice, as well as batch 
variations in the glucose testing strips may also impact upon the BGL readings during the later 
time points for this study.  
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 Figure 3-7. Overview of NOD mouse procedure 
Every two weeks (from 4-18 weeks of age) four NOD mice were euthanased, and whole blood, ETDA-plasma, pancreas and 
liver samples were taken. Red arrows indicate the samples, while blue arrows indicate the downstream analysis.  
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Figure 3-8. NOD mice total body and pancreas weight 
(a) Total body weight and (b) pancreas weight of the NOD mice at each age group. Mean ± SEM N = 4 mice/group. 
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Figure 3-9. NOD mice fasting blood glucose levels 
NOD mice were fasted for 12-14 hours overnight prior to BGL measurement. N = 4 mice at each timepoint. Mean ± SEM. Red 
and blue indicate the two groups of mice used (see section 3.3.4). Hatched bars indicate time points that were omitted for 
further analysis, possibly due to reasons discussed in section 3.4.3. * = P<0.05 ** = P<0.01 ***= P<0.001. ANOVA with post-
hoc Tukey’s multiple comparisons test.  
 
The accumulation of immune cells within the periductal areas of the pancreas (peri-insulitis) 
and within the islets themselves (intra-insulitis) became evident at 6-weeks of age 
(Figure 3-10). The degree of insulitis was quantified by one investigator using an insulitis score, 
with 0 = no insulitis, 1 = peri-insulitis with up to 25% of the islet area showing immune 
infiltration, 2 = 25-50% infiltration, 3 = 50-75% infiltration, and 4 = greater than 75% 
infiltration. Examples of islets fitting each of these categories can be found in Figure 3-10b.  
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A noticeably large drop in islets with no insulitis (from 85.3% to 44.8%) can be seen between 
6 to 8 weeks of age, prior to the increase in fasting BGL seen in Figure 3-9. Another drop (41.4% 
to 12.4%) can be seen between 10 and 12 weeks of age as the BGLs significantly increase. By 
18 weeks of age, only 1.9% of islets are free from insulitis. No immune infiltration was 
observed within liver sections from the same mice. 
The extensive immune infiltration seen in these animals causes a reduction in insulin 
expression. Figure 3-11 contains representative images from animals at all time points; 
immune cells are clearly visible, with insulin staining reduced within the area of infiltration. 
This is especially evident within the 12-week image (Figure 3-11e), where insulin, but not 
glucagon, staining is reduced in the periphery of the islet where numerous immune cells have 
infiltrated. Figure 3-11h demonstrates a quintessential T1D islet; there is no insulin present, 
indicating a loss of β-cells, but glucagon staining remains substantial, indicating the presence 
of significant numbers of α-cells. No insulin or glucagon staining was seen within liver sections 
from the same mice, which were used as a negative control.    
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Figure 3-10. NOD insulitis scores 
(a) Percentage of islets scored as 0 (no insulitis), 1 (peri-insulitis with up to 25% infiltration), 2 (25-50% infiltration), 3 (50-75% 
infiltration), or 4 (>75% infiltration). Percentages were based on H&E stained islets from four mice at each time point, with 
multiple layers being analysed. (b) Representative photos of islets with insulitis scores of 0, 1, 2, 3 or 4. N = 4 mice per time 
point. Total islet numbers used for calculations = 106 (4wk), 95 (6wk), 145 (8wk), 133 (10wk), 89 (12wk), 64 (14wk), 133 
(16wk), 106 (18wk).  
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Figure 3-11. Immunostaining of NOD mice islets. 
Representative images of insulin (green), glucagon (red) and DNA (blue) stained NOD mice islets at (a) 4, (b) 6, (c) 8, (d) 10, 
(e) 12, (f) 14, (g) 16, and (h) 18 weeks of age.  
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3.4.4. Circulating MicroRNAs in NOD Mice 
MicroRNA quantitation revealed that a subset of circulating miRNAs was elevated in young 
NOD mice, prior to significant insulitis and the development of elevated fasting BGLs 
(Figure 3-12). Due to the abnormally low fasting BGLs of the 16 and 18 week old mice, miRNA 
abundance trend analysis was conducted both with and without the results from these mice. 
The overall abundance of these miRNAs decreases over time, with a significant linear trend. 
The abundance of miR-375, a miRNA that has been identified within the circulation of this 
mouse model previously (156), can be seen in Figure 3-13. Its abundance spiked in the 
circulation of mice at 8-weeks of age, although the increase was not a statistically significant 
one.   
Not all circulating miRNAs that were measured demonstrate this pattern of abundance. 
Figure 3-14 details seven miRNAs that were stable within the circulation of NOD mice 
throughout all time points. This suggests that the miRNAs identified in Figure 3-12 have an 
association with the progression to diabetes within this murine model. 
Furthermore, to assess whether there was an association between circulating miRNAs and β-
cell function, their abundance was compared to the fasting BGL of the same mouse. As above, 
the abnormal fasting BGL results of the 16 and 18 week old mice necessitated analysis with 
and without these mice. The correlations were strengthened by omitting data from 16 and 18 
week old mice. Interestingly, 17-18 miRNAs were found to have a significant correlation with 
fasting BGL (Figures 3-15 and 3-16). As with age, the correlation was negative, and so a higher 
miRNA abundance is indicative of a lower fasting BGL. This strengthens the potential of these 
miRNAs as indicators or predictors of β-cell function.  
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Figure 3-12.1. Circulating miRNAs change in abundance with age of NOD mice 
Circulating miRNAs decrease over time and significantly correlate with age. Mean ± SEM. Linear trend, P<0.05 significant. 
Linear trend P-values are presented below of the respective graph, with the results from 16 and 18 weeks of age included 
(Incl. 16 & 18 Wks) and excluded (Excl. 16 & 18 Wks). Hatched bars are indicative of omitted groups. N = 4 mice at each time 
point, except 4 weeks (N=3, see section 3.3.4). * P<0.05 (Kruskal-Wallis non-parametric ANOVA with corrected Dunn’s 
multiple comparison test). 
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 Figure 3-12.2. Circulating miRNAs change in abundance with age of NOD mice 
Circulating miRNAs decrease over time and significantly correlate with age. Mean ± SEM. Linear trend, P<0.05 significant. 
Linear trend P-values are presented below of the respective graph, with the results from 16 and 18 weeks of age included 
(Incl. 16 & 18 Wks) and excluded (Excl. 16 & 18 Wks). Hatched bars are indicative of omitted groups. N = 4 mice at each time 
point, except 4 weeks (N=3, see section 3.3.4). * P<0.05 (Kruskal-Wallis non-parametric ANOVA with corrected Dunn’s 
multiple comparison test). 
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Figure 3-12.3. Circulating miRNAs change in abundance with age of NOD mice 
Circulating miRNAs decrease over time and significantly correlate with age. Mean ± SEM. Linear trend, P<0.05 significant. 
Linear trend P-values are presented below of the respective graph, with the results from 16 and 18 weeks of age included 
(Incl. 16 & 18 Wks) and excluded (Excl. 16 & 18 Wks). Hatched bars are indicative of omitted groups. N = 4 mice at each time 
point, except 4 weeks (N=3, see section 3.3.4).  
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Figure 3-13. MicroRNA-375 abundance peaks at eight weeks of age. 
Mean ± SEM. N = 4 mice at each time point, except 4 weeks (N=3, see section 3.3.4). Hatched bars are indicative of groups 
omitted from other analyses. 
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Figure 3-14. Other circulating miRNAs are stable in NOD mice 
Seven of the miRNA tested show no significant differences or trends between age groups of NOD mice (with or without 
omitted groups).  Mean ± SEM. N = 4 mice at each time point, except 4 weeks (N=3, see section 3.3.4). Hatched bars are 
indicative of groups omitted from other analyses. 
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Figure 3-15. Circulating microRNAs correlate with fasting blood glucose in NOD mice 
(a) 17 miRNAs were found to significantly correlate with the fasting BGLs in NOD mice. (b) Three representative miRNAs were 
plotted against the respective fasting BGL using Spearman ranks. Colours correspond to highlighted miRNAs in (a). The line 
of best fit (solid) with 95% confidence interval (dotted) is shown. N = 27 mice. Spearman correlation, significance P<0.05.  
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Figure 3-16. Circulating microRNAs demonstrate stronger correlation with fasting blood glucose in NOD mice with 16 and 
18 week old groups omitted 
(a) 18 miRNAs were found to significantly correlate with the fasting BGLs in NOD mice. (b) Three representative miRNAs were 
plotted against the respective fasting BGL using Spearman ranks. Data from 16 and 18 week old mice were omitted. Colours 
correspond to highlighted miRNAs in (a). The line of best fit (solid) with 95% confidence interval (dotted) is shown. N = 27 
mice. Spearman correlation, significance P<0.05.  
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3.5. Discussion 
In vitro and in vivo models are often utilised to understand and investigate the intricate 
molecular mechanisms underlying human diseases, such as T1D. They allow researchers to 
view aspects of disease progression, and its potential molecular mechanisms, in a controlled 
environment. Within this chapter, two models were used to investigate the central 
pathophysiology of T1D: β-cell death and immune infiltration. While it must be noted that 
models such as these may not always translate well to the human condition, they are a cogent 
starting point that inform subsequent clinically-focused investigations (Chapters 4 and 5).  
3.5.1. Replicating Islet Cell Death In Vitro 
To replicate islet cell death, primary human islets were cultured in the presence of SNP. As 
this compound is metabolised, it first releases nitric oxide and then subsequently hydrogen 
peroxide, both of which have been identified as the cause of SNP’s apoptotic properties (192; 
193). SNP has been utilised for over 20 years to cause cell death in pancreatic islets, with NO 
highlighted as the causative agent in these cells (192). Indeed, streptozotocin (STZ), a 
compound with selective β-cell toxicity used to initiate diabetes in animal models, may also 
function through the generation of NO (195).  
SNP was selected to induce islet cell death over more selective β-cell toxins, such as STZ and 
alloxan, as the investigation was focused on the response of cellular stress and death of the 
entire islet. While β-cells are the clear victim of immune-mediated T1D, the surrounding cells 
must also undergo cellular stress as they are caught in the metaphorical cross-fire. Indeed, a 
reduction of α-cells in patients with T1D (especially fulminant T1D) has been demonstrated 
previously (196). In support of this, the majority of T1D-associated antigens, such as ICA and 
GAD, have been found on all endocrine cells, rather than just β-cells (197). Furthermore, STZ 
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and alloxan both gain entry to β-cells through the GLUT2 transporter; rodent β-cells have an 
abundance of GLUT2, while human β-cells predominantly utilise GLUT1 (198). This may explain 
the documented resistance of human islets to STZ-mediated β-cell death (199).  
As shown within this chapter, SNP exposure results in significant cell death, with the islets 
exhibiting morphological signs of apoptosis, such as blebbing (Figure 3-1). An increase in DNA 
fragmentation and hypodiploid nuclei (Figure 3-2) – a marker of cell death – was also 
demonstrated, mirroring previous studies (192). The highest concentration, 10 mM, caused 
rapid cellular disintegration and DNA fragmentation (Figure 3-2f), highlighting the cytotoxicity 
of SNP at this concentration.  
3.5.2. In Vitro MicroRNA and Cell-free DNA Release 
The cellular stress and death that resulted from SNP exposure caused the release of both 
miRNAs and cfDNA into the surrounding supernatant (Figures 3-3 and 3-6). Twenty-seven 
miRNAs displayed a significant, dose-dependent release at 1 and 10 mM, however, the cellular 
abundance of these miRNAs was only reduced in those islets exposed to 10 mM SNP 
(Figure 3-4). This suggests that 1 mM SNP initiated an active cellular release of these miRNAs, 
while 10 mM caused leakage of miRNAs due to a significant rupturing of the plasma 
membrane. Some of these miRNAs have been identified as important for islet development 
and function, such as miR-375 (101) and miR-7 (83), while others, such as miR-92a, have not. 
Whether these miRNAs have a previously unknown islet function, or are only released in 
response to stress, requires additional investigations. As these 27 miRNAs are stable after 
active and passive release into the extracellular environment, they display immense potential 
as biomarkers of islet stress and islet death.  
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Interestingly, it was only a subset of miRNAs that exhibited a significant, dose-dependent 
release. Other ncRNAs, such as those outlined in Figure 3-5, are either not released due to 
islet stress/death, or are rapidly degraded upon exiting a cell. The former explanation is more 
likely, as miRNAs display impressive stability once outside the cell (discussed in Section 1.5.1.). 
Two of these are the commonly used “housekeeping” small nucleolar (sno)RNAs, U6 and 
RNU44. Both of these snoRNAs are highly expressed within animal cells, and so it is intriguing 
that their extra-cellular abundance did not increase in response to cell death. This gives weight 
to the notion that the release of specific miRNAs can be used as a signature of islet cell 
stress/death. 
Methylated and unmethylated cell-free Ins DNA displayed a slightly different pattern of 
release. Both cfDNA species increased their copy numbers within the supernatant after human 
islets were exposed to 1 mM SNP, however 10 mM caused them to plateau (unmethylated) 
or decrease (methylated), suggesting subsequent degradation (Figure 3-6). The immense cell 
death evident after 24 hours in 10 mM SNP is likely to have released the entirety of the cellular 
contents of a large number of islet cells into the extracellular milieu. Unlike miRNAs, cfDNA is 
not complexed with microvesicles, apoptotic bodies or lipoproteins; this leaves it vulnerable 
to degradation by endogenous nucleases. This conclusion correlates with previous studies that 
have found cfDNA’s half-life to be exceptionally short (minutes to hours) within the peripheral 
circulation (163; 164). Alternatively, the release of cfDNA may reach a saturation threshold, 
causing a plateu of cfDNA abundance in cells treated with ≥1mM SNP. 
3.5.3. Modelling Immune Infiltration and T1D Progression 
Since its generation in 1980 (173), the NOD mouse model has been extensively used to 
investigate the progression of autoimmune diabetes. These mice develop extensive immune 
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infiltration and spontaneously exhibit polyuria, hyperglycaemia and lowered plasma insulin 
concentrations around 12 weeks of age (173). Interestingly, the incidence of diabetes is highly 
variable within this model. Unlike humans, there is a clear link between the incidence of 
diabetes of the sex of the NOD mouse; 80-90% of female mice develop diabetes, while only 
30-40% of males develop the disease (173). Due to this, most studies, including the one 
outlined within this chapter, utilise female NOD mice to ensure high disease incidence. 
Numerous other factors influence the disease penetrance in this model, including the 
intestinal microflora (200), temperature (201), diet (202), and even sleep (203).  
To ensure that all NOD mice used in this study had the same risk of developing diabetes, all 
variables were kept constant; four mice were housed in each cage, the cages were placed next 
to one another in the middle of the rack to minimise temperature variation, and the mice all 
had unrestricted access to normal chow and non-sterile water. Despite this, a reduction in 
fasting BGL was seen at 16 and 18 weeks of age, although it was not significantly different to 
12- and 14-weeks of age (Figure 3-9). Indeed, the removal of these results strengthened the 
correlation between circulating miRNAs and fasting BGLs (Figures 3-15 and 3-16). The NOD 
mice detailed in this chapter demonstrated extensive insulitis (Figure 3-10), commencing 
around 6-weeks of age, and a significant increase in fasting BGL at 12-weeks of age (Figure 3-
9), mirroring previous reports (173). A limitation of this study, however, was the use of a single 
investigator to grade to insulitis, with no data on reproducibility. Despite the variability of 
disease incidence seen in this animal model, the results outlined here support its use as a 
model of T1D.  
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3.5.4.  Circulating MicroRNAs and Β-cell Function 
NOD mice represent an exciting model to investigate the change in circulating miRNAs during 
the progression to T1D. Despite the many differences between mice and man, miRNAs display 
an impressive conservation between animal species (204). Due to this, the majority (86%) of 
the miRNAs that were investigated in NOD mice have homologs in humans.  
Technical limitations meant that the study described here was conducted in a cross-sectional 
manner, however, these results give an insight into circulating miRNA abundance as these 
mice progress to autoimmune diabetes. Seventeen miRNAs were found to be elevated in the 
circulation of 4-week old NOD mice and subsequently declined over time (Figure 3-12). 
Indeed, these miRNAs demonstrated a significant linear trend. As these mice get older, their 
risk of developing diabetes increases (173), and so these miRNA present as possible markers 
of progression to T1D. Interestingly, these miRNAs were elevated prior to any evidence of 
insulitis, which began around 6-weeks of age, and elevated fasting BGL, which was significantly 
higher by 12-weeks of age. While circulating miRNA abundance may be influenced by age 
(205), the short duration of the study (14-weeks) and the genetic predisposition of this mouse 
model, point to minimal confounding age-linked effects. Furthermore, miRNA-375 
demonstrated a spike in abundance at 8-weeks, prior to the elevation of fasting BGL. Although 
it was not a significant increase, it reflects an earlier study that identified elevations of this 
miRNA in the circulation of NOD mice prior to the onset of diabetes (156).  
Not all miRNAs demonstrated changes in abundance over time. Seven miRNAs presented here 
(Figure 3-14) remained stable within NOD circulation at all time points. As with the islet SNP 
experiments discussed above, these unchanged miRNAs give weight to the notion that specific 
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miRNAs within circulation can be used as a signature of islet cell stress/death and the 
progression to autoimmune diabetes. 
To assess the β-cell function of NOD mice, the fasting BGL was recorded. Eighteen miRNAs 
demonstrated a significantly negative correlation with fasting BGL (Figure 3-16). This indicates 
an association with these miRNAs and β-cell function within this model. Whether these 
miRNAs directly affect β-cell function or are simply a reflection of it remains to be confirmed. 
Either way, these miRNAs have potential as markers of β-cell function. 
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3.6. Conclusions 
The use of in vitro and in vivo models has assisted in the identification of interesting miRNAs 
in the progression of T1D. Here, we confirm that SNP-mediated β-cell stress/death causes the 
release of 27 candidate miRNAs (Aim 1). Insulin cfDNA is also released in response to SNP 
exposure, however it seems to be rapidly degraded at the highest SNP concentration (Aim 1). 
Circulating miRNAs are also found to be elevated in plasma of NOD mice prior to the presence 
of insulitis and glycaemic dysfunction. These miRNAs (N=17) continued to decrease through 
the increasing age groups, with a significant negative correlation between miRNA abundance 
and age (Aim 2). Additionally, there is an association evident between circulating miRNAs in 
NOD mice and fasting blood glucose. Nineteen miRNA demonstrate a negative correlation 
with fasting BGLs, indicating an association between these markers and β-cell function (Aim 
3). Taken together, these data give functional insights into miRNA and cfDNA release and 
highlights miRNAs that merit  further analysis in human clinical cohorts.  
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4. Characterising a Circulating MicroRNA Signature in 
Patients with Type 1 Diabetes 
4.1. Chapter Overview 
Type 1 diabetes is a complex, multi-faceted disease. Despite originating through the 
destruction of pancreatic β-cells, T1D has an enormous systemic impact upon the individual. 
Hyperglycaemia, hypoglycaemia and glycaemic variability has been shown to have adverse 
effects on cultured cells, animal models and in humans and to be associated with increased 
risk of chronic complications (206-208). T1D chronic complications attest to this; chronic stress 
within the circulatory and nervous systems result in significant damage to numerous organs 
and tissues. This widespread stress may cause additional miRNAs to be released into the 
circulation, even before β-cell death or diabetes complications may become clinically evident, 
thus altering the overall miRNA signature measured in circulation. The level of glycaemic 
control and drugs such as those used to prevent or treat complications may also impact miRNA 
signatures, but as yet there are few clinical studies to understand such changes.  
Within this chapter, the circulating miRNAs from individuals with newly-diagnosed and 
established T1D, and their age and gender matched controls have been profiled, using a qPCR 
panel of 754 miRNA assays. Thirty-one miRNAs were found to have differential abundance 
(fold change >2, P-value <0.05) within the T1D circulation (27 increased, four decreased). 
These data, along with the previous data outlined in Section 1.7 and the in vivo and in vitro 
modelling data discussed in Chapter 3, allowed the identification of 50 candidate miRNAs as 
circulating markers of β-cell death. Interestingly, less than half of these have been previously 
identified in the literature in relation to β-cell development or function, supporting the idea 
that cellular stress outside of the pancreas contributes to the circulating miRNA profile. These 
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miRNAs then underwent preliminary assessment in a larger clinical cohort of patients with 
established T1D and their age and gender matched non-diabetic controls. Two of the miRNAs 
were confirmed to be increased in the circulation of these T1D individuals, while additional 
subsets were found to associate with residual C-peptide, disease duration and microvascular 
complications in T1D. This exploratory approach highlights the potential of these miRNAs post-
diagnosis.  
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4.2. Chapter Aims 
Studies in this chapter aimed to: 
1. identify miRNAs that have differential abundance within the circulating plasma or 
serum of patients with newly diagnosed and established T1D, compared to their age 
and gender matched controls;  
2. compile a signature of miRNAs with potential to reflect β-cell death, and 
3. assess these miRNAs in a larger group of individuals with established T1D, including 
any association with clinical characteristics such as residual C-peptide, disease 
duration and the presence of microvascular complications.  
  
Chapter 4                                          Characterising a circulating miRNA signature of T1D 
125 
 
4.3. Methods 
4.3.1. Sample Cohorts 
Six serum samples from patients with newly diagnosed T1D, as well as further six age and 
gender matched control subjects, were kindly provided by Professor Maria Craig. Samples 
were taken ≤5 days after T1D diagnosis. Plasma samples from patients with established T1D 
(N=183, mean disease duration 20 years) and age and gender matched controls (N=141) were 
kindly provided by Professor Alicia Jenkins. A subset of these were used for the initial miRNA 
profiling (N=3 from each group). Differentially abundant miRNAs in newly-diagnosed and/or 
long-standing T1D circulation were selected for further analysis. 
4.3.2. RNA Isolation 
RNA was isolated using the manual method outlined in Appendix B. RNA concentration and 
purity was assessed using a spectrophotometer.  
4.3.3. C-peptide 
C-peptide levels were carried out by Dr. Andrzej Januszewki (NHMRC CTC, Sydney Australia) 
using the ultra-sensitive ELISA (Mercodia), with a detection limit of 1.25 pmol/L.  
4.3.4. MicroRNA Profiling 
MicroRNA profiling was undertaken using OpenArray Human miRNA qPCR Panels (Applied 
Biosystems) utilising the protocol published previously. To remove non-specific amplification, 
assays with an AMP score <1.24 were omitted. Data were normalised using the global 
normalisation method (209). Differential abundance was classified as a >2-fold change with a 
P-value <0.05. The newly diagnosed and established T1D groups were analysed separately to 
avoid confounding the results.  
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4.3.5. Candidate MicroRNA Assessment 
The 50 candidate miRNAs were assessed using Custom OpenArray miRNA qPCR panels 
(Applied Biosystems) using the protocol outlined in Appendix D. To remove non-specific 
amplification, assays with an AMP score <1.24 were omitted. Data was normalised to the RNA 
isolation and RT ath-miR spike-ins. For details of these, please refer to Supplementary Chapter 
1. All changes between groups were required to differ by at least one cycle, regardless of the 
statistical significance, as this is the smallest difference detectable by qPCR.  
4.3.6. Data Presentation and Statistical Analysis 
MicroRNA profiling results are presented using a volcano plot (Figure 4-2), with >2-fold change 
(or 1 cycle difference) and P<0.05 regarded as a significant change.  
To compare miRNA abundance between groups, the normalised CRT values of both groups 
were investigated. The average difference between groups had to exceed one cycle (or a 
doubling of the amplicon), as this is the minimum difference that qPCR can detect. Significant 
differences were identified using a t-test on any group comparisons with a >1 CRT difference. 
MicroRNAs displaying a significant difference between groups (P<0.05) were presented as 
transcript abundance using the fold over detectable method (limit of detection is 39 cycles) 
described earlier (190). Due to the exponential nature of this method, differences were 
confirmed using the non-parametric Mann-Whitney U-test with significance deemed P<0.05. 
An overview of this procedure can be found in Figure 4-1. Correlations were assessed using 
non-parametric Spearman method, with significance P<0.05. No corrections were made for 
multiple comparisons, as this chapter has an exploratory focus and so strives to minimise type 
II (false negative) errors. 
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Figure 4-1. Flowchart for data analysis 
Diagrammatical overview of the analytic process of identifying significant differences in miRNA abundance within different 
groups. U test refers to Mann-Whitney U test as described in Section 4.3.6. 
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4.4. Results 
4.4.1. Differential MicroRNA Abundance in T1D Circulation 
MicroRNA profiling of serum and plasma samples from individuals with newly diagnosed or 
established T1D (ND-T1D and E-T1D respectively) revealed 31 miRNAs that were either 
increased or decreased within T1D circulation (ND-T1D and/or E-T1D circulation) compared to 
age and gender matched controls. The majority of these (27 miRNAs) were increased, 
suggesting that they were released as a result of the cell stress/death that is associated with 
T1D. Figure 4-2 provides an overview of all detectable miRNAs, including those with 
significantly different abundance. In Figure 4-2b, three miRNAs with the largest or most 
significant changes are plotted.  
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Figure 4-2. Circulating microRNA profiling of patients with T1D 
(a) Volcano plot of differentially abundant miRNAs measured within the circulation of patients with newly-diagnosed (ND-
T1D) and established (E-T1D) T1D, compared to age and gender matched controls (Con(ND) and Con(E) respectively). Dotted 
line = 2-fold change. (b) Subset of significant miRNAs highlighted in (a) with newly diagnosed T1D and controls in green and 
established T1D and controls in blue. Mean ± SEM.  N = 9 T1D (6 ND-T1D, 3 E-T1D), 9 Control (6 ND-Con, 3 E-Con). * P<0.05, 
** P<0.01.   
 
MicroRNA-410 was significantly decreased in the individuals with established T1D, but not the 
newly diagnosed T1D group. The other miRNAs, miR-99b and miR-125a, show an increase in 
the circulation of both ND-T1D and E-T1D compared to the age and gender matched controls. 
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Based on the results outlined above, in combination with the previously generated data 
(discussed in section 1.8), a list of 50 candidate miRNAs was generated (Table 1-A).  
 
4.4.2. Assessment of Candidate MicroRNAs in Patients with Established 
T1D 
As a preliminary assessment of this miRNA signature, the levels of these miRNAs were 
quantified within the plasma of 180 individuals with established T1D and 138 age and gender 
controls. The group characteristics are outlined in Table 4-B.  
 
Table 4-B. Cohort summary of patients with established T1D and their age and gender matched non-diabetic controls 
 
a Chi-square test 
b T-test 
 
 
 T1D Controls P-value 
N 180 138 - 
Females, % 61 51 nsa 
Age, yrs 
(mean ± SD) 
38.9 ± 1.05 39.0 ± 1.26 nsb 
T1D Duration, yrs 
(mean ± SD) 
20 ± 13 - - 
HbA1c 
(mean ± SD) 
8.0 ± 1.3% 
64.4 ± 14.7 mmol/mol 
5.1 ± 0.4% 
32.7 ± 3.9 mmol/mol 
<0.0001b 
Microvascular Cx, N 58 - - 
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Within the T1D group, 58 individuals (32.2%) presented with microvascular complications (Cx), 
defined as proliferative retinopathy and/or increased albuminuria.  
Two miRNAs, miR-146a and miR-22-5p, were confirmed to be elevated in the circulation of 
subjects with established T1D (Figure 4-3). Interestingly, only miR-146a has been previously 
reported as differentially abundant in T1D circulation (154).  
 
Figure 4-3. MicroRNAs are elevated in T1D circulation 
Two miRNAs were found to be significantly elevated in the circulation of individuals with established T1D compared to age 
and gender matched controls. N = 138 controls, 180 T1D. **** P<0.0001. Mean ± SEM. 
 
4.4.3. Circulating MicroRNAs Differ with C-peptide and HbA1c Status 
C-peptide levels were measured as an indicator of residual β-cell function. Controls subjects 
had an average C-peptide concentration of 559.5 ± 245.4 pM, while T1D subject had 29.3 ± 
87.6 pM (P<0.0001, unpaired t-test with Welch’s correction). Due to the use of an ultra-
sensitive ELISA, C-peptide was detectable in 123 of the T1D subjects. Five miRNAs were found 
to be significantly elevated in the circulation of T1D subjects with detectable C-peptide as 
compared against those with no detectable C-peptide (Figure 4-4). Furthermore, eight miRNAs 
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had a significantly positive correlation with detectable C-peptide concentrations in T1D 
subjects (Table 4-C). MicroRNA-222 and -99b were found be to both significantly elevated in 
those with detectable C-peptide and positively correlate with the levels, indicating an 
association between these miRNAs and β-cell function. No correlation between miRNA 
abundance and C-peptide level was found in control subjects. 
 
 
 
 
Figure 4-4. MicroRNAs differ by C-peptide status 
Five miRNAs were significantly elevated in the circulation of T1D patients with detectable C-peptide (C-pep+), compared to 
those without detectable C-peptide (C-pep-). N = 53 C-pep-, 123 C-pep+. Mean ± SEM. 
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Table 4-C. MicroRNAs positively correlate with detectable T1D C-peptide levels 
miRNA Spearman R P 
miR-375 0.32 0.00027 
miR-24 0.21 0.021 
miR-93 0.21 0.016 
miR-21 0.19 0.035 
miR-22-5p 0.19 0.035 
miR-99b 0.18 0.045 
miR-222 0.18 0.044 
miR-92a 0.18 0.048 
 
Spearman correlation, P<0.05 significant. N = 123.  
HbA1c levels were measured as an indicator of glycaemic variability. As expected, there was a 
significant difference in the HbA1c levels of the Control and T1D subjects (Table 4-B). Three 
miRNAs displayed a significant negative correlation with the HbA1c levels of the control 
subjects (Table 4-D). Interestingly, one of these, miR-25, displayed a similar correlation in T1D 
subjects. MicroRNA-375 displayed a significant positive correlation with the HbA1c levels of 
T1D subjects.  
Table 4-D MicroRNAs correlate with HbA1c levels in control and T1D subjects  
Group miRNA Spearman R P 
Control miR-25 -0.34 0.0001 
Control miR-16 -0.23 0.0094 
Control miR-20a -0.18 0.046 
T1D miR-25 -0.18 0.022 
T1D miR-375 0.16 0.041 
 
Spearman correlation, P<0.05 significant. Control N =122, T1D N = 168.  
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4.4.4. Disease Duration and Microvascular Complications 
Of the candidate miRNAs outlined in this chapter, eight demonstrate a decreased abundance 
in T1D subjects that had lived with the disease for greater than 20 years (Figure 4-5). This cut-
off point of 20 years was chosen as this was the average disease duration for this group. 
Additionally, nine miRNAs significantly correlated with disease duration, with all but one 
decreasing with time post-diagnosis (Table 4-E). MicroRNA-24, -27a, -27b, -93, and -199a-3p 
were found to both decrease significantly in those T1D subjects with a disease duration >20 
years and negatively correlate with disease duration, indicating an association between these 
miRNAs and the progression of T1D post-diagnosis.  
Similarly, seven of the miRNA candidates were decreased in T1D subjects that had 
microvascular complications (Figure 4-6). The longer that an individual has T1D, the higher 
their risk of developing associated complications, including those of the microvasculature such 
as retinopathy. Three of these, miR-27b, -103, and-199a-3p, were previous identified to be 
significantly reduced in T1D subjects with longer disease duration. 
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Figure 4-5. Lower circulating miRNAs levels associated with with longer T1D duration 
Eight miRNAs have significantly lower abundance in T1D patients with longer disease duration (greater than 20 years post-
diagnosis, >20y) compared to those with shorter duration (less than or equal to 20 years post-diagnosis, ≤20y). N = 98 (≤20y), 
82 (>20y). * P<0.05 ** P<0.01 **** P<0.0001. Mean ± SEM.  
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Table 4-E. MicroRNAs correlate with T1D duration 
 
miRNA Spearman R P 
miR-27a -0.24 0.0016 
miR-199a-3p -0.19 0.012 
miR-146a -0.18 0.02 
miR-93 -0.18 0.015 
miR-20a -0.17 0.023 
miR-24 -0.16 0.037 
miR-222 -0.16 0.036 
miR-27b -0.15 0.045 
miR-126 -0.15 0.046 
miR-186 0.17 0.028 
 
 Spearman correlation, P<0.05 significant. N = 173. 
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Figure 4-6. Circulating microRNAs are reduced in T1D patients with vs without microvascular complications 
Seven miRNAs were significantly reduced in the circulation of T1D patients with microvascular complications (Cx+), compared 
to those without complications (Cx-). Microvascular complications were defined as proliferative diabetic retinopathy and/or 
increased albuminuria. N = 117 Cx-, 58 Cx+. Mean ± SEM. 
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4.5. Discussion 
4.5.1. MicroRNA Profiling 
Currently, there are over 2,500 mature miRNAs identified within the human genome (miRBase 
release 21). Due to the enormity of this class of non-coding RNAs, candidate-based 
approaches, whereby the miRNA/s of interest are decided prior to quantitation, present 
severe limitations when trying to identify circulating biomarkers. The rise of next generation 
sequencing has allowed researchers to identify all small non-coding RNAs within a sample, 
including novel sequences, and so present an unbiased method of ncRNA quantitation. The 
downside of this technique, however, is its inherent requirement for copious amounts of 
starting RNA (usually in the order of micrograms). Serum and plasma samples from clinical 
cohorts are a precious resource; investigators often do not have access to large sample volume 
to isolate the RNA needed for NGS. Here, 754 miRNAs have been profiled within the serum 
and plasma of subjects with T1D and their age and gender matched controls using an ultra-
high throughput qPCR platform. This allowed the capture of the most abundant and well 
characterised miRNAs using only 200 ng of RNA isolated from 200 µl of starting sample. 
Interestingly, these miRNAs do not always show the same difference when examining the ND-
T1D and E-T1D groups separately. MicroRNA-410 for example, does not show any difference 
at the time of diagnosis but is significantly reduced in patients with long-term T1D. This 
indicates that miR-410 may not be indicative of β-cell death prior to, or at the point of, 
diagnosis. The resulting data, combined with the data generated from previous experiments, 
facilitated the identification of 50 miRNAs of interest. These miRNAs have the potential to 
reflect β-cell death in the progression into T1D as they are important in the development of 
the human pancreas, and have been seen to be released in in vitro islet cell death experiments 
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and genetically predisposed mouse models. Of course, these miRNAs must be quantitated in 
other, larger cohorts to fully assess their potential as markers of β-cell death. 
Subsequent exploratory assessment of these miRNAs in a larger group of subjects with 
established T1D and their age and gender matched non-diabetic controls was conducted. This 
analysis revealed that subsets of these molecules have the potential to not just differentiate 
between subjects with and without T1D, but also residual β-cell function, disease duration and 
the presence of microvascular complications. Initial results confirm two miRNAs, miR-22-5p 
and 146a, were significantly elevated in the circulation of subjects with T1D. MicroRNA-146a 
has been previously identified with regard to subjects with newly diagnosed T1D (154), 
although the study was focused upon PBMCs rather than serum or plasma. The authors of this 
study concluded that miR-146a was decreased in subjects with newly diagnosed T1D, and that 
its abundance correlated with GADA antibody titres (154). Whether the PBMCs or another cell 
type are releasing this miRNA into the circulation of individuals with T1D remains to be 
investigated. Isolating PBMCs from individuals with T1D and culturing them in the presnce of 
islet antigens would mimic the in situ scenario enabling identification of released miRNAs. The 
other elevated miRNA, miR-22-5p, has not been the subject of extensive evaluation, 
presumably due to the fact that until recently it has been known as miR-22*, the antisense or 
passenger miRNA. This miRNA may present a novel circulating biomarker, however, additional 
evaluations of this miRNA’s abundance in other groups of individuals with T1D must be made. 
While these two miRNAs only represent 4% of the original list of candidate miRNAs (Table 1-C), 
this does not discount the other miRNAs as biomarkers of T1D. As the average disease 
duration within this cohort was 20 years, the majority of the candidate miRNAs may not be 
actively released anymore, especially if they were originally released by β-cells. Indeed, the 
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elevated abundance of these miRNAs two decades after an individual’s diagnosis indicates 
that they are either released from the remaining β-cell fraction still undergoing cell 
stress/death, or from another cellular source, such as PBMCs, endothelial cells or cardiac 
muscle (154; 210). In either case, this group provided a preliminary assessment of these 
candidate miRNAs in subjects with T1D; further analysis of this signature in the progression 
into T1D will be discussed in the following chapter. 
4.5.2. Residual β-cell Function and Glycaemic Variability 
C-peptide levels were quantified as a measure of residual β-cell function as it is released in 
equimolar amounts with insulin. T1D requires the use of exogenous insulin to maintain 
glucose homeostasis so C-peptide allows an indirect quantitation of endogenous insulin 
secretion. Due to the increased sensitivity of modern assays, the majority of individuals with 
T1D were found to be C-peptide positive. Higher miRNA abundance was associated with 
increased C-peptide expression, and those individuals with detectable C-peptide had 
significantly higher levels of candidate miRNAs that those without detectable C-peptide. This 
mirrors what was found in the previous chapter; in NOD mice higher miRNA abundance 
associated with a lower fasting BGL (Figure 3-14). Indeed, miR-22-5p and miR-93 were both 
found to significantly correlate with C-peptide concentrations in humans with established 
T1D, and fasting BGL in NOD mice (positive and negative correlations respectively). Despite 
the clear association of these candidate miRNAs with β-cell function, no correlation was found 
with C-peptide levels in non-diabetic control individuals, indicating that these miRNAs may be 
indirect markers of function rather than directly involved in the manufacturing, processing or 
secretion of insulin.  
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Circulating microRNA abundance was also compared to the HbA1c levels, a measure of 
glycaemic variability. Here, three miRNAs significantly correlated with HbA1c levels in control 
subjects, and two miRNAs correlated with levels in T1D subjects. Interestingly, one miRNA, 
miR-25, was found to negatively correlate with HbA1c levels in both control and T1D subjects; 
therefore, an increase in the miR-25 abundance relects a decrease in HbA1c levels. This miRNA 
was shown to be significantly increased in T1D subjects with detectable C-peptide (Figure 4-4), 
and so the decrease in HbA1c levels may be a result of increased insulin secretion. 
Furthermore, miR-375 was found to have a positive correlation with HbA1c levels, indicating 
that its increased abundance in circulation may reflect greater β-cell injury or death, a 
relationship that has been previously reported (156; 157).   
4.5.3. Microvascular Complications 
Another area of significant interest within diabetes research is the identification of circulation 
biomarkers of diabetic complications. Complications, such as retinopathy, nephropathy and 
neuropathy, have dramatic impacts on the quality of life of individuals with T1D, and so early 
detection and stratification is vital. Understanding of the mechanisms of vascular tissue 
damage and protection are also of interest, as they may help identify and validate therapeutic 
targets and/or agents. Within this cohort, seven miRNAs were found to be significantly 
decreased within T1D subjects with microvascular complications. Of these, three have been 
previously reported in retinopathy or nephropathy. A recent examination of two T1D 
retinopathy clinical trials identified a higher abundance of miR-27b within an individual’s 
serum resulted in a decreased risk of developing the condition (OR = 0.67) (211). This finding 
correlates with the decrease found in the plasma of T1D individuals with microvascular 
complications outlined in this chapter. MicroRNA-199a-3p has also been implicated in DR, 
with a decrease of this miRNA found within the retina of STZ-treated rats (212). Again, this is 
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in line with the findings presented here, and this change within the retina could potentially 
contribute to the reduction in circulating miR-199a-3p. 
A recently published paper has delved into the role of miR-25 in the early stages of diabetic 
nephropathy (213). Intriguingly, the authors found that the precursor and mature miR-25 was 
decreased within the glomeruli of STZ-treated C57BL/6 mice, but the primary miRNA was 
increased. This was found to result from the inhibition of DGCR8 (also known as Pasha), an 
important RNA binding protein involved in the initial processing of primary miRNA transcripts 
(see section 1.4.1). The subsequent decrease of this miRNA resulted in an increase in one miR-
25’s validated targets, NOX4 (213), which has a well-known role in the development of 
diabetic nephropathy (214). This decrease in the production of mature miR-25 may result in 
the reduction of circulating miR-25 seen in T1D individuals with microvascular complications. 
The other miRNAs identified within this chapter (mir-9, -30e-3p, -103, and -326) have 
remarkable potential as biomarkers of diabetic complications. Further investigation needs to 
be completed to confirm the role of these molecules in diabetic complications, including the 
source tissue. Caution must be applied to miR-103, however, as this miRNA was also identified 
as reduced in patients who have been living with T1D for longer than 20 years. Longer disease 
duration can be a risk factor for complications and so any change seen could be from longer 
duration rather than complications.  
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4.6. Conclusions 
The miRNA profiling and preliminary assessment outlined within this chapter gives credence 
to the notion that miRNAs have potential as circulating biomarkers in T1D.  MicroRNA profiling 
of circulating plasma/serum samples from patients with newly diagnosed and established T1D, 
and their age and gender matched controls, highlighted 31 differentially abundant miRNAs. 
This data, combined with the preliminary data and literature searches (see Figure 1-9), 
resulted in a list of 50 miRNA candidates being generated. Subsets of these 50 miRNAs had 
differential abundance when examining T1D and controls, as well as C-peptide levels, disease 
duration and microvascular complications within the T1D group. These results suggest that 
these miRNAs have potential as biomarkers of additional aspects of T1D, however, as β-cell 
death and T1D progression is the focus of this project they will undergo further examination 
with this focus in the next chapter.    
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5. Molecular Signature in Type 1 Diabetes Progression  
5.1. Chapter Overview 
The previous chapters have been focussed upon the different stages in identifying and 
characterising a circulating signature of various aspects of diabetes, specifically Type 1 
diabetes (T1D): identifying the appropriate technology, modelling the disease, and profiling 
the samples from patients. This chapter is focussed on assessing this molecular signature 
during the life course of T1D. Samples and related data kindly provided by  collaborators, 
Professors Maria Craig (UNSW, Sydney, Australia), Tim Jones (UWA, Perth, Australia), Alicia 
Jenkins (University of  Sydney, Sydney, Australia) and Kristina Rother (NIH, Bethesda, USA), 
have allowed the quantitation of the molecular signature in the circulation of 19 individuals 
at high risk of T1D (prior to diagnosis), 199 subjects at or within 48 hours from clinical 
diagnosis of T1D, 57 after diagnosis (within 6 weeks and 12 months), and 220 with long-
standing T1D (20 years post-diagnosis).  
Both unmethylated and methylated Ins cfDNA decrease within the circulation of individuals 
at the point of diagnosis, but then return to levels similar to pre-diagnosis within 6 weeks. 
Individuals at 20 years after diagnosis, however, show decreased unmethylated and  
methylated insulin cfDNA abundance. The miRNA signature displays a different profile within 
high risk individuals and those at the time of T1D diagnosis, when compared to individuals 
soon after diagnosis. When analysed individually, the miRNAs tended to conform to four 
general patterns of expression, with the majority displaying increased abundance in the high 
risk group. Interestingly, the miRNAs tended to reflect the immune and glycaemic status of 
individuals when T1D diagnosis occurs. Twenty-three of the fifty miRNAs demonstrated a 
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linear tend with GAD autoantibody titres, while eight miRNAs, as well as insulin cfDNA, had a 
quadratic trend with HbA1c levels at diagnosis.  
Additional analysis conducted on individuals with newly diagnosed T1D treated with ingested 
interferon-α found that immune modulation caused a change in the abundance of seven 
candidate circulating miRNAs.  
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5.2. Chapter Aims 
Studies presented within this chapter  aimed to: 
1. assess the microRNA and insulin cfDNA signature in peripheral circulation of 
individuals before, during, and after T1D diagnosis; 
2. investigate whether insulin cfDNA or candidate miRNAs are indicative of the immune 
status or glucose control over three months (as measured by HbA1c) in individuals at 
diagnosis; and  
3.  identify any effects that immune modulation may play on the molecular signature.  
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5.3. Methods 
5.3.1. Sample Cohorts 
5.3.1.1. Children at High Risk of T1D 
Plasma and serum samples and related data from 19 children at high risk of developing T1D 
were kindly provided by Professor Maria Craig and her team at the Prince of Wales Hospital 
Virology Research Laboratory in Sydney. These samples are comprised of children whoe’s 
parent(s) or sibling had T1D, with 79% also presenting with islet autoantibodies. These 
children are currently being followed by Prof. Craig and her team as part of an on-going 
prospective study to assess whether they develop T1D, and so the individuals analysed in this 
chapter have an average of 3.5 samples taken at different time points (3.2 ± 2.4 (mean ± SD) 
years of follow-up) (Table 5-A).  
5.3.1.2. Children at T1D Diagnosis 
Plasma samples and related clinical data from 199 children at T1D diagnosis were kindly 
provided by Professor Timothy Jones and his team from the Princess Margaret Hospital in 
Perth. These samples were taken, mostly within two days from clinical diagnosis of T1D (Table 
5-A).  
5.3.1.3. Individuals Within the First Year of T1D Diagnosis 
Paediatric (N=115) and adult (N=40) plasma samples from N=57/40 individuals respectively 
with T1D were kindly provided by Professor Kristina Rother and her team at the National 
Institute of Health in Bethesda, USA. Paediatric samples were taken from subjects within 6-
weeks of T1D diagnosis. Subjects were then randomly assigned to receive daily ingested 
human recombinant interferon-α (hrIFNα), at either 5,000 or 30,000 units, or a placebo for 
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one year, as published previously (51). The baseline samples from this cohort form the <6 
Weeks Post Dx group, while the placebo samples taken until 12 months form the <12 Months 
Post Dx group, outlined in Table 5-A.  
5.3.1.4. Individuals with Long-standing T1D 
Samples and related clinical data from patients with long-standing T1D were kindly provided 
by Professor Alicia Jenkins and her team from the NHMRC Clinical Trials Centre, Sydney and 
the University of Melbourne Dept. of Medicine (St. Vincent’s) Health, Melbourne (N=180, see 
Table 4-B), and Professor Kristina Rother and her team at the National Institute of Health in 
Bethesda, USA. Professor Rother’s samples came from a previously published cohort on the 
effects of exenatide on patients with long-standing T1D (215), however all samples tested 
here were taken from individuals at screening (N=40), prior to any intervention. Together, 
these samples were taken from individuals with an average of 20 years disease duration (Table 
5-A). The use of individuals with long standing T1D provides a more thorough investigation of 
the changes in circulating miRNAs and insulin cfDNA during the life course of T1D. 
5.3.2. RNA Isolation 
RNA was isolated using either the manual RNA isolation protocol outlined in Appendix B, or 
the automated protocol outlined in Appendix C. Isolated RNA concentration was quantitated 
using a spectrophotometer.  
5.3.3. MicroRNA Quantitation 
The signature of 50 miRNAs, discussed in the previous chapter, was quantitated using custom 
OpenArray gene expression slides. RT, PA, and qPCR was undertaken as per the protocol 
outlined in Appendix D. Each of the slides also contained assays for RNA isolation and RT spike-
in miRNAs (ath-miRs, see Supplementary Chapter 1), as well as a negative control 
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(ath-miR-394) and two endogenous controls (U6 and RNU44). To remove non-specific 
amplification, results with an AMP score of <1.24 and/or a Cq confidence score of <0.6 were 
omitted. Results were normalised to the RNA isolation and RT ath-miR spike-in miRNAs (see 
Supplementary Chapter 1 for optimisation). Any samples with detectable amplification within 
the negative control assay were removed from the analysis. Repeats and slide controls were 
also employed to ensure the integrity of the clinical data; the results of these can be found in 
the Supplementary Data.  
5.3.4. Cell-free DNA Isolation and Bisulfite Conversion 
Cell-free DNA was isolated from 50 µl of serum or plasma using the protocol outlined in 
Appendix E, and bisulfite conversion was undertaken using the protocol outlined in Appendix 
I.  
5.3.5. Insulin cfDNA Quantitation 
Methylated and unmethylated insulin cfDNA were quantified using the digital droplet PCR 
protocol outlined in Appendix J. Each plate contained a positive control, which consisted of a 
mixture of control plasmids (10% unmethylated, 90% methylated plasmid, 1 ng total per 
reaction), and a no template control (nuclease-free water). Control plasmids, kindly provided 
by Professor Raghu Mirmira at Indiana University USA as part of an existing collaboration with 
A/ Prof. Hardikar, were amplified using the transformation protocol outlined in Appendix H. 
FAM and VIC thresholds were identified based on the positive control and then applied to the 
entire plate. In addition to the controls, repeats were employed to ensure the integrity of the 
data; the results of these can be found in the Supplementary Data.  
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5.3.6. Data Presentation and Statistical Analysis 
In the previous chapter, differences between groups were confirmed to be >1 cycle and then 
tested for significance. As there are five groups to analyse in this chapter for each miRNA, 
differences were confirmed to be >1 cycle after testing for significance to streamline analysis. 
Firstly, microRNA data is converted from CRT to transcript abundance using the fold over 
detectable method (limit of detection is 39 cycles) described earlier (190). Linear trend 
analysis was performed, with the P-value reported if <0.05. Kruskal-Wallis non-parametric 
ANOVA was used to assess changes within groups. Any miRNA that demonstrated a significant 
difference (P<0.05) was further investigated using Dunn’s test (corrected for multiple 
comparisons) to identify which pairs of groups demonstrated a significant difference. An 
adjusted P value of <0.05 indicated significance. Any miRNA displaying a significant difference 
was then confirmed to show a >1 cycle difference between the compared groups. To be 
deemed a significant difference the miRNA must display atleast >1 cycle difference and an 
adjusted P-value of <0.05. Figure 5-1 gives an overview of this analysis. 
Insulin cfDNA is presented as either copies/µl, or log transformed copies/µl as described 
earlier (168) and differences were assessed using Kruskal-Wallis non-parametric ANOVA with 
corrected Dunn’s multiple comparison test. 
Linear or quadratic regression was used to determine trend significance (P<0.05) between 
miRNA abundance and clinical parameters at T1D diagnosis.  
To assess changes due to interferon treatment, data are kept as CRT and repeated measures 
ANOVA was used to identify any differences between treatment groups, time points or the 
interaction between treatment and time. Sum of squares test was used to identify and 
significant differences in treatment groups at individual time points. 
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Figure 5-1. Flowchart for data analysis 
Diagrammatical overview of the analytic process of identifying significant differences in miRNA abundance within different 
stages of T1D progression. 
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5.4. Results 
5.4.1. T1D Progression – Sample Details 
The details of the samples used in the assessment of the molecular signature in the 
progression of T1D can be found in Table 5-A. A significant difference was found in the age, 
HbA1c levels, and gender proportions between the groups. 
To assess whether age impacted upon the abundance of the candidate miRNAs and insulin 
cfDNA, Spearman correlations were conducted independently for each cohort. No significant 
correlation (R2>0.1, P<0.05) was observed between age and any miRNA or cfDNA within any 
group or cohort.  
Multiple t-tests (with a false discovery rate of 1%) were employed to identify gender 
differences. No candidate miRNA or cfDNA significantly differed (P<0.05) between genders 
for any of the cohorts. Therefore, no adjustments were made for age or gender. Furthermore, 
as HbA1c levels are indicative of the stage of T1D, and may influence the molecular signature, 
no adjustments were made.      
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Table 5-A. Details of samples used in the analysis of T1D progression   
 High 
Risk 
At 
Diagnosis 
(Dx) 
<6 
Weeks 
Post-Dx 
6 Weeks 
- 12 
Months 
Post-Dx 
20 Years 
Post-Dx 
P-Value 
Cohort 
(Section)a 
1 
(5.3.1.1) 
2 
(5.3.1.2) 
3A 
(5.3.1.3) 
3B 
(5.3.1.3) 
4 
(5.3.1.4) 
- 
Subjects, N 19 199 57 19 220 - 
Time point 
samples 
per subject, 
N 
(mean ± 
SD) 
3.5 ± 
1.6 
1 1 3 ± 1.2 1 - 
Females, % 58 47 32 37 57 0.0047b 
Age, yrs 
(mean ± 
SD) 
7.0 ± 
4.0 
8.6 ± 4.1 
10.1 ± 
4.6 
9.4 ± 4.0c 
39.5 ± 
13.5 
<0.0001d 
Time since 
diagnosis 
- 
2 ± 1.4 
days 
(mean ± 
SD) 
Up to 6 
weeks 
Between 
6 weeks 
and 12 
months 
20.2 ± 
12.7 
years 
- 
HbA1c, % 
(mean ± 
SD) 
NA 
11.6 ± 
2.06 
7.5 ± 1.2 
6.97 ± 
1.03 
7.9 ± 1.3 <0.0001d 
HbA1c, 
mmol/mol 
(mean ± 
SD) 
 
103.2 ± 
22.5 
58.3 ± 
13.0 
53.2 ± 
11.2 
63.3 ± 
14.5 
<0.0001d 
 
NA = Not available 
a See section text for further details. 
b Chi-square test 
c Calculated using the age at the beginning of the study 
d ANOVA 
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5.4.2. MicroRNA Abundance Changes During T1D Progression 
Cluster analysis reveals that the High Risk and At Diagnosis groups have a similar miRNA profile 
(Figure 5-2). Interestingly, the individuals within 6 weeks and 12 months post-diagnosis cluster 
differently, and demonstrate a lower abundance of multiple miRNA (lighter colour, higher 
cycle threshold). Those patients with a disease duration of 20 years cluster slightly closer to 
those at high risk and at diagnosis, however, their expression profile seems distinct. 
The individual candidate miRNAs presented with four overarching patterns of expression 
throughout the life course of T1D. The majority of the miRNAs demonstrated higher 
abundance in the High Risk and/or At Dx groups (Figure 5-3.1, 3.2, 3.3, and 3.4). Some of these 
miRNAs, such as miR-99b, increase in abundance in the 20 Years Post-Dx group. Interestingly, 
the snoRNA U6 was highly elevated in those at high risk of T1D and demonstrated a 
significantly linear trend. 
Three other miRNAs, miR-125a-5p, -146a, and -375, tended to be elevated at diagnosis 
(Figure 5-4). MicroRNA-375 was significantly elevated at diagnosis, compared to those at high 
risk, and then decreased in the subsequent groups.  
Furthermore, eight miRNAs demonstrated the highest, albeit variable, abundance within the 
<12 Months Post-Dx group and then decreased in the 20 Years Post-Dx group (Figure 5-5.1 
and 5.2). Finally, miR-152 and -186 are increased in the 20 Years Post-Dx group, both with 
significant linear trends indicating successive increases in abundance throughout the life 
course of T1D (Figure 5-6). 
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Figure 5-2. Heatmap of miRNA signature expression during T1D progression 
Each square represents the mean value of the particular miRNA in each cohort. Complete linkage, Euclidean distance. N = 75 
(High Risk), 187 (At Dx), 54 (<6 Wks and <12 Mths Post-Dx), 218 (20 Yrs Post-Dx). 
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Figure 5-3.1. MicroRNAs are elevated in high risk individuals and at T1D diagnosis 
N = 75 (High Risk), 187 (At Dx), 54 (<6 Wks and <12 Mths Post-Dx), 218 (20 Yrs Post-Dx). Mean ± SEM. Multiple comparisons 
and adjusted P-values are listed in the table below each graph. Significant differences are highlighted. Linear trend 
significance P < 0.05. 
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Figure 5-3.2. MicroRNAs are elevated in high risk individuals and at T1D diagnosis 
N = 75 (High Risk), 187 (At Dx), 54 (<6 Wks and <12 Mths Post-Dx), 218 (20 Yrs Post-Dx). Mean ± SEM. Multiple comparisons 
and adjusted P-values are listed in the table below each graph. Significant differences are highlighted. Linear trend 
significance P < 0.05. 
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Figure 5-3.3. MicroRNAs are elevated in high risk individuals and at T1D diagnosis 
N = 75 (High Risk), 187 (At Dx), 54 (<6 Wks and <12 Mths Post-Dx), 218 (20 Yrs Post-Dx). Mean ± SEM. Multiple comparisons 
and adjusted P-values are listed in the table below each graph. Significant differences are highlighted. Linear trend 
significance P < 0.05. 
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Figure 5-3.4. MicroRNAs are elevated in high risk individuals and at T1D diagnosis 
N = 75 (High Risk), 187 (At Dx), 54 (<6 Wks and <12 Mths Post-Dx), 218 (20 Yrs Post-Dx). Mean ± SEM. Multiple comparisons 
and adjusted P-values are listed in the table below each graph. Significant differences are highlighted. Linear trend 
significance P < 0.05. 
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Figure 5-4. Two miRNAs are elevated at T1D diagnosis 
N = 75 (High Risk), 187 (At Dx), 54 (<6 Wks and <12 Mths Post-Dx), 218 (20 Yrs Post-Dx). Mean ± SEM. Multiple comparisons 
and adjusted P-values are listed in the table below each graph.  
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Figure 5-5.1 Candidate miRNAs increase in the 12 months following T1D diagnosis 
N = 75 (High Risk), 187 (At Dx), 54 (<6 Wks and <12 Mths Post-Dx), 218 (20 Yrs Post-Dx). Mean ± SEM. Multiple comparisons 
and adjusted P-values are listed in the table below each graph. Significant differences are highlighted.  
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Figure 5-5.2 Candidate miRNAs increase in the 12 months following T1D diagnosis 
N = 75 (High Risk), 187 (At Dx), 54 (<6 Wks and <12 Mths Post-Dx), 218 (20 Yrs Post-Dx). Mean ± SEM. Multiple comparisons 
and adjusted P-values are listed in the table below each graph. Significant differences are highlighted.  
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Figure 5-6. MicroRNA-152 and -186 are elevated in patients with long-standing T1D 
N = 75 (High Risk), 187 (At Dx), 54 (<6 Wks and <12 Mths Post-Dx), 218 (20 Yrs Post-Dx). Mean ± SEM. Multiple comparisons 
and adjusted P-values are listed in the table below each graph. Significant differences are highlighted. Linear trend 
significance P < 0.05.  
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5.4.3. Cell-free DNA Decreases at Diagnosis 
In contrast with the miRNA signature, methylated insulin cfDNA decreases significantly at the 
point of T1D diagnosis (Figure 5-7). In the following 6 week and 12 month period, the 
abundance of these cfDNA species returns to levels similar to that found in the high risk group, 
and then decrease again in the 20 Years Post-Dx group. The methylated insulin cfDNA 
demonstrates a similar pattern, however not all of the changes are statistically significant.   
Chapter 5                                          Molecular signature before, during and after T1D diagnosis 
165 
 
 
Figure 5-7. Insulin cfDNA is reduced at T1D diagnosis 
N = 61 (High Risk), 198 (At Dx), 57 (<6 Weeks Post-Dx), 59 (<12 Months Post-Dx), 40 (20 Years Post-Dx). Mean ± SEM. Multiple 
comparisons and adjusted P-values are listed in the table below each graph. Significant differences are highlighted. 
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5.4.4. MicroRNAs Correspond to GAD Autoantibody Titres at Diagnosis 
To assess whether the candidate miRNAs could reflect the immune status of individuals at the 
point of diagnosis, associations between miRNA abundance and islet autoantibody titres were 
examined. Within the cohort of 199 individuals at T1D diagnosis, the majority had data for 
GADA (89.9%) and IA-2 (85.4%) titres, with 77.7% and 92.3% of these being seropositive for 
GADA and IA-2 respectively. IA-2 did not show any significant associations with the candidate 
miRNAs or cfDNA. When analysed in tertiles (Table 5-B), a clear linear trend formed between 
GADA titres and twenty-three candidate miRNAs (Figure 5-8). The abundance of these miRNAs 
increased with GADA titres, with a significant increase found in tertile 3, providing evidence 
that these miRNAs are reflective of the immune status of individuals at diagnosis. 
 
Table 5-B. Tertiles of GADA titres in individuals at T1D diagnosis 
GADA Tertile Individuals (N) Range (U/ml) Median (U/ml) 
Negative 35 - - 
1 43 1.3 – 5.3 3.55 
2 41 5.7 – 27 17.00 
3 48 30 – 2000 295.00 
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Figure 5-8.1. Candidate miRNAs correspond to GADA titres at T1D diagnosis 
(a) Box plot (median, min-max) of GADA tertile spread. (b) MicroRNA abundance in seronegative individuals, and those in 
each GADA tertile. Mean ± SEM. Linear trend significance P < 0.05. ** Adjusted P < 0.01, *** Adjusted P < 0.001, **** 
Adjusted P < 0.0001 compared to Neg (Kruskal-Wallis non-parametric one-way ANOVA with corrected Dunn’s multiple 
comparison test). 
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Figure 5-8.2. Candidate miRNAs correspond to GADA titres at T1D diagnosis 
MicroRNA abundance in seronegative individuals (Neg), and those in each GADA tertile. Mean ± SEM. Linear trend 
significance P < 0.05. ** Adjusted P < 0.01, *** Adjusted P < 0.001, **** Adjusted P < 0.0001 compared to Neg (Kruskal-Wallis 
non-parametric one-way ANOVA with corrected Dunn’s multiple comparison test). 
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5.4.5. MicroRNAs and Cell-free DNA Associate with HbA1c Levels at 
Diagnosis 
To investigate whether the molecular signature was indicative of β-cell function, it was 
compared to HbA1c levels measured at diagnosis. As with GADA titres, the HbA1c levels of 
individuals at diagnosis were split into tertiles and the trend analysed. The details of the 
tertiles can be found in Table 5-C. Methylated and unmethylated insulin cfDNA, as well as 
eight candidate miRNAs demonstrated a significant association with HbA1c levels. Unlike 
GADA titres, all of these molecules demonstrated a quadratic trend, with abundance 
increasing in tertiles 2 and then dropping again in tertile 3 (Figure 5-9). It must be noted that 
14% was the upper limit of detection (any results higher than this were reported as 14.1%) of 
the HbA1c assay used at the Princess Margaret Hospital, and so tertile 3 could contain 
individuals with a higher HbA1c at diagnosis. 
 
Table 5-C. HbA1c tertiles of individuals at T1D diagnosis 
HbA1c Tertile Individuals (N) Range (%) Median (%) 
1 62 6.1 – 10.7 9.3 
2 62 10.8 – 12.8 12.0 
3 63 12.9 – 14.1* 14.1 
  
* The highest reported value for glycated haemoglobin was 14.1% by the pathology lab. In Tertile 3, 58.7% of individuals 
had a HbA1c reported at 14.1%. 
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Figure 5-9. Insulin cfDNA and candidate miRNAs have a quadratic relationship with HbA1c at T1D diagnosis 
(a) Boxplot (median, min-max) of HbA1c tertiles. Cell-free DNA (b) and eight candidate miRNAs (c) demonstrate a quadratic 
relationship with tertiles of HbA1c at diagnosis. Mean ± SEM. Quadratic trend significance P < 0.05.  
* Adjusted P < 0.05, ** Adjusted P < 0.01, *** Adjusted P < 0.001, compared to tertile 1 (Kruskal-Wallis non-parametric one-
way ANOVA with corrected Dunn’s multiple comparison test). 
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5.4.6. Immune Modulation Affects the Circulating Molecular Signature 
 Immune modulation has been proposed as a clinical tool to reduce the loss of residual β-cell 
loss after T1D diagnosis. To assess whether the immune modulatory effect of ingested 
interferon-α causes a change in the molecular signature of β-cell death investigated 
throughout this thesis, the cfDNA and miRNA abundance was measured within the circulation 
of individuals randomised to placebo, 5,000 units, or 30,000 units of hrIFNα, as published 
previously (51). Plasma samples were taken from these individuals at baseline (within 6 weeks 
after diagnosis) and then four subsequent time points. Table 5-D details the average duration 
of each time point. Both methylated and unmethylated insulin cfDNA show no significant 
change over time or between treatment groups. Three miRNAs, miR-27b, -145, and -223, 
demonstrate a significant (P<0.05) elevation in abundance in the placebo group at one time 
point (Figure 5-10). A further four miRNAs, miR-21, -24, -92a, and -152, show a trend toward 
elevated abundance in the placebo group (indicated by a P-value between 0.5 and 0.1). 
Interestingly, miR-27b also demonstrated a significant difference between time points 
(P=0.0329) and a significant interaction between time and treatment (P = 0.0398 measured 
by repeated measures ANOVA). This indicates that the IFNα treatment had a significant 
impact upon this miRNA over the course of the study. 
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Table 5-D. Time points for IFNα or placebo treatment samples 
 
  
 
   
Time Point  
Individuals, N 
(Placebo/5,000/30,000) 
Days After Baseline (mean ± SD) 
T0 13/8/10 0 
T1 13/8/10 102.2 ± 17.3 
T2 13/8/10 203.2 ± 16.3 
T3 13/8/10 307.2 ± 22.4 
T4 13/8/10 420.5 ±43.8 
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Figure 5-10. Changes in miRNA abundance during treatment with hrIFNα or placebo 
Placebo (grey), 5,000 units (red) or 30,000 units (green) of hrIFNα at baseline and four subsequent time points. * P < 0.05 
# P < 0.1 between treatments at the respective time point (test of sum of squares). Mean ± SEM. Dotted line is the limit of 
detection (CRT = 39). 
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5.5. Discussion 
5.5.1. Circulating MicroRNA Signature During T1D Progression 
Previous studies have demonstrated that miRNAs display differential abundance within the 
circulation of individuals with T1D (148-150; 152; 154; 216). What they have yet to 
demonstrate, however, is the change in abundance that these small ncRNAs may show during 
the progression T1D – before, during and after diagnosis. Data from this chapter demonstrate 
that individuals at high risk of T1D (prior to diagnosis) and those at the point of diagnosis 
present with an elevated abundance of numerous candidate miRNA identified throughout the 
remainder of this thesis. Indeed, some of these miRNAs, such as let-7e and miR-103, show a 
significant linear trend, indicating a progressive decline after diagnosis. Furthermore, three of 
these miRNAs, miR-26a, -27a and -374, exhibit similar patterns of abundance within the 
circulation of NOD mice as they progressed to T1D (Figure 3-12). They were elevated in the 
mice prior to the onset of T1D and reduced as they progressed. 
This elevated abundance may be indicative of the chronic underlying β-cell death in the 
progression to clinical disease. Indeed, this may be one of the reasons as to why many of the 
miRNAs display the lowest abundance in the 6 week period following diagnosis; many patients 
enter a “honeymoon phase”, or partial remission, soon after diagnosis, where the 
combination of increased immune tolerance and decreased glucotoxicity and lipotoxicity 
reduce β-cell stress (217). Unfortunately, this phase does not last; the majority of patients 
who enter the honeymoon phase exit it within 12 months (218). The subsequent return of β-
cell stress may drive the increased abundance of select miRNAs, such as miR-21, -27b, and -
222, seen in the <12 months post-Dx group (Figure 5-3) .  Interestingly, some of these miRNAs, 
including miR-127, -145, -22-5p, 27b, -99b, 125a-5p, -152, and -186, significantly rise in the 
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circulation of patients with long-standing T1D, compared with those who were newly-
diagnosed. This may be indicative of β-cell regeneration and the return of a stressed state in 
these individuals. 
Not all of the miRNAs were elevated prior to diagnosis. MicroRNA-375 was significantly 
increased at diagnosis compared to those at high risk. Previous findings (mouse models) 
reported that only a minute proportion (~1%) of miR-375 is actively released into the 
circulation by β-cells, and so this miRNA may be an indicator of acute cell death at diagnosis 
(157). While this miRNAs displays an association with T1D, their use as markers to stratify 
those at high risk may be limited.  
5.5.2. Insulin Cell-free DNA Abundance During T1D Progression 
Unlike the candidate miRNAs, both methylated and unmethylated insulin cfDNA decreased at 
diagnosis and then returning to levels similar to those prior to diagnosis with 12 months 
(Figure 5-5). Patients with long-standing T1D (20 years post Dx) display decreased levels of 
insulin cfDNA, similar to that at diagnosis. This finding is at odds with previous work completed 
by Professor Mirmira’s group, who found them to be elevated at diagnosis and then decrease 
over the following 8 week and 12 month period (168). This study did not evaluate the levels 
in patients with a long disease duration. 
The finding that the insulin cfDNA is reduced in our hands at the point of diagnosis, in contrast 
to opposing findings on similar (at diagnosis) samples by Prof. Mirmira’s group, demands 
further analysis of such at –diagnosis samples with shared analytical as well as sample 
collection protocols to confirm the potential use of these molecules as biomarkers of T1D 
progression. Furthermore, the propensity of these molecules to degrade once released from 
dying cells (seen in the short reported half-life (161; 163; 164) and the islet cell death data 
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discussed in Chapter 3), may explain why previous studies have not been able to easily identify 
individuals that progress to T1D using insulin cfDNA assessment (163). Additionally, freeze-
thaw cycles negatively impact upon the detectable abundance of cfDNA (data not shown). 
This, as well as other parameters, including sample collection, storage conditions and assay 
sensitivity, may account for the discord between multiple research groups.Collaborative 
studies planned between the Hardikar (Sydney) and Mirmira (Indianapolis) groups will 
potentially address these issues in the coming months through exchange of protocols and 
deidentified sample sets for validation across the two labs.   
5.5.3. Clinical Parameters at T1D Diagnosis 
Another important potential use for a molecular signature of T1D progression is to predict or 
assess the immune function and glycaemic control of patients. In this chapter, the relationship 
between the molecular signature and antibody tertiles, as well as HbA1c, at the point of 
diagnosis was also investigated.  
Few studies have examined associations between circulating miRNAs and autoantibody titres 
in subjects with T1D (152; 154). Here, this study has  identified 23 miRNAs that have a 
significantly positive linear relationship with GADA titres, including miR-146a, which has 
previously been identified as reduced in PBMCs with increasing GADA titres (154). This 
reduction in PBMCs may reflect a release of this miRNA into circulation. Increased titres of 
GADA may reflect an increase in immune-mediated islet cell death, causing an increase in 
circulating miRNAs. Furthermore, when the tertiles were examined individually, the majority 
of the identified miRNAs were significantly elevated in tertile 3 when compared to the 
negative group or tertiles 1 and 2 (Figure 5-6). These individuals may be undergoing immense 
islet cell stress or death.  
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 Glycated haemoglobin is a common measure for average BGLs over the previous three-
month period and is used to monitor glucose control in people with diabetes. This measure 
has also been investigated as both a diagnostic criterion (219) and a predictive marker (220) 
of diabetes progression. Both cfDNA and eight miRNAs demonstrated a significant trend with 
HbA1c levels, however it presented as a quadratic relationship (Figure 5-7). This means that 
those individuals with the lowest and highest tertiles of HbA1c demonstrated lower 
abundance of these markers, when compared to the middle tertile. Increased glycaemic 
variability within the second tertile may explain this increase, with tertile 1 and 3 predicted to 
have consistently lower or higher BGLs respectively. Another explanation is that those with a 
lower HbA1c (tertile 1) present with less aggressive β-cell loss at diagnosis, while those at the 
upper tertile have lost a significant portion of functional β-cell mass. Both situations would 
result in decreased release of these microRNA biomarkers. Further investigation is required 
to disseminate the relationship between these markers and measures of glycaemic control. 
For example, the measurement of fructosamine or 1,5-anhydroglucitol in these patients 
would allow the estimation of glycaemic control within a much shorter time span (1 to 2 weeks 
instead of 3 months) (221) to investigate the relationship between these markers short-term 
changes in blood glucose.  Such measurements (i.e Fructosamine assays for glycated albumin 
or the GlycoMark test for 1’5 anhydroglucitol) may be of specific importance in other cohorts 
of islet graft recepients, which are planned for future analysis at the Hardikar lab.  Since islet 
cell death is known to stabilize within 2 to 14 days post-islet transplantation, these 
measurements will provide valuable information to understand the abundance of these 
molecular biomarkers (microRNAs and insulin cfDNA) in such individuals.   
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5.5.4. Effects of Immune Modulation on the Molecular Signature of Β-cell 
Death 
Immune modulation has been presented as a potential therapy for subjects with newly 
diagnosed T1D to preserve the residual β-cell function. Residual β-cell function was previously 
shown to correlate with decreased complication rates (6) and so preservation of this would 
have a significant clinical impact. Ingested IFNα has previously been shown to reduce the 
incidence of diabetes in NOD mice (222) and has been investigated as a treatment for multiple 
sclerosis (223), however its exact biological function remains unclear. The study conducted by 
Rother and colleagues investigating the use of ingested hrIFNα found that the lower dose 
(5,000 units/day) resulted in a significant increase in β-cell function assessed via stimulated C-
peptide AUC when compared to placebo or 30,000 units (51). These samples were analysed 
within this chapter, with seven candidate miRNAs showing changes (Figure 5-8). Overall, 
treatment with ingested hrIFNα seemed to reduce miRNA abundance. This suggests that 
modulating the immune system causes a decrease in the markers of β-cell death, which was 
clinically diagnosed as increase in β-cell function (C-peptide AUC). Additional investigations 
must be conducted to determine differences between the 5,000 units/day and the 30,000 
units/day hrIFNα doses. As mentioned previously, increased residual C-peptide is associated 
with a lower risk of chronic complications (6), and so these therapeutic agents and the 
markers of -cell death and C-peptide secretion could be immensely useful in assessing the 
prognosis of T1D individuals. 
5.5.5. Strengths and Limitations 
This study is the first to offer an insight into circulating miRNAs and cfDNA in individuals 
before, during and after T1D diagnosis, both in those newly diagnosed as well as those with 
long-standing disease and in response to immunomodulation with IFNα. The inclusion of 
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children at high risk of developing T1D is a significant strength. Although not all of the children 
will develop T1D, their high risk status provides a crucial starting point. Samples are still being 
collected from this group, and so further analysis may be completed in the future when it is 
clear as to which individuals have progressed to clinical disease. 
Furthermore, the inclusion of almost 200 individuals at the point of diagnosis allows the 
assessment of these circulating markers with minimal medical intervention (application of 
exogenous insulin). A number of samples from this cohort were taken on the day of diagnosis. 
Other studies have utilised samples from newly-diagnosed patients, some only one month 
post-diagnosis (151; 224), however one cannot discount the effects of medical intervention 
or the honeymoon phase during this time. 
As with all studies, there are limitations. The high risk and <12 months post-Dx groups both 
contained a small number of individuals (N=19) but analysed multiple samples taken on 
different time points. This could assert individual bias into the results and should be repeated 
with larger numbers of individuals. Furthermore, not a significant number of age and gender 
matched control samples were assessed to ensure that the signature allowed clear 
identification and stratification between these groups. Unfortunately, gaining blood samples 
from healthy children tends to be difficult, however, this analysis will be completed in the 
near future as part of the PREDICT T1D study ld by A/Prof. Anand Hardikar at the NHMRC CTC, 
University of Sydney.  This study will also include ~400 and ~700 at diagnosis of T1D individuals 
from HongKong and India, with another subset of samples from Denmark and the Middle East. 
These future studies planned by A/Prof Hardikar as part of the PREDICT T1D study will also 
provide insights in understanding the potential of these molecular biomarkers in T1D 
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individuals from different ethenic backgrounds.  Control samples from age and gender 
matched healthy (non-diabetic) children and adults are available for future analyses.   
5.6. Conclusions 
The miRNA signature identified throughout this thesis exhibits incredible potential to monitor 
individuals progressing to T1D as well as understand the effects of potential therapeutics. The 
abundance of these circulating molecules show significantly different profiles in individuals 
before, during and after T1D diagnosis. The majority (N=27) of the miRNAs are elevated in 
people at high risk of T1D, those at the point of diagnosis, or both. Other miRNAs reach peak 
abundance within 12 months (N=8) or 20 years after diagnosis (N=2). They also demonstrate 
relationships with clinical parameters at diagnosis, including GADA titres and HbA1c. The 
linear relationship seen between miRNA abundance and GADA titres indicates an association 
between these miRNAs and immune function. Insulin cfDNA needs further validation for its 
potential use as a direct biomarker of islet β-cell death and T1D progression, as it decreases 
at the point of diagnosis and after 20 years, making it difficult to stratify individuals solely 
based on cfDNA analysis. It does, however, show a significant relationship with glycaemic 
control at diagnosis. Future studies described above will help to ascertain and cross-validate 
these findings through more rigorous and detailed shairing of protocols, deidentified samples 
and testing in larger numbers of ethnically diverse study samples. 
The application of immune modulatory therapy to subjects with newly diagnosed T1D causes 
a shift in the miRNA signature of β-cell death. The use of hrIFNα often resulted in a decrease 
in miRNA abundance. This underscores the use of these microRNAs as an indicator of the 
residual functional β-cell mass preservation during immune-mediated β-cell death in 
individuals with Type 1 Diabetes. 
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6. Conclusions 
This thesis, and the four years of work dedicated to its composition, details the journey of 
identification and characterisation of a molecular signature of β-cell death and T1D 
progression. There are numerous conclusions to be made from this body of work, each 
discussed in detail in the relevant chapters. Together, these chapters highlight the impact that 
the choice of a technology/platform can make on a miRNA signature, the central use of models 
of disease, and the importance of unbiased profiling. Due to the completion of these initial 
stages, the resulting molecular signature displays great potential in identifying individuals 
before, during and after T1D diagnosis.  
This thesis investigated the use of a preliminary miRNA signature as a biomarker of β-cell 
death and T1D progression. As discussed within the introduction, there were 50 miRNAs that 
made up this preliminary signature. Figure 6-1 gives an overview of some of the important 
miRNAs highlighted through the studies outlined in this thesis. Seven of these miRNAs were 
found to be released due to islet cell stress/death, elevated in NOD mice, and elevated in 
human clinical samples from individuals at high risk of T1D or at the point of diagnosis. These 
miRNAs should be the focus of subsequent investigations in order to further refine this 
signature. While this thesis describes a substantial body of evidence for the use of these 
miRNAs as biomarkers of β-cell death, it is important to note that 10 miRNAs that were initially 
identified did not show significant changes during islet SNP exposure, NOD mice progression, 
or in high risk individuals or patients at the point of diagnosis (Figure 6-1).  
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Figure 6-1. Overview of major miRNA findings 
Venn diagram of PREDICT T1D miRNAs found to be elevated in NOD mice (blue circle), released after human islet SNP 
exposure (yellow circle), elevated in individuals at high risk of T1D or at the point of diagnosis (red circle), or a combination 
of all three. MicroRNA-9, -126, -155, -188, -210, -220c, -301b, -326, -340-3p, -409-5p, -558, and -625 were not found to 
significantly change in any of these studies. 
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6.1. Implications of Thesis Findings 
The data presented within this thesis has wide ranging implications for researchers and 
clinicians interested in monitoring the progression of individuals to T1D or response to 
potential therapeutics, or indeed anyone investigating the use of miRNAs as biomarkers of 
islet β-cell death and diabetes progression. First and foremost, the technology used to identify 
and characterise circulating miRNAs can have a tremendous impact upon the final signature. 
This is a factor that seldom receives the attention it deserves. For the signature to have proven 
efficacy, and to make this transition to diagnostics, the detection method must be highly 
reliable and reproducible. Furthermore, the studies presented in Chapter 2 demonstrate that 
moving to higher throughput platforms resulted in a reduction of sensitivity, especially for the 
low abundance transcripts. A balance must be struck between sensitivity and throughput; this 
is especially difficult due to the immense number of human miRNAs that one needs to assess.  
Using the OpenArray technology, a signature of miRNAs that are released during islet cell 
stress/death, which are elevated in NOD mice prior to immune infiltration and glycaemic 
dysfunction, and those that are differentially abundant in subjects with T1D compared with 
controls, and whose levels change during T1D progression, were identified. Although the 
signature requires further refinement to increase its power to stratify individuals undergoing 
β-cell death, it presents a solid platform from which to do so. This is underscored by the 
evident associations of these miRNAs with measures of autoimmunity, glycaemic control and 
β-cell function.  
Methylated and unmethylated insulin cfDNA, the focus of much recent interest, did not 
appear to function as efficiently as a marker of β-cell death. While it was released during islet 
cell death assays, it can be promptly degraded; a finding in line with previous studies that 
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identified a short half-life of cfDNA in vivo (161; 163; 164). Furthermore, insulin cfDNA was 
decreased at the point of diagnosis and after 20 years, which is in contrast to a report (168) 
on similar at-diagnosis of T1D samples, necessitating further testing/validation of these 
biomarkers. This observation is also significantly different to previous studies employing 
methylated and unmethylated insulin cfDNA as a biomarker of T1D progression (163; 168; 
172). These molecules do, however, demonstrate an association with glycaemic control at 
diagnosis, and so their use as clinical markers should not be dismissed without future testing.  
In conclusion, these thesis findings support the use of circulating miRNAs and cfDNA as 
markers of pancreatic islet β-cell death, T1D progression, immune function and glucose 
homeostasis .  
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6.2. Future Directions 
The present study was planned by A/Prof. Anandwardhan A. Hardikar (NHMRC CTC, University 
of Sydney), as part of his JDRF Australia T1D Clinical Research Network fellowship. Future 
investigations can build upon and refine the findings outlined in this thesis. In particular future 
studies will focus on refining the signature to achieve the desired power to stratify individuals 
who progress to T1D. To enable this, the following studies will be performed: 
1. Assessment of this signature in low risk children without T1Dto assess who do and do 
not progress to T1D over time.  This  would confirm its elevation and determine the 
power with which one can utilise it to discriminate between these populations. These 
studies are currently being carried out on pediatric plasma samples obtained through 
Professors Kim Donaghue and Alicia Jenkins. 
2. Refinement of this signature coupled with further analysis in high risk individuals that 
do and do not progress to T1D would highlight the power of this signature to identify 
and stratify progressors.  
3. Longitudinal studies are needed to investigate whether this molecular signature could 
predict the time to diagnosis. As demonstrated earlier, the microRNA abundance-
based prediction of residual C-peptide mass will help in understanding the potential 
benefit conferred by a treatment strategy (eg. Interferon therapy). 
In addition to the important studies outlined above, it would be of great interest to 
researchers to: 
4. Identify the tissue of origin of the miRNAs. As discussed earlier, not all of the candidate 
miRNAs are release by islets, and so studies could aim to identify which other cell 
types are responsible for their release into circulation. Such studies are already being 
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carried out as part of another PhD project in the Hardikar lab wherein microRNA 
discovery analyses in several hundreds of human tissues (including islets), will 
generate expression maps of tissue-nriched microRNAs. 
5. Assess whether the release is active or passive. Active release would suggest that the 
miRNAs are not merely markers of disease but signalling molecules released in 
response to stress.  
6. As each microRNA can target several mRNAs, it would be important to investigate the 
mRNA target(s) for a signature of microRNAs so as to identify whether these miRNAs 
have a role in bringing about β-cell death rather than just being circulating biomarkers 
of the process. 
Future studies that are underway in the Hardikar lab as well as in several other leading 
laboratories worldwide will help to address these and several other important questions in 
understanding the potential of these molecular biomarkers of β-cell death. The data 
presented through this thesis offer further advance to the existing data from the Hardikar lab 
in terms of protocol optimization, T1D biomarker discovery and clinical validation studies that 
will help to guide further research. Hopefully, future studies will answer these and many other 
questions in predicting the progression to Type 1 Diabetes and offer simpler and more 
powerful tools to assessing the potential of such therapies in preserving functional β-cell mass 
in individuals at high risk of Type 1 Diabetes. 
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Supplementary Chapter 1: MicroRNA Spike-in Optimisation 
S1.1. Chapter Overview 
The use of endogenous controls is a crucial aspect of many techniques utilised in molecular 
biology. Many ncRNAs have been identified and utilised as endogenous controls in plasma and 
serum samples, however there has not been a consensus regarding which ncRNA/s are the 
most effective controls for this sample type. Due to the cell-free nature of serum and plasma, 
all ncRNAs present within these samples originally came from the surrounding cells, either 
through organised secretion, or as a result of cellular stress and/or death.  
The expression of 11 commonly used endogenous controls was analysed within these 
circulating samples.  These studies identified that the oftn-cited “housekeeping” microRNAs 
have marked variability within biofluids. The use of synthetic spike-in miRNAs was therefore 
optimised taking into consideration the microRNAs from two genetically diverse organisms; 
Caenorhabditis elegans and Arabidopsis thaliana, as potential spike-in controls for both RNA 
isolation and reverse transcription. The optimal spike-in amount was optimized to be 250 
femtomoles (fmol) for RNA isolation and 150 attomoles (amol) for reverse transcription. 
Interestingly, while none of the synthetic miRNAs demonstrated homology to human ncRNAs, 
C. elegans miRNAs were detectable in sample that did not contain the spike-in, indicating 
some cross-talk in the miRNA assays designed for these analysis. Furthermore, the use of an 
automated RNA isolation technology greatly improved the stability of spike in controls, 
possibly as a result of less human error. The use of synthetic non-human miRNAs to control 
for introduced variability allows researchers to avoid inherent issues with circulating 
endogenous controls.   
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S1.2. Chapter Aims 
Studies in this chapter  aimed to: 
1. assess the suitability of commonly used endogenous control ncRNAs for 
normalisation of qPCR data; 
2. investigate the use of synthetic miRNA spike-in molecules as controls for variation 
introduced during different stages along the RNA isolation and reverse 
transcription workflow for microRNA estimation; 
3. (a) identify the optimal amount of spike-in to be added, and (b) at which protocol 
step to do so; and 
4. compare the impact of manual versus automated RNA isolation on the recovery 
of spike-in controls. 
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S1.3. Methods 
S1.3.1. Synthetic MicroRNAs 
Synthetic miRNAs were selected from the nematode Caenorhabditis elegans and the plant 
Arabidopsis thaliana. The names and sequences can be found below: 
Organism miRNA Sequence (5’-3’) 
Caenorhabditis elegans 
cel-miR-39 UCACCGGGUGUAAAUCAGCUUG 
cel-miR-54 UACCCGUAAUCUUCAUAAUCCGAG 
cel-miR-238 UUUGUACUCCGAUGCCAUUCAGA 
Arabidopsis thaliana 
ath-miR-159a UUUGGAUUGAAGGGAGCUCUA 
ath-miR-172a AGAAUCUUGAUGAUGCUGCAU 
Table S1-A. Synthetic microRNA sequences. 
 
All synthetic miRNAs were manufactured by Sigma. The miRNAs were reconstituted in 
nuclease-free water and spiked-in at the appropriate amount to the relevant samples. Each of 
these synthetic miRNAs were compared with human miRNA database using the BLASTN 
function of miRBase. None of these sequences exhibited homology to known human miRNAs. 
 
S1.3.2. RNA Isolation 
RNA was isolated from plasma samples using the manual SOP outlined in Appendix B or the 
automated SOP outlined in Appendix C, apart from the spike-in step.  Synthetic miRNAs were 
added at differing amounts and at different steps within the manual SOP as outlined within 
the results. For each comparison, plasma samples were mixed thoroughly and then aliquots 
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were created for each experimental condition, thereby eliminating any differences from 
improper mixing  and sampling. The samples that underwent automated RNA isolation did so 
as per the SOP outlined in Appendix C.                      
S1.3.3. Reverse Transcription and Quantitative PCR 
Reverse transcription and quantitative PCR for all spike-in comparisons was conducted using 
the 96-well plate protocol published previously (188). The samples included in the manual 
versus automated RNA isolation comparison underwent RT, pre-amplification and qPCR as per 
the OpenArray LSI protocol outlined in Appendix D. 
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S1.4. Results 
S1.4.1. Endogenous Controls  
The abundance of eleven small nucleolar (sno)RNAs were measured in four plasma samples. 
These snoRNAs are commonly utilised as endogenous controls, however Figure S1-1 shows 
that these ncRNAs demonstrate marked variability. Indeed, six of the eleven ncRNAs were 
undetectable in one or more of the samples tested. U6, the most commonly used ncRNA 
endogenous control, had a higher abundance than the other ncRNAs tested, although it 
demonstrated considerable variability between samples, with a CT range of 21.7 to 28.9.  
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Figure S1-1. Circulating endogenous ncRNA controls demonstrate marked variability 
Eleven ncRNAs commonly used as endogenous controls were measured using RNA isolated from four plasma samples. Each 
sample was run in duplicate. Limit of detection (dotted line) is 39 cycles. Solid line = mean. 
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S1.4.2. Synthetic Caenorhabditis elegans MicroRNAs 
To determine the optimal RNA isolation spike-in amount, four differing amounts of C. elegans 
miRNAs, cel-mir-39, -54 and -238, were added to three plasma samples during RNA isolation. 
The abundance of these spike-in miRNAs can be found in Figure S1-2. The optimal amount was 
deemed to be 250 fmol as it displays a final abundance that will work effectively on both low, 
medium and high-throughput qPCR systems. Medium and high-throughput qPCR systems, 
such as the TLDA and OpenArray platforms respectively, require pre-amplification before 
quantitation, which may reduce the CT value. Therefore, using 2.5 pmol of spike-in that 
displays an average CT value of 10.1 on a low-throughput platform may not be assessed 
accurately on higher throughput technologies. Interestingly, the endogenous U6 also seems 
to decrease in abundance with the C. elegans spike-in, despite being isolated from the same 
plasma sample.  
Figure S1-2. Optimisation of synthetic miRNA input for RNA isolation.  
Three synthetic C. elegans miRNAs (cel-miR-39, cel-miR-54 and cel-miR-238) were spiked into plasma samples during RNA 
isolation at 2.5 picomoles (pmol), 250 fmol, 25 fmol or 5 fmol. These miRNAs were then quantitated via qPCR. U6 is included 
as an indicator of endogenous miRNA. Limit of detection (dotted line) is 39 cycles. Solid line = mean. 
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When samples were assessed with and without C. elegans RNA isolation spike-in, those 
without the spike in still demonstrated amplification, albeit at a much lower CT (Figure S1-3). 
This suggests the possibility of assay crosstalk or sequence homology with an as-yet 
uncharacterised human miRNA. This severely undermines the use of C. elegans miRNAs as 
synthetic RNA isolation controls.  
Figure S1-3. Evaluation of synthetic C. elegans microRNAs as controls for RNA isolation.  
Two synthetic miRNAs (cel-miR-39 and -238) were spiked into plasma samples during RNA isolation (black circles). They were 
then quantitated via qPCR and compared to the same plasma samples with no spike in miRNAs (No spike-in, red circles). N = 7 
per group. Limit of detection (dotted line) is 39 cycles. Solid line = mean. 
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Figure S1-4. Optimisation of synthetic miRNA input for reverse transcription. 
Cel-miR-54 was added to the reverse transcription reaction at 25 fmol, 5 fmol or 150 amol and then quantitated by qPCR. 
Limit of detection (dotted line) is 39 cycles. N = 3 for 25 fmol (upside down triangles), 4 for 5 fmol (circles), 7 for 150 amol 
(squares), and 14 for No spike-in (triangles). Solid line = mean. 
 
One C. elegans miRNA, cel-miR-54, was selected to optimise the amount needed for a reverse 
transcription spike-in. As there should be ~100% conversion of miRNAs during this process, 
the amount of spike in was reduced to either 25 fmol, 5 fmol or 150 attomoles (amol) per 
reaction. The abundance of these spike-in miRNAs can be found in Figure S1-4. As with the 
RNA isolation spike-in, 150 amol was deemed to be the optimal RT spike-in amount as it 
displays a final abundance (average CT = 16.8) that will work effectively on both low, medium 
and high-throughput qPCR systems. Again, samples without the C. elegans spike-in still 
displayed amplification (average CT = 29.9), undermining the use of this miRNA as an RT 
control. 
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S1.4.3. Synthetic Arabidopsis thaliana MicroRNAs 
Although the use of C. elegans miRNAs allowed for the optimisation of RNA isolation and RT 
spike-in amounts, the detection of these miRNAs in samples with no spike-in added 
undermines the efficacy of these molecules as controls. As such, miRNAs from another model 
organism, Arabidopsis thaliana, were assessed as RNA isolation and RT spike-in controls 
(Figure S1-5).  
Two A. thaliana miRNAs, ath-miR-159a and -179a, were used for RNA isolation and RT 
respectively. One sample displayed significantly lower RNA isolation spike-in, possibly due to 
the variability of manual RNA isolation. The other samples displayed minimal variability (CT 
range 17-17.4). Ath-miR-159a was not detectable in samples with no spike-in. The majority of 
samples without the RT spike-in had no detectable ath-miR-172a. One sample demonstrated 
very low abundance of ath-miR-172a (CT = 36.3). One sample demonstrated very low 
abundance of ath-miR-172a (CT = 36.3). Endogenous U6 abundance was not affected by the 
presence of ath-miR spike-ins.   
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Figure S1-5. Evaluation of synthetic A. thaliana microRNAs as controls for RNA isolation and reverse transcription. 
250 fmol of ath-miR-159a was added to four plasma samples during RNA isolation, and 150 amol ath-miR-172a was added 
during reverse transcription. They were then quantitated via qPCR. U6 is included as an indicator of endogenous miRNA. Limit 
of detection (dotted line) is 39 cycles. Solid line = mean. 
 
To determine the optimal stage of RNA isolation to introduce the synthetic ath-miR spike-in, 
250 fmol was added directly to the plasma sample, after the addition of the TRIzol reagent 
(step 4 of the SOP in Appendix B) or after incubation with TRIzol (step 5 of the SOP). Despite 
adding the ath-miR spike-in to the plasma sample ~5 mins prior to the addition of the TRIzol 
reagent, significant degradation of this miRNA was seen when measured via qPCR (Figure 
S1-6). No significant difference was observed when the spike-in was added after TRIzol 
addition or incubation.  
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Figure S1-6. Addition of spike-in control during different steps of RNA isolation. 
250 fmol of ath-miR-172a was added to six plasma samples at different steps in the RNA isolation protocol. Isolated RNA was 
quantitated for ath-miR-172a expression via qPCR. Limit of detection (dotted line) is 39 cycles. Solid line = mean. **** 
P<0.0001 (T-test). 
 
S1.4.4. Manual Versus Automated RNA Isolation 
To determine the efficacy of automated RNA isolation (QIAcube HT), plasma samples 
underwent manual and automated RNA isolation using 250 fmol ath-miR spike-in. These were 
then quantitated using the OpenArray qPCR platform; the CRT values are shown in Figure S1-7. 
The manual RNA isolation protocol resulted in a lower average abundance of the ath-miR 
spike-in. The manual method also demonstrated a large spread of CRT values, while the 
automated method only had two samples with a CRT value >10.  
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Figure S1-7. Manual versus automated RNA isolation. 
Quantitation of the ath-miR spike-in added to plasma samples that underwent manual (red circles) and automated (green 
squares) RNA isolation. N = 367 manual, 633 automated. Solid line = mean. **** P<0.0001 (T-test).  
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S1.5. Discussion  
Controls are essential in many facets of molecular biology, including qPCR. They allow 
researchers to account for variability introduced during the experimental procedure or 
subsequent analysis. The use of these controls relies on the basis that their expression, inspit 
of being low or high in abundance, is within the measurable (linear) range and is unchanged 
in different conditions or across different groups of individuals. As shown in this chapter, the 
commonly used endogenous snoRNAs, such as U6 and RNU6B (225; 226), demonstrated 
marked variability within circulating plasma samples. Indeed, some of these ncRNAs were 
undetectable in some samples, making them ineffectual controls for this sample type. 
A growing number of studies are employing synthetic miRNA spike-ins to their samples as an 
alternative to endogenous controls. The majority of these use C. elegans derived miRNAs, 
particularly the three described here, cel-miR-39, -54, and -238 (227; 228). This may be due 
largely to the fact that they utilise Qiagen miRNA isolation kits, which routinely include or 
recommend synthetic cel-miR-39 as a spike-in control. All three of these cel-miRs were 
detectable within human plasma samples (Figures S1-3 and S1-4), despite no spike-in being 
added, and no homology to known human miRNAs. This suggests a possible crosstalk between 
miRNA assays, or homology to unknown human ncRNAs. Either possibility undermines the use 
of this family of miRNAs as spike-in controls. Furthermore, endogenous U6 appeared to 
decrease with the cel-miR spike-in. As these experiments were conducted using identical 
plasma samples, this indicates that cel-miR spike-ins could impact the quantitation of 
endogenous miRNAs. These data demonstrate that synthetic cel-miR spike-in controls may 
have troubling effects upon generated data and should not be utilised as controls.  
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Synthetic miRNAs derived from Arabidopsis thaliana do not seem to share these unintended 
effects.  Plasma samples absent of the ath-miR RNA isolation spike-ins demonstrated no 
detectable amplification when using the associated assays. One spike-in negative sample had 
detectable ath-miR RT spike-in, however the transcript abundance was very low (CT = 36.3) 
and so may have been unintentional contamination when setting up the RT reactions. The 
abundance of endogenous U6 was unchanged with the addition of ath-miR spike-in. 
Previously, naked cel-miRs were found to degrade quickly when added into plasma sample 
due to the inherent nuclease activity. This correlates with the data presented here (Figure S1-
6), and confirms that the spike-in must be introduced after the addition of TRIzol, which 
denatures these enzymes. Due to these results, ath-miR spike-in controls were introduced to 
the RNA isolation and RT protocols that are used throughout this thesis. 
The RNA isolation protocol has also been adapted to take place upon an automated platform 
(QIAcube-HT), which not only increases the sample throughput, but also increases the 
retrieval of the spike-in and reduces sample-to-sample variability (Figure S1-7).     
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S1.6. Conclusions  
Synthetic Arabidopsis thaliana miRNAs were found to be the most effective spike-in controls, 
when utilised at 250 fmol (RNA isolation) or 150 amol (RT). Furthermore, the RNA isolation 
protocol was optimised by identifying the optimal step to introduce the spike-in, as well 
moving the procedure to an automated platform. By comparing and optimising these 
processes, any introduced variability in the generated data will be minimised.  
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Supplementary Chapter 2: Digital PCR Platform 
Comparison 
S2.1. Chapter Overview 
Digital PCR (dPCR) is becoming an increasingly popular method of quantifying nucleic acids as 
it is able to provide absolute quantitation of target gene/transcript copies, thereby offering a 
more sensitive and absolutely quantifiable technology than conventional real-time qPCR 
technologies that allow relative quantification of target genes/transcripts.  It is a technological 
refinement of qPCR that is achieved by splitting the clonal amplification into thousands of 
distinct reactions. By reading the fluorescence of each of these reactions as positive (the 
sequence of interest is present) or negative (no sequence of interest), digital PCR can apply 
the Poisson distribution to calculate the absolute copy number of the sequence of interest. 
Like any other technique, multiple platforms have been developed to utilise it and these must 
be compared to ensure robust reproducibility and ease of use.  
This chapter compares two of the three currently available digital PCR platforms; the 
QuantStudio 3D (QS3D, Applied Biosystems) and the QX200 (Bio-Rad).  The third currently 
available platform (RainDrop Plus™ Digital PCR system from RainDance®) was not assessed 
due to unavailability of a distributor in Australia at the time of this testing.  The QS3D uses a 
finely-crafted chip with 20 thousand individual wells to partition the amplification reaction, 
while the QX200 system relies on a droplet generator that splits the PCR reaction into up to 
20 thousand aqueous droplets within an emulsion oil. The reproducibility of each platform 
was assessed using mixtures of methylated and unmethylated insulin DNA plasmids, obtained 
from Professor RG Mirmira, as part of an existing collaboration with A/Prof. Hardikar. The 
QX200 was more reproducible than the QS3D, and allows a significantly higher number of 
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samples to be analysed in each run. The QS3D produced higher copy numbers but also 
detected copies in the no template controls more frequently. Overall, the QX200 provided the 
reproducibility and throughput needed for large scale clinical analysis.  These analyses were 
carried out prior to finalization of procurement of the digital PCR platform in the Hardikar lab.  
All samples and data described in the thesis were assessed on the BioRad® QX200 system 
using droplets generated on the automated droplet generator from BioRad®.  
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S2.2. Chapter Aims 
Studies in this chapter aimed to: 
• assess the reproducibility of the QS3D and QX200 digital PCR platforms, and 
• compare their ease of use, as well as the capability of their softwares for downstream 
analysis. 
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S2.3. Methods 
S2.3.1. Plasmids 
Unmethylated (UM) and methylated (M) Ins plasmids were kindly provided by Professor 
Raghu Mirmira from Indiana University, USA as part of the existing collaboration with A/Prof. 
Hardikar, NHMRC CTC, University of Sydney. Plasmids were amplified using the plasmid 
transformation protocol outlined in Appendix H. Purified plasmids were combined to create 
solutions with varying percentages of each unmethylated (UM) and methylated (M) plasmids. 
The percentages used were 100, 99.9, 99, 90, 75, 50, 25, 10, 1, 0.1 and 0%. Each mixture had 
the remaining percentage made of the other plasmid (i.e. the 90% UM plasmid solution had 
10% M plasmid). Each solution had a final concentration of 0.5 pg/μl.  
S2.3.2. Digital PCR 
Digital PCR was completed using manual droplet generation/chip loading as per the respective 
manufacturer’s protocol. Each plasmid mixture (described in S2.4.1) and a no template control 
(NTC) was run in triplicate. To effectively compare the two platforms, the digital PCR reaction 
was identical: 1X QuantStudio 3D Digital PCR Mastermix v2 (Applied Biosystems) or 1X ddPCR 
Supermix for Probes (No dUTP) (Bio-Rad), 1X Custom TaqMan SNP assay AH21BH1, 10U 
EcoR1, nuclease-free water and 0.5 pg (1 μl) of the plasmid mix. Once the reactions were 
partitioned, they were thermocycled using the following cycling conditions: 95°C for 10 mins, 
40 cycles (94°C for 3 mins, 57.5°C for 1 min), 98°C for 10 mins, 12°C hold. The ramp rate for 
thermocyling was set to 2˚C/sec for all steps.  
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S2.4. Results 
S2.4.1. Overview of Digital PCR Platforms 
Figure S2-1 gives an overview of the dPCR technologies that have been compared; the 
QuantSudio 3D system uses a chip containing 20,000 wells (Figure S2-1b), while the QX200 
generates up to the same number of oil droplets (Figure S2-1d). During normal operation, 
however, neither of these platforms utilise the maximum 20,000 partitions. Rather, the QS3D 
employed 17,300 ± 624.3 (mean ± SD) wells and the QX200 generated 16,524 ± 1863 
(mean ± SD) usable droplets (Figure S2-2). While both platforms had enough partitions to 
estimate absolute copy numbers, the QS3D demonstrated more consistent partitioning.  
   
 
Figure S2-1. Digital PCR platforms 
(a-b) QS3D platform with (a) chip reader and (b) close-up of QS3D chip wells. (c-d) QX200 platform with (c) manual droplet 
generator (right) and reader (left), and (d) generated dPCR droplets. Images taken from each of the manufacturer’s websites.  
a 
b 
c 
d 
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Figure S2-2. Number of partitions created for digital PCR. 
Scatterplot showing the number of wells (QS3D, blue) or droplets (QX200, green) utilised for the calculation of absolute DNA 
copy numbers. N = 36 per group. Mean ± SEM.   
 
Once the dPCR reactions have been completed, a threshold must be placed on both the FAM 
and VIC fluorescence to determine which partitions are negative for both probe, which are 
positive for a single probe, and which are positive for both probes. As seen in Figure S2-3, the 
QX200 consistently separates droplets into these four distinct populations. The identification 
of these populations varies on the QS3D platform, resulting in an overlay with no discernible 
populations. This makes setting a threshold for multiple samples difficult using this platform. 
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Figure S2-3. Overlay of dPCR results 
Overlay of negative, single probe positive (FAM or VIC) and dual positive wells/droplets from 36 dPCR reactions run on the 
(a) QS3D and (b) QX200.  
Additional comparative parameters are listed in Table S2-A. The QS3D is more suited to lower 
throughput experiments as the minimum number of samples required to complete a run is 
lower than the QX200. However, the time needed to load and partition a sample is significantly 
longer using the QS3D, meaning that the maximum number of sample that can be run in a 
single day is dramatically less. This increase in throughput using the QX200 can be further 
expanded utilising an automated droplet generator. Unfortunately, the QS3D had no 
automated platform at the time of this comparison, or even until the submission of this thesis. 
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Table S2-A. Digital PCR platform comparison  
 QS3D QX200 
Minimum samples per run 4* 8 
Maximum samples per run 24 96 
Maximum samples per day  48 192 
Time to load one sample 
(mins) 
5 1 
Ease of loading ++ +++ 
Ease of analysis +++ +++ 
Possibility of automation? No Yes 
 
* Whilst one sample can be run at a time, the included reagents necessitate multiples of four to be run to avoid wastage. 
 
S2.1.1. Digital PCR Platform Accuracy and Reproducibility 
The plasmid mixtures outlined in S2.4.1 were analysed on both dPCR platforms, with their 
expected and observed percentages plotted in Figure S2-4. Data obtained from both platforms 
show that the methylated Ins plasmid was estimated to have a greater percentage than 
expected in all combinations (Figure S2-4). This may be due to the fact that the probes only 
differ by one base and so some crosstalk may occur. Indeed, FAM positive wells/droplets show 
a small degree of VIC fluorescence, while those positive for VIC show a small amount of FAM 
fluorescence (Figure S2-3).  
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Figure S2-4. Expected versus observed plasmid mixtures. 
Dotted lines are expected percentages. Each plasmid mixture was run in triplicate. 
 
Interestingly, when the absolute copy numbers were examined, the QS3D demonstrated 
consistently higher measurements than the QX200 (Figure S2-5). However, the measurements 
obtained from the QS3D also demonstrated a higher level of variability, with significantly 
higher assay CVs than the QX200 platform (Figure S2-6).  
 
Figure S2-5. Absolute quantification of plasmid mixtures. 
Absolute copy numbers generated from QS3D and QX200 platforms. Each plasmid mixture was run in triplicate. 
Solid line = mean.  
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Figure S2-6. Digital PCR coefficient of variation analysis 
CV distribution for unmethylated and methylated assays run on QS3D (blue) and QX200 (green). Mean ± SEM. ****P<0.0001. 
 
Finally, when NTCs were analysed on the dPCR platforms, the QS3D detected DNA copies more 
frequently than the QX200 (Figure S2-7). This may be due to an inherent overestimation of 
DNA copy numbers, which could then explain why plasmid copy numbers were also elevated 
compared to the QX200, or an increased risk of contamination as all plasmids and NTCs were 
run together.   
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Figure S2-7. Absolute quantitation of no template controls. 
NTC was run in triplicate on the QS3D (blue) and QX200 (green) platforms. Solid line = mean. 
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S2.2. Discussion 
 Digital PCR offers advantages over other PCR technologies; it allows absolute quantitation of 
very low nucleic acid copy numbers, and therefore is able to detect much smaller differences 
between samples. As a result, it is the favoured method of quantitating the low levels of 
circulating cfDNA. As discussed within Chapter 2, the choice of technology can heavily 
influence the generation and reproducibility of the data. As such, the two currently available 
dPCR technologies, the QuantStudio 3D and the QX200 were directly compared in this 
chapter. Despite generating consistently more reaction partitions, the QS3D demonstrated 
greater sample variability than the QX200 (Figure S2-6) and was therefore the least preferred 
system.  Studies planned and carried out herein led to the procurement of the BioRad QX200 
system with the manual as well as the automated droplet generators in the Hardikar lab.  
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S2.3. Conclusions 
This analysis has demonstrated that the QX200 dPCR system has greater reproducibility, 
throughput and ease of use, when compared to the QS3D. As such, it is the preferable 
platform to undertake cfDNA quantitation in larger clinical cohorts.    
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Supplementary Data: Clinical Data Integrity 
Standard operating procedures in the Hardikar Lab emphasize on the need for replicates, 
repeats and controls.  These are introduced in every sample assay procedure carried out in 
the lab so as to ensure data integrity, especially when assessing large number of clinical 
samples within the same plate/slide or across multiple plates/slides.  As a general rule, specific 
requests to the manufacturer were made to order OpenArrays from the same batch and also 
to cross-check assay performance between different batches.  For the custom OpenArray 
slides, the sample that lay at position A1 was repeated at a random position in the same slide.  
This “repeat” sample would allow identification of any position effects for the same assay on 
the array. One sample was chosen at the start to the study to be present at the same position 
(D12) on each slide. This “Control”sample ensured the performance of these OpenArrays 
across different plates, across different runs as well as between different batches of arrays.  
Technical “replicates” were carried out to assess for any variation in the automated array 
loading procedres. A schematic representation of the plate map/desin is presented in Figure 
SD-1.  
The intra-slide repeats demonstrated significantly high correlation with their corresponding 
sample (Figure SD-2), while the inter-assay control exhibited low coefficient of variation 
(Figure SD-3). This indicates little variation both within and across OpenArray slides. 
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Figure SD-1. Schematic of control samples for custom OpenArray slides 
The sample at position A1 (blue) is repeated at a random position (R, blue) throughout the slide (intra-slide repeat). A control 
sample is placed at position D12 (C, green) on every slide (inter-assay control). 
 
 
 
 
 
Figure SD-2. Correlation of intra-slide repeats 
Box and whiskers plot of Spearman R-values for correlations between samples located at position A1 and their repeats. All 
correlations P<0.0001. Mean = 0.93. Median = 0.95. Whiskers = min/max. N = 25 samples. 
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Figure SD-3. Coefficient of variation analysis of inter-assay control 
CVs are plotted for all detectable miRNAs within the inter-assay control sample. Mean ± SEM. N = 46 miRNAs. 
 
 
 
As the ddPCR plates all contained positive plasmid controls, only repeats were conducted. As 
seen in Figure SD-4, the repeats demonstrated a highly significant correlation with their 
original sample, indicating minimal technical variation. 
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Figure SD-4. Digital droplet PCR sample repeat correlations 
(a) Unmethylated and (b) methylated Ins cfDNA correlations for samples repeated on the ddPCR platform. Pearson R. N = 54 
pairs.  
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These supplementary datasets demonstrate the optimization procedures that were finalized 
prior to in vitro, animal model and clinical sample assessment, presented in this thesis.  
These optimization procedures help to achieve the desired clarity for reproducing the 
findings presented in this thesis as well as to provide a guide for similar studies from other 
research groups in assessing a large number of biomarkers using the molecular 
technologicalworkflows described in this thesis.    
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Appendix A: Cellular RNA Isolation SOP 
Reagents 
1) 1.7 ml microcentrifuge tubes (Axygen, MCT-175-C) 
2) TRIzol (Ambion, 15596018) 
3) Chloroform (Sigma, 2432-500ml) 
4) Isopropyl alcohol, IPA (Sigma, 59304-1L-F) 
5) 100% ethanol (Sigma, E7023-500ml) 
6) Fresh aliquot of nuclease-free water 
7) P10, P20, P200 and P1000 filtered tips 
8) RNase AWAY (highly preferred but not essential) 
 
All plastic ware should be nuclease free. Never stick your hands into containers of nuclease-
free plastic ware. Always pour out what is required.     
 
Equipment 
1) Refrigerated centrifuge for Eppendorf tubes set at 4°C 
2) Vortex mixer 
3) Well calibrated micropipettes designated for (pre-PCR) nucleic acid isolation 
 
Reagent Setup 
1) Allow samples to thaw thoroughly on ice prior to commencing. 
a. Due to the time involved in each stage of processing, a maximum of 8 
samples should be processed at a time. 
2) Set temperature on centrifuge to 4°C 
a. Run “Fast Temp” program if changing rotor or a quick cool down is required. 
b. Use a dedicated centrifuge with appropriate rotor 
3) Clean gloves with RNase Away prior to commencing. 
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Procedure 
1) Lyse cells by adding 1 ml of Trizol to each sample in a 1.7 ml Eppendorf tube. For this 
protocol use 1 ml of Trizol. If a different volume of Trizol is used, the volume of all other 
reagents must be altered accordingly to maintain the correct ratios.  
2) Add 200 µl of chloroform to each sample and shake vigorously for 1 min. This ensures 
correct mixing. Do not vortex at this stage. 
3) Immediately centrifuge the tubes at 12,000 xg for 15 mins at 4°C.  
4) Carefully remove the upper aqueous (clear) layer (400-500 µl) into a fresh 1.7 ml 
microcentrifuge tube. Use a 200 µl pipette and tips to remove this gradually. Note: 
There will be a large amount of white precipitate at the interface between the organic 
and aqueous layers. Do not disturb this layer. After the removal of 400-500 µl there 
will still be some of the aqueous layer left; try to remove as much as possible without 
contamination. 
5) Add 500 µl of IPA. 
6) Mix gently by inverting 7-10 times. Do not vortex or shake tubes. 
7) Incubate for 10 mins at RT.  
8) Centrifuge at 12,000 xg for 15 mins at 4°C. A pellet may not always be visible at this 
stage, so always orient the tubes with the hinge facing outwards to allow estimation 
of the pellet location – in the bottom towards the hinge. 
9) Prepare a fresh volume of 75% ethanol while the samples are spinning. For 8 samples, 
add 6.75 ml of 100% ethanol to 2.25 ml of nuclease-free water (9 ml in total). 
10) Carefully aspirate and discard the supernatant by placing the pipette tip along the 
wall of the tube opposite to the hinge. When removing the supernatant, reduce the 
size of the pipette as you go to minimise disturbance to the pellet. Ideally, use a P200 
initially, then a P20 when getting closer to the pellet. 
11) Add 1 ml of freshly prepared 75% ethanol to each tube and briefly vortex.  
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12) Centrifuge at 12,000 xg for 15 mins at 4°C. As in #8, orient tubes with the hinge facing 
outwards. 
13)  Carefully aspirate and discard the supernatant by placing the pipette tip along the 
wall of the tube opposite to the hinge. As before (#10), reduce the size of the pipette 
when removing the supernatant. Ideally, use a P200 initially then a P10 to remove as 
much ethanol as possible. 
14) Allow the tubes to dry at RT for 5 minutes. Lay the tubes flat with their lids open. If 
there are large droplets, gently twist the tube to spread out the liquid, allowing it to 
dry faster. Note: Do not over dry the samples as this will reduce the solubility of the 
RNA. 
15) Add 15 μl of nuclease-free water to each tube and resuspend. Always store RNA on 
ice after this stage. The volume may vary depending on the pellet size. 
16) Measure concentration of RNA using Nanodrop. If you are not going to proceed with 
downstream analysis immediately, skip this step and store your RNA. Always measure 
(Nanodrop, Qubit or Bioanalyzer) before downstream processing. 
17) Store RNA at -80°C. Always log your sample details in the -80°C freezer log on the 
networked lab drive. 
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Appendix B: Biofluid RNA Isolation SOP 
Reagents 
1) Nuclease-free 2 ml microcentrifuge tubes (Axygen, MCT-200-C) 
2) Glycogen (nuclease-free) 10 μg/μl (Sigma)  
3) TRIzol (Ambion, 15596018) 
4) Chloroform (Sigma, 2432-500ml) 
5) Isopropyl alcohol, IPA (Sigma, 59304-1L-F) 
6) 100% ethanol (Sigma E7023-500ml) 
7) Fresh aliquot for nuclease-free water 
8) P10, P20, P200 and P1000 filtered tips 
9) RNase AWAY (highly preferred but not essential) 
 
All plastic ware should be nuclease free.   Never stick your hands into containers of nuclease-
free plastic ware.  Always pour out whatever is required. 
 
Equipment 
1) Refrigerated centrifuge for Eppendorf tubes set at 4°C 
2) Vortex mixer 
3) Well calibrated micropipettes designated for (pre-PCR) nucleic acid isolation 
 
Reagent Setup 
1) Allow samples to thaw thoroughly on ice prior to commencing. 
a. Due to the time involved in each stage of processing, a maximum of 8 samples 
should be processed at any time by a single user. 
2) Set temperature on centrifuge to 4°C 
a. Run “Fast Temp” program if changing rotor or a quick cool down is required. 
b. Use a dedicated centrifuge with appropriate rotor. 
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3) Clean gloves with RNase Away prior to commencing. 
Procedure 
1) Mix sample by gently pipetting up and down, then take out 200 l* into a 2ml 
microcentrifuge tube. 
2) Vortex and briefly spin glycogen (20 mg/ml stock) to mix, then add 1μl to each sample. 
3) Add 1 ml of Trizol to each tube.  Yellow globules appear in the solution after adding 
TRIzol. These dissipate following vortexing and do not seem to affect downstream 
processing.  
4) Vortex each tube for 20 seconds. 
5) Incubate at RT (22-24°C) for 10 minutes. 
6) Add 5 µl of 50 nM ath-miR-172a spike in control to each tube, then vortex for 5 secs. 
7) Add 200 μl of chloroform to each tube and shake vigorously for 40 seconds. Place the 
tubes in a rack and ensure each tube is secured properly with your hand. This ensures 
proper mixing of Trizol and chloroform after addition. Note: DO NOT vortex the tubes 
at this stage. 
8) Incubate at RT for 15 minutes. 
9) Centrifuge 12,000 xg for 15 minutes at 4°C. 
10) Transfer 600-800 μl of the upper aqueous (clear) phase to a fresh 2 ml microcentrifuge 
tube. Use a 200 μl pipette and tips to remove this gradually. Note: There will be a large 
amount of white precipitate at the interface between the aqueous and organic layer. 
Do not disturb this layer. After the removal of 800 μl there will still be some aqueous 
layer left; try to remove as much as aqueous layer that you can without any 
contamination. 
11) Add 1.1 ml of IPA to each tube in 2x 550 μl aliquots. Note: It is normal that the tubes 
will be very full at this stage. Be careful to label tops and have clean (dry) fingers to 
avoid accidental erasure of labels.   
12) Vortex each tube for 5 seconds. 
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13) Incubate at RT for 10 minutes. 
14) Centrifuge at 12,000 xg for 8 minutes at 4°C. A pellet may not be visible at this stage, 
so always orient the tubes with the hinge facing outwards to allow estimation of the 
pellet location - in the bottom towards the hinge.   
15) Prepare a fresh volume of 75% ethanol while the samples are spinning. For 8 samples, 
add 6.75 ml of 100% ethanol to 2.25 ml of nuclease-free water (9 ml in total) 
16) Carefully aspirate and discard the supernatant by placing the pipette tip along the 
wall of the tube opposite to the hinge. When removing the supernatant, reduce the 
size of the pipette as you go to minimise disturbance to the pellet. 
17) Add 1 ml of freshly-prepared 75% ethanol to each tube and invert 5 times. If a pellet 
is visible, you will see it floating after inversion. 
18) Centrifuge at 7,500 xg for 5 minutes at 4°C. 
19) Carefully remove and discard supernatant. As before (step 16), reduce the volume of 
the pipette when removing the supernatant.  
20) Allow the tubes to dry at RT for 5 minutes. Do not over dry the samples as this will 
reduce the solubility of the RNA.  If you have left excess ethanol and are not confident 
in removing it without disturbing the pellet, you may need to incubate tubes at 37°C 
for maximum of 3 minutes.  Any longer can damage RNA quality. 
21) Add 10 – 15 μl of nuclease-free water to each tube and resuspend. Always store RNA 
on ice after this stage. The volume may vary depending on the pellet size. 
22) Measure concentration of RNA using Nanodrop. The 260/280 ratio may be as low as 
1.3 but this does not affect downstream processing.  If you are not going to proceed for 
downstream analysis immediately, then skip this step and proceed to store your RNA.  
Always measure (Nanodrop, Qubit or Bioanalyzer) before downstream processing. 
23) Store RNA at -80°C. Always log your sample details in the -80°C freezer log on the 
networked lab drive.   
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Appendix C: Automated RNA Isolation SOP 
Reagents 
1) Collection microtubes (Qiagen, 19560) 
2) Lids for collection microtubes (Qiagen, 19566) 
3) Glycogen (nuclease-free) 10 μg/μl (Sigma)  
4) TRIzol (Ambion, 15596018) 
5) Chloroform (Sigma, 2432-500ml) 
6) Isopropyl alcohol, IPA (Sigma, 59304-1L-F) 
7) 50 nM ath-miR-172a (8-well strips, stored in -80°C freezer) 
8) RNeasy 96 QIAcube HT kit (Qiagen, CAT 74171) 
9) QIAcube HT Plasticware (Qiagen, CAT 950067) 
10) Tip disposal box (Qiagen, CAT 990550) 
11) Reagent trough with lid, 70 ml (Qiagen, CAT 990554) 
12) Reagent trough with lid, 170 ml (Qiagen, CAT 990556) 
13) Filter tips, OnCor C, 200 µl (Qiagen, CAT 990610) 
14) P10, P20, P200 and P1000 filtered tips 
15) RNase AWAY (highly preferred but not essential) 
 
All plastic ware should be nuclease free.   Never stick your hands into containers of nuclease-
free plastic ware.  Always pour out whatever is required. 
 
Equipment 
1) QIAcube HT 
2) Refrigerated centrifuge for plates set at 4°C 
3) Vortex mixer 
4) Well calibrated micropipettes designated for (pre-PCR) nucleic acid isolation 
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Reagent Setup 
1) Allow samples to thaw thoroughly on ice prior to commencing. 
2) Clean gloves with RNase Away prior to commencing. 
 
Procedure 
1) Mix sample by gently pipetting up and down, then aliquot 100l into one collection 
microtube (96 racked). 
2) Vortex and briefly spin glycogen (10 µg/µl stock) to mix, then add 1μl to each sample. 
3) Add 500 µl of Trizol to each tube.  Yellow globules appear in the solution after adding 
Trizol. These dissipate following vortexing and do not seem to affect downstream 
processing.  Wear appropriate PPE and be careful when vortexing or shaking tubes 
containing Trizol. 
4) Vortex the microtubes for 40 secs or until the yellow globules disappear. 
5) Incubate at RT (22-24°C) for 10 minutes. 
6) Briefly centrifuge (1 min, 1500 rpm) the racked microtubes at 4°C to remove Trizol 
from the caps. 
7) Add 2.5 µl of 50 nM ath-miR-172a spike in control to each tube. One 8-well strip 
contains enough for an entire 96-well plate. 
8) Add 100 μl of chloroform to each tube and shake vigorously for 40 seconds. Secure 
the caps using an upside down plastic lid and elastic bands as shown below. 
Note: DO NOT vortex the tubes at this stage. 
 
  Appendices 
250 
 
              
 
9) Incubate at RT for 15 minutes. 
10) Centrifuge 3,200 x g for 25 minutes at 4°C. 
11) Turn on QIAcube HT system. Remove tip eject cover (red). Open the pre-treatment 
run file. 
12)  Place microtubes into position C1 of the QIAcube HT. The trough holder in this 
position must be removed first. 
13) Load an empty S-block into position B1. Load tips. 
14) Begin the run. This program will transfer 300 µl of aqueous phase into the S-block. 
15) Remove the microtubes. For protein/DNA analysis, store these samples at -80°C. Place 
the trough holder back into this position. 
16) Open the purification run file. 
17) Load the appropriate reagents in their respective troughs. See software for specific 
volumes. Ensure there is a little excess volume to avoid running out mid-cycle.  
18) Load RNeasy plate and Elution plate in A1 (left/right respectively). Ensure that A1 is 
top left. The left section of A1 is for waste, while the right is for elution. 
19) Load tips (2x96). Start the run and complete the pre-run checklist. 
20) Remove the Elution plate. Cap these tubes and then store at -80°C. Always log your 
sample details on the networked database. 
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21) Remove the reagent troughs and discard remaining liquid. All troughs, except the Top 
Elute, may be rinsed with nuclease-free water and left to dry. The Top Elute trough 
must be wiped out with a Kim wipe. Reagent troughs can be used for a maximum of 
one month or one full RNeasy kit before being discarded. 
22) Remove channel block (three pieces) and pour 20 ml of RO water down the waste 
chute. Replace the tip eject cover (red). Ensure that the rubber gasket is removed from 
the filter carriage for cleaning.  
23) Soak channel block in 1% Trigene for 15 – 30 mins. Rinse with RO water. Dry. 
24) Run cleaning cycle, including UV if this is the last run of the day. Select to turn off after 
the cleaning cycle is completed.   
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Appendix D: OpenArray Low Sample Input SOP 
Reagents 
1) Custom OpenArray Slides (Applied Biosystems, 4470813) 
2) Custom RT primers (included with custom slides) 
3) Custom PreAmp primers (Applied Biosystems, 4441856) 
4) TaqMan microRNA reverse transcription kit (Applied Biosystems, 200 rxn 4366596, 
1000 rxn 4366597) 
5) 15 nM ath-miR-159a synthetic miRNA (Sigma) 
6) OpenArray 384-well sample plate (Applied Biosystems, 4406947) 
7) Aluminium Seal (Beckman-Coulter, 538619) 
8) TaqMan PreAmp mastermix (Applied Biosystems, 1 ml 4391128, 5 ml 4488593) 
9) TE Buffer (Invitrogen, 12090015) 
10) OpenArray accessories kit (Applied Biosystems, 4453975) 
11) TaqMan OpenArray real-time PCR mastermix (Applied Biosystems, 1.5 ml 4462159, 
5 ml 4462164) 
12) AccuFill tips (Applied Biosystems, 1 box 4457246, 10 boxes 4458107) 
13) Filtered pipette tips 
14) Nuclease-free water (Qiagen, 129117) 
15) 0.2 ml 96-well plates (Axygen, PCR-96M2-HS-C) 
 
All plastic ware should be nuclease free.   Never stick your hands into containers of nuclease-
free plastic ware.  Always pour out whatever is required. 
 
Equipment 
1) Thermocycler  
2) QuantStudio™ 12K Flex Accufill System 
3) QuantStudio™ 12K Flex Real-Time PCR System 
4) Vortex 
5) Centrifuge 
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6) Axymat Silicon Seals (Axygen, AM-96-PCR-RD) 
 
Reagent Setup 
1) Download the relevant run file/s (.tpf) from the Life Technologies website 
(https://www.thermofisher.com/au/en/home/products-and-services/product-
types/download-openarray-tpf-and-spf-plate-files.html) using the lot and serial 
number of the slide. 
2) Thaw all reagents on ice, except for the RT enzyme, which must remain at -20°C 
until use. 
 
Procedure 
 
Reverse Transcription 
 
1. Dilute the RNA samples to <10 ng/µl. This protocol is designed for samples with low RNA 
concentrations. Diluting to <10 ng/µl (around 8.5 ng/µl is sufficient) allows for >1µl to be 
taken in the next step, increasing accuracy. 
2. Add 10 ng of RNA to the respective well of a 96-well plate and then bring the volume to 
3 ul. 
3. Create an RT mastermix using the components from the reverse transcription kit, as 
detailed below. It is recommended to add 5% excess to account for pipette error. 
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Component Per reaction (μl) 
Custom RT Primers 0.75 
dNTPs with dTTp (100 mM) 0.15 
RT Buffer (10X) 0.75 
MgCl2 (25 mM) 0.9 
RNase Inhibitor (20 U/µl) 0.09 
Nuclease-free Water 0.25 
ath-miR-159a Spike In (15 nM) 0.10 
Multiscribe Reverse Transcriptase (50 U/µl) 1.5 
Total 4.5 
 
4. Pipette to mix and then centrifuge briefly at 10,000 x g for 10 sec (quick spin). 
5. Aliquot 4.5 µl of the mastermix into each well. Seal with a silicon seal. 
6. Invert to mix and then quick spin. 
7. Incubate on ice for 5 min. 
8. Place into the thermocycler and run the following program: 40 cycles (16 °C for 2 min, 42 
°C for 1 min, 50 °C for 1 sec), 85 °C for 5 min, hold at 4 °C. 
9. cDNA can be stored at -20°C or used immediately. 
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Preamplification 
  
10. Create a preamp mastermix using the components listed below. Swirl the PreAmp 
mastermix prior to use. It is recommended to add 5% excess to account for pipette error. 
Component  
Per reaction 
(μl) 
TaqMan PreAmp Mastermix (2X) 20 
Custom PreAmp Primers (10X) 4 
Nuclease-free water 8.5 
Total 32.5 
 
11. Invert to mix, and then quick spin. 
12. Aliquot 32.5 µl of the mastermix into each well. 
13. Invert to mix, and then quick spin. 
14. Incubate on ice for 5 mins. 
15. Place into thermocycler and run the following program: 95°C for 10 mins, 55°C for 2 mins, 
72°C for 2 mins, 16 cycles (95°C for 15 secs, 60 °C for 4 mins), 99°C for 10 mins, hold at 4°C. 
16. Invert preamplified cDNA and then quick spin. 
17. Dilute 1:20 by adding 4 µl of preamplified cDNA to 76 µl of 0.1X TE buffer. 
18. Both diluted and undiluted preamplified cDNA can be stored at -20°C for up to 1 week 
or used immediately. 
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Loading OpenArray Slides and Performing qPCR 
 
19. Combine 5 µl of diluted, preamplified cDNA to 5 µl of TaqMan OpenArray real-time PCR 
mastermix in a new 96-well plate. Seal with a silicon seal. 
20. Vortex and quick spin. 
21. Aliquot 5 μl of each sample into 1 well of the 384-well sample plate. The position of each 
sample will depend on the configuration of the custom slide. Each well of the sample plate 
corresponds to one subarray of the OpenArray slide. An entire slide will take 48 wells (4 
rows, 12 columns, see figure below). 
 
 
22.  Seal the samples plate. It is advisable to pre-cut the seal into the required sections, so 
the sections may be sealed/unsealed individually to reduce evaporation. Alternatively, the 
plate may be sealed with an intact seal, and then sections can be individually cut out when 
loading. 
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23. Centrifuge the sample plate at 490 xg for 1 min at 4°C. Load the OpenArray slides within 
1 hr.    
24. Remove the required slides from the freezer and allow them to come to room 
temperature (~15 mins). As these slides work on hydrophobic/hydrophilic interactions, 
condensation should be avoided.  
25. Set up consumables from the accessory kit. 
25.1. Gently pull on the plunger of the immersion fluid syringe to loosen. Remove cap, 
place tip on and flush air from the tip.  
25.2. Removed slide lid and plug from packaging. 
25.3. Place the loading system tips within the machine and remove lid.  
25.4. Place sample plate within PCR system.  
25.5. Put gloves on. Use a size lower than normal to minimise the risk of accidentally 
marking the slide lid. 
25.6. Carefully open slide packaging. Slowly tip slide into hand. Do not touch the top of the 
slide. Place slide into the AccuFill, with the barcode on the left. 
25.7. Remove seal from the portion of the sample plate intended for loading. Use the 
loading system software to enter the slide barcode, slide position, sample position 
and tip configuration. 
26. When all relevant checks are completed, press load slide. While the PCR system is 
loading the slide, remove the clear and red plastic from the bottom of the slide lid. When 
finished loading, carefully remove and seal the slide within 90 sec. 
26.1. Place the slide within the plate clamp. Place the slide lid onto the slide. Clamp for 30 
sec. Ensure the lid is positioned so that barcode is correctly displayed. Remove the 
assembly from the plate clamp. 
26.2. Position immersion fluid syringe within the slide so that the tip is pressing against the 
lid. Slowly fill slide with immersion fluid, ensuring the fluid runs along the lid. Once 
full, seal the slide with the plug, turning the screw until the handle breaks off. 
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26.3. Remove the plastic cover on the top of the slide lid, and then carefully place into the 
slide carrier of the real-time PCR system. Ensure there is support on the bottom of 
the slide as it is being lowered, so it does not drop suddenly, and do not touch the 
top of the slide. It is OK to touch the sides of the slide/cassette.  
27. Initialise the QuantStudio 12K Flex and start the qPCR run. 
27.1. Select “OpenArray” within the PCR-system software. Press “Find Slide IDs”. This will 
take a few mins. If the software cannot find the plate ID, it will ask for it to be entered 
manually. 
27.2. Press “Confirm Plate Centres”. Again, this will take a few mins. Check that the red dot 
is within the centre and that there are no fingerprints/marks on the top of the slide. 
Load the respective tpf file for each slide and specify a result file name and location. 
Press “Start Run”. The program will take approximately 2 hr to complete. 
  
  Appendices 
259 
 
Appendix E: Cell-free DNA Isolation SOP 
Reagents 
1) 1.7 ml microcentrifuge tubes (Axygen, MCT-175-C) 
2) QIAmp DNA Blood Mini Kit (Qiagen, 50 rxns 51104, 250 rxns 51106) 
3) Poly(A) (10mg/ml) (Sigma 9403) 
4) Dulbecco’s Phosphate Buffered Saline, DPBS (Gibco, 14190-250) 
5) 100% Ethanol (Sigma, E7023-500ml) 
6) Fresh aliquot for nuclease-free water 
7) 15 ml tubes (Falcon, FAL352096) 
8) P10, P20, P200 and P1000 filtered tips 
 
All plastic ware should be nuclease free.   Never stick your hands into containers of nuclease-
free plastic ware.  Always pour out whatever is required. 
 
Equipment 
1) Centrifuge for Eppendorf tubes. 
2) Vortex mixer 
3) Well calibrated micropipettes designated for (pre-PCR) nucleic acid isolation 
4) Thermomixer or convection oven set at 56°C. 
 
Reagent Setup 
1) Allow samples to thaw thoroughly on ice prior to commencing. 
2) Set temperature on thermomixer or convection oven to 56°C. 
3) Prepare buffers as per Qiagen manual. 
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Procedure 
1. Bring sample volume1 to 200 µl total, using DPBS. 
2. Add 20 µl Qiagen protease. 
3. Add 200 µl Buffer AL. 
4. Add 1 µl poly(A).  
5. Vortex for 8 sec. 
6. Incubate at 56°C for 10 min.  
7. Briefly centrifuge for 7 sec. 
8. Add 230 µl of 96-100% Ethanol.  
9. Vortex for 8 secs and then briefly centrifuge. 
10. Add the sample mixture (~630 ul) to QIAamp Mini Spin column.  
11. Centrifuge at 6,000 xg for 1 min.  
12. Place column in a clean tube and discard flow-through.  
13. Add 500 µl Buffer AW1 to column.  
14. Centrifuge at 6,000 xg for 1 min and discard flow-through. 
15. Add 500 µl Buffer AW2 to column.  
16. Centrifuge at full speed (20,000 xg) for 3 min. 
17. Put column in a new 2 ml collection tube.  
18. Centrifuge at full speed (20,000 xg) for 1 min. 
19. Put column in a 1.7 ml microcentrifuge tube.  
20. Put 60 µl Buffer AE directly on the filter. Switch tips between samples to avoid cross-
contamination. 
                                                     
1 It is recommended to use 50 µl, however this protocol works with volumes between 20-200 µl. 
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21. Incubate at room temperature for 5 min.  
22. Centrifuge at 6,000 xg for 1 min. Discard filters. 
23. Measure concentration of cfDNA, go straight to bisulfite conversion, or store cfDNA 
at -20°C. Due to the addition of poly(A), the Nanodrop will not provide accurate 
quantitation of the DNA. Qubit or Bioanalyzer must be used for DNA quantitation. For 
long-term storage, place the DNA in -80°C. For high sensitivity applications, store in 
aliquots to avoid multiple freeze-thawing.  
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Appendix F: Human Islet Cell Death Assay SOP 
Reagents 
1) Sterile 1.7 ml microcentrifuge tubes (Axygen, MCT-175-C) 
2) Sterile 15 ml tubes (Falcon, FAL352096) 
3) Ethanol (70%) for disinfection 
4) Sodium Nitroprusside (SNP) (Sigma, 71778) 
5) CMRL media (no glutamine) (Gibco, 11530037) 
6) CMRL media + 2% bovine serum albumin, BSA (Roche, 10775835001) + 
2X GlutaMAX* (Gibco, 35050-061) 
7) Dulbecco’s phosphate buffered saline, DPBS (Gibco, 14190-250) 
8) P10, P20, P200 and P1000 autoclaved tips 
9) P1000 autoclaved tips with the end cut off 
10) 10 ml serology pipette tips 
11) 24 well cell suspension plates 
12) 0.2 µm syringe filter 
13) 2 ml syringe 
 
Equipment 
1) Water bath set at 37°C 
2) Centrifuge with 15ml swing-bucket rotor 
3) Microcentrifuge 
4) Well calibrated micropipettes designated for cell culture 
5) Electronic serological pipette 
 
Reagent Setup 
1) Set water bath to 37°C 
a. Place PBS and CMRL + 2% BSA + 2X GlutaMAX into the water bath for >15 
mins 
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2) Label 1.7ml Eppendorf tubes 
a. One per well for the islet cell pellet 
b. Three per well for the supernatant aliquots 
3) Clean gloves, and anything else entering the biosafety cabinet, with 70% ethanol 
prior to use 
 
Procedure 
Plate Setup 
 
1) Prepare a fresh stock solution of 40 mM SNP by dissolving the SNP crystals in PBS. 
0.0596 g SNP in 5 ml PBS. Vortex to dissolve crystals.  
2) Dilute SNP to 20 mM in CMRL (nothing added). 
3) Sterilise 20 mM SNP solution by passing it through a 0.2 um syringe filter. Remove 
plunger from syringe, attach filter, pour in 20 mM SNP solution, and then push liquid 
through using the plunger. Ensure there is a sterile tube to collect the sterilised solution. 
It is also recommended to pre-wet the syringe filter by passing through a small amount of 
CMRL media to avoid binding SNP to the filter. 
4) Serially dilute the SNP solution in sterile CMRL (nothing added). This should be 
completed as 1:10 dilutions to make 2 mM, 200 uM, 20 uM and 2 uM SNP. 
5) Aliquot 500 ul of each SNP dilution into the respective well of a 24-well suspension plate. 
It is recommended to perform three technical replicates. If you are intending to perform 
staining or FACS on these cells, create additional replicates. 
6) Place the plate into an incubator at 37°C with 5% CO2. This will warm the media prior to 
the addition of the islets. 
 
Islet Addition 
 
7) Place islets into a 15 ml Falcon tube and centrifuge at 1500 rpm for 2 min. Discard 
supernatant. 
8) Resuspend islets in 10 ml warm PBS.  
9) Centrifuge at 1500 rpm for 2 mins. Discard supernatant. 
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10) Repeat steps 8 and 9. 
11) Resuspend islets in CMRL + 2% BSA + 2X GlutaMAX. Add an appropriate volume of media 
so 200 IEQs will be added in 500 ul of media, with 5-10% extra to account for pipette error.  
12) Gently mix islets and then add 500 ul of the islet suspension to each well of the SNP 
plate. Use the P1000 pipette tips with the end cut off to avoid shearing the islets. It is very 
important to mix the islets between every aliquot. It is also recommended to add the islets 
across the SNP dilutions rather than adding to all replicates of one condition before moving 
on to the next. This will evenly spread out any variation among all of the conditions.  
13)  Place the plate into the incubator at 37°C with 5% CO2 for 24 hours. Take note of the 
time when the plate was placed into the incubator. 
 
Islet and Supernatant Harvest 
 
14) Gently mix the islets and media, and then transfer to a sterile 1.7 ml Eppendorf tube. 
Use the P1000 pipette tips with the end cut off to avoid shearing the islets. 
15) Centrifuge at 2000 rpm for 2 mins. Always orient the tubes with the hinge facing outwards 
to allow estimation of the pellet location - in the bottom towards the hinge. 
16) Carefully aspirate 900 ul of the supernatant into a fresh 1.7 ml Eppendorf tube by placing 
the pipette tip along the wall of the tube opposite to the hinge. Place the supernatant on 
ice at this stage.  
17) Mix supernatant by pipetting 5 times, and then aliquot 300 ul in two additional 1.7 ml 
Eppendorf tubes. 
18) Centrifuge the tubes containing the islets at 2000 rpm for 2 mins. Always orient the tubes 
with the hinge facing outwards to allow estimation of the pellet location - in the bottom 
towards the hinge 
19) Carefully aspirate and discard the remaining supernatant by placing the pipette tip along 
the wall of the tube opposite to the hinge.  
20) Store the supernatant aliquots and islet pellets at -80°C. Always log your sample details 
in the -80°C freezer log on the networked lab drive.   
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Appendix G: Mouse Terminal Blood Collection 
and Dissection SOP 
Reagents1 
1) 1.7 ml microcentrifuge tubes (Axygen, MCT-175-C) 
2) 0.1 M EDTA, pH 7.5-8 
3) Dulbecco’s Phosphate Buffered Saline, DPBS (Gibco, 14190-250) 
4) 4% paraformaldehyde, PFA 
5) 21G needles 
6) 2ml syringes 
7) Liquid nitrogen or dry ice 
8) Wet ice 
9) 70% Ethanol for disinfection 
10) Isofluorane  
11) Blood glucose testing strips 
 
Equipment 
1) Isofluorane anaesthetising equipment 
2) Secured nose cone 
3) Calibrated blood glucose testing meter 
4) Sterilised dissection equipment (160 °C overnight/200 °C for ≥2 hours) 
5) Working area with absorbent mat 
 
Setup 
1) Mice should be fasted for 12-14 hours overnight prior to this procedure. 
2) Weigh and record the tubes containing DPBS. 
3) Attach a needle to a syringe for each mouse to be processed. 
                                                     
1 Reagents required will depend on the downstream applications. 
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4) Ensure there is a different set of scissors and forceps for each tissue, kept in 
separate, labelled positions. 
5) Aliquot the following reagent into separate 1.7 ml tubes as necessary: 
a. 10 µl 0.1M EDTA pH7.5-8 (1 per mouse) 
b. 500 µl DPBS (1 per mouse) 
c. 500 µl 4% PFA (1 per tissue) 
 
Procedure 
1. Weigh mouse. Record their weight on the Record Sheet. 
2. Anaesthetise the mouse using 3% isofluorane with 0.5 L/min oxygen. Ensure that reflexes are 
absent before moving to the next step. 
3. Transfer mouse to the working area (laying it on its back) and continue to anaesthetise using 1.5-
2% isofluorane administered through the nose cone. 
4. Disinfect the abdomen with 70% ethanol. 
5. Collect blood via cardiac puncture. Insert a 21 G needle under the ziphoid process (base of the 
sternum), parallel to the mouse’s body, angled slightly to the right (mouse’s left). Once blood is 
seen in the syringe, gently pull back on the plunger. 
6. Euthanise the mouse via cervical dislocation. Turn off the isofluorane. 
7. Remove the needle from the syringe and then slowly dispense the blood into the tube containing 
0.1M EDTA (pH7.5-8). Place used needle in the appropriate sharps container. 
8. Invert to mix and then place on ice.  
9. Measure the blood glucose using the small amount of blood left in the syringe. 
10.  Disinfect the abdomen again using 70% ethanol. 
11. Using scissors, cut away the skin to expose the peritoneum. Use forceps to pinch the skin away 
from the peritoneum, create a small incision, and then separate the skin from the peritoneal 
membrane. This minimises fur contamination.   
12. Open the peritoneum, being careful not to cut any of the underlying organs. 
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13. Identify the pancreas and carefully remove the organ. The pancreas is located on the right side 
(left side of the mouse) and is easily located by gently pulling on the dark red spleen. The pancreas 
is attached to several points of the spleen, stomach and duodenum; these points must be carefully 
cut away to release the pancreas.  
14. Place the pancreas into the tube containing DPBS, weigh the tube, and then record this 
measurement. This will allow measurement of the pancreas weight. 
15. Remove the pancreas from the DPBS, gently remove excess liquid by dabbing it onto some tissue 
paper and then store appropriately. If the pancreas is needed for RNA/DNA isolation, place into 
an empty tube and snap freeze using dry ice or liquid nitrogen. If it is required for staining, store 
in 4% paraformaldehyde and place on wet ice. If both are required, use a sterile scalpel to cut the 
pancreas lengthwise prior to storage. 
16. Remove any other tissues that are required and store appropriately.  
17. Discard the carcass by placing it into the provided plastic bag and store it in the animal house 
freezer for disposal. 
18. Centrifuge the blood at 2000 xg for 20 mins at 4°C. 
19. Aliquot the plasma into fresh 1.7 ml tubes.  
20. You may isolate RNA directly from the fresh plasma, or store the aliquots at -80°C. Always log 
your sample details in the -80°C freezer log on the networked lab drive. 
21. Store snap-frozen tissues at -80°C. Always log your sample details in the -80°C freezer log on the 
networked lab drive. 
22. Store tissues in 4% PFA at 4°C. 
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Appendix H: Plasmid Transformation SOP 
Reagents: 
1) MAX Efficiency® DH5α™ Competent Cells (Invitrogen, CAT 18258-
012) 
2) S.O.C media (included with the cells, stored in the fridge) 
3) Luria-Bertani (LB) agar plates with 50 µg/ml ampicillin 
4) LB broth with 50 µg/ml ampicillin (100 ml per plasmid of interest) 
5) Filtered pipette tips 
6) Wet ice 
7) 1.7 ml Eppendorf tubes 
8) 75% ethanol 
9) ZymoPURE Plasmid Midi Prep DNA Isolation Kit (Zymo D4200) 
 
All plastic ware should be nuclease free.   Never stick your hands into containers of nuclease-
free plastic ware.  Always pour out whatever is required. 
Equipment 
1) Culture spreader (glass pasteur pipette moulded using a bunsen burner) 
2) Bunsen burner 
3) Bacterial incubator set at 37°C 
4) Water bath or thermoblock set at 42°C 
5) Bacterial shaking incubator set at 37°C 
 
Reagent Setup 
1) Allow plasmids to thaw thoroughly on ice prior to commencing 
2) Place the required number of Eppendorf tubes on ice (number of plasmids to be 
transformed plus one control) 
3) Bring the S.O.C media to room temperature 
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Procedure 
1. Thaw cells on wet ice. It is recommended not to freeze-thaw the cells often as it 
reduces the transformation efficiency. 
2. Gently mix the cells and then aliquot 100 µl into each of the pre-chilled Eppendorf 
tubes. Refreeze any unused cells in a dry ice/ethanol bath for 5 minutes before 
returning to the -70°C freezer.  Do not use liquid nitrogen. 
3. Add 5 µl (50 pg) of pUC19 control plasmid DNA to one tube of cells. Move the pipette 
through the cells while dispensing. Tap the cells to mix. 
4. Add 1 µl (1-10 ng) of your plasmid of interest into their respective tubes of cells. 
Move the pipette through the cells while dispensing. Tap the cells to mix. 
5. Incubate cells on ice for 30 mins. 
6. Add cells to the waterbath or thermoblock at 42°C for 45 secs. Do not shake. 
7. Place on ice for 2 mins. 
8. Add 900 µl of room temperature S.O.C. medium. 
9. Incubate at 37 °C shaking at 225 rpm for 1 hour. 
10. Dilute the control 1:100 with S.O.C. medium and then spread 100 µl onto one LB agar 
plate. This step should always be done next to a lit Bunsen burner to minimise 
contamination. The spreader should be sterilised by soaking it in 75% ethanol and then 
using the burner flame to burn away the alcohol. This should be done before spreading 
and between each plate.  
11. Spread 200 µl of the cells transformed with your plasmid of interest onto an LB agar 
plate. To increase your chances of growing a viable colony, you may plate the full 1 ml 
onto five (5) separate plates. 
12. Place the plates upside down in the 37°C bacterial incubator overnight. 
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13. Count the colonies on the control pUC19 plate, and then use the following equation 
to determine the transformation efficiency: 
 
𝑪𝑭𝑼
𝝁𝒈
=
𝒄𝒐𝒍𝒐𝒏𝒊𝒆𝒔
𝟓𝟎 𝒑𝒈
×(𝟏×𝟏𝟎𝟔𝒑𝒈/𝝁𝒈)×
𝟏 𝒎𝒍
𝟎. 𝟏 𝒑𝒍𝒂𝒕𝒆𝒅
×𝟏𝟎𝟐 
 
14. Identify any colonies growing on the other plates. 
15. Transfer a colony to a 4 ml of LB broth with 50 µg/ml ampicillin. Use a sterilised wire 
loop or pasteur pipette to pick up the colony. 
16. Cover the flask with parafilm and then place the LB broth in the bacterial shaking 
incubator at 37°C for 3 hours, shaking at 300 rpm. 
17. Transfer this 4 ml into the remaining 96 ml in a flat-bottom flask. 
18. Incubate overnight in the shaking incubator at 37°C, shaking at 200 rpm. 
19. If the media looks turbid, use 50 ml of the liquid to isolate the plasmid. Plasmid 
isolation is done using the Zymo Plasmid DNA Isolation Kit as per the manufacturers 
protocol. 
 
  
  Appendices 
271 
 
Appendix I: Bisulfite Conversion SOP 
Reagents: 
1) Nuclease-free 1.7 ml microcentrifuge tubes (Axygen, MCT-175-C) 
2) EZ DNA Methylation-Lightning Kit (Zymo Research 50 rxns D5030, 
200 rxns D5031)  
3) Filtered pipette tips 
 
All plastic ware should be nuclease free.   Never stick your hands into containers of nuclease-
free plastic ware.  Always pour out whatever is required. 
 
Equipment 
1) Centrifuge designed for 2 ml tubes 
2) Vortex mixer 
3) Well calibrated micropipettes designated for (pre-PCR) nucleic acid isolation 
4) Thermocycler 
 
Reagent Setup 
1) Allow samples to thaw thoroughly on ice prior to commencing. 
 
Procedure 
1) Add 130 µl of Lightning Conversion Reagent to 20 µl1 of DNA sample. If <20 µl of DNA 
is to be used, make up the additional volume with nuclease-free water. 
2) Mix thoroughly by pipetting 20 times. Briefly centrifuge. 
3) Place samples into a thermocycler and run the following program: 
                                                     
1 A maximum of 20 µl of isolated DNA may be used in this kit. If a greater input is required, concentrate your 
sample or complete the bisulfite conversion in multiple 20 µl aliquots. 
  Appendices 
272 
 
a. 98˚C for 8 min 
b. 54˚C for 60 min 
c. Hold at 4˚C for up to 20 hours 
4) Place a Zymo-Spin IC Column for each sample into a collection tube.  
5) Add 600 µl of M-Binding Buffer to each column. 
6) Load sample into the respective column. Mix by pipetting 10 times. 
7) Centrifuge at full speed (20,000 xg) for 30 sec. Discard flow-through. 
8) Add 100 µl of M-Wash Buffer to column. 
9) Centrifuge at full speed (20,000 xg) for 30 sec.  
10) Add 200 µl of L-Desulphonation Buffer to the column. 
11) Incubate at RT for 20 min. 
12) Centrifuge at full speed (20,000 xg) for 30 sec. 
13) Add 200 µl of M-Wash Buffer to the column. 
14) Centrifuge at full speed (20,000 xg) for 30 sec. 
15) Repeat steps 13 and 14. 
16) Place the column into a fresh 1.7 ml tube. 
17) Add 10 µl of the Elution Buffer directly onto the column filter. 
18) Incubate at RT for 1 min.  
19) Centrifuge at full speed (20,000 xg) for 30 sec. 
20) Store eluent at -20°C or -80°C for long term storage. Always log your sample details in 
the -80°C freezer log on the networked lab drive. 
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Appendix J: Digital Droplet PCR – Automated 
Droplet Generation SOP 
Reagents: 
1) Custom TaqMan Assay AH21BH1 (Applied Biosystems) 
2) ddPCR Supermix for Probes, no dUTP (Bio-Rad, 186-3024)  
3) Semi-Skirted 96-well plate (Eppendorf, 951020346) 
4) 20 U/µl EcoR1 (New-England Biolabs, R0101L) 
5) 96-well aluminium foil plate seal (Beckman-Coulter, 538619)  
6) Automated droplet generator oil (Bio-Rad, 186-4110) 
7) Automated droplet generator tips (Bio-Rad, 186-4121) 
8) Automated droplet generator cartridges (Bio-Rad, 186-4109) 
9) Pierceable foil heat seal (Bio-Rad, 1814040) 
10) Filtered pipette tips 
 
All plastic ware should be nuclease free.   Never stick your hands into containers of nuclease-
free plastic ware.  Always pour out whatever is required. 
 
Equipment 
1) Automated droplet generator 
2) Heat sealer 
3) QX200 Droplet Reader 
4) Vortex mixer 
5) Well calibrated micropipettes designated for pre- and post-PCR 
6) C1000 thermocycler with deep 96-well block  
7) Automated droplet generator cold block (stored at -20˚C) 
 
Reagent Setup 
1) Allow samples to thaw thoroughly on ice prior to commencing. 
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2) Thaw supermix on ice. 
3) Turn on the QX200 droplet reader 30 mins before use. 
 
Procedure 
1) Create the ddPCR mastermix. Below is the volume (µl) of each reagent per reaction. It 
is recommended to add 5% extra to account for pipetting error. 
a. Supermix   12.5 
b. AH21BH1 Primer/Probe  1.25 
c. Water1    8.25 
d. EcoR1     0.5 
e. Total    22.5 
2) Briefly vortex and centrifuge the mastermix. 
3) Add 22.5 µl of the mastermix to the respective wells in the Eppendorf 96-well plate. 
Ensure that the samples are configured in groups of eight (8), positioned in the columns 
of the plate. If you do not have samples in multiples of eight, place the appropriate 
number of NTC controls to fill the remaining wells. 
4) Briefly vortex and spin the samples and then add 2.5 µl1 of the bisulfite converted 
(bc)DNA to the respective well. Mix by pipetting twenty (20) times. 
5) Seal the plate with an aluminium plate seal and centrifuge at 1500 rpm for 1 min at 
room temperature. 
6) Allow the plate to sit at room temperature for 10 mins. It is important to let the 
samples come to room temperature for optimal droplet generation. 
7) Set up the automatic droplet generator. Load consumables from the back to the front 
of the machine to minimise contamination.  
a. Configure the sample plate. 
                                                     
1 If a different volume / amount of DNA is required, please adjust the water accordingly. 
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b. Insert the required droplet generation cartridges and tips (two tips per sample 
are required) within the machine. Completely remove the lid of the tip boxes.  
c. Check the tip waste. 
d. Place the cool block into the machine with an Eppendorf 96-well plate. 
8) Place the sample plate into the machine and remove the foil seal. 
9) Run the droplet generation program. The cycle will take ~45 mins for a full 96-well 
plate. Remove the droplet plate within two (2) hours. 
10) Seal the droplet plate with the pierceable heat seal (180°C, 5 secs). Make sure the red 
stripe on the seal is visible. Be careful when placing the block into the heat sealer; 
support the base to minimise damage to the rails. Remove the block after sealing. Turn 
on the heat sealer a few minutes before use to allow it to reach to 180°C. 
11) Thermocycle the sealed plate using the following cycling protocol. Ensure that the 
ramp rate is set to 2°C/sec. 
a. 95°C for 10 mins, 40 cycles (94°C for 3 mins, 57.5°C for 1 min), 98°C for 10 mins, 
12°C hold. 
12) Place the plate into the droplet reader. 
13) Input the sample details. Ensure that the experiment type is rare even detection (RED), 
the supermix is Probes (no dUTP), channel 1 (FAM) is unmethylated and channel 2 (VIC) 
is methylated.  
14) Check if all lights are solid green on the QX200. If they are flashing or yellow, either 
the waste is too full or the oil is low. Empty the waste into the liquid waste bottle, wipe 
out excess oil and store upside down to drain. Replace with the secondary waste bottle. 
Top up or replace reader oil.  
15) Press Run. Choose if you want the reader to go by columns or rows, and ensure it is set 
to FAM/VIC. 
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Appendix K: Immunofluorescent Staining of 
Paraffin Embedded Tissues SOP 
Reagents: 
1) Normal donkey serum (Thermo Fisher, 14190250) 
2) 100% ethanol (Sigma, E7023-500ml) 
3) Distilled (or MilliQ) water 
4) Tissue paper or Kimwipes 
5) Xylene (Thermo Fisher, AJA2342-5L) 
6) Primary antibody/ies  
7) Dulbecco’s phosphate buffered saline, DPBS (Gibco, 14190-250) 
8) Secondary antibody/ies 
9) Vectashield (Vector Laboratories, H-1000) 
10) Hoechst 33342 nuclear stain (10 mg/ml) 
11) Coverslips 
12) Nail polish 
 
All plastic ware should be nuclease free.   Never stick your hands into containers of nuclease-
free plastic ware.  Always pour out whatever is required. 
 
Equipment 
1) Convection oven set at 85-90°C. 
2) Coplin Jars 
3) Forceps 
4) Hydrophobic marker 
5) Moist chamber 
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Reagent Setup 
1) Fill two Coplin jars with Xylene. 
2) Fill four Coplin jars decreasing concentrations of ethanol in this order: 100%, 90%, 
70% and 50% (50 ml in distilled water). 
3) Fill one Coplin Jar with distilled water. 
4) Dilute normal donkey serum (NDS) with dPBS to 4% NDS 
5) Dilute primary antibodies to a working stock in 4% NDS. The actual dilution factor 
with depend on the antibody used [for example the Guinea Pig anti-insulin 
polyclonal (from DAKO, catalogue number-A0564(01)) insulin is usually 1:100]. 
Multiple antibodies can be combined into one stock ONLY if they were raised in 
different animals. 
6) Dilute secondary antibodies 1:100 to a working stock in 4% NDS. Ensure the 
antibodies target the animal in which the primary antibody was raised  
7) Set up moist chamber by placing moist paper towel within the chamber.  
8) Create the mounting solution by adding 10 µl of Hoechst to 1 ml of Vectashield. 
 
Procedure 
Primary Antibody 
1. Place slide at 85–90°C for 2-5 mins or until the paraffin wax becomes translucent (check 
every minute after the first 2 minutes). The tissue will still be opaque. 
2. Immediately place slide into the first xylene Coplin jar for 2-3 mins. When adding the 
slide to a Coplin jar, gently wash the slide by dipping into the liquid 3-4 times. 
3. Transfer slide to the second xylene Coplin jar for 5 mins. When transferring the slide 
between jars, gently dab the edge of the slide onto tissue paper or Kimwipes to remove 
excess liquid. 
4. Transfer the slide to 100% ethanol for 5 mins. 
5. Transfer the slide to 90% ethanol for 5 mins. 
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6. Transfer the slide to 70% ethanol for 5 mins. 
7. Transfer the slide to 50% ethanol for 5 mins. 
8. Transfer the slide to distilled water for 5 mins. 
9. Remove slide and dab off excess liquid. 
10. Using the hydrophobic marker, draw around your tissue section. Ensure that the line is 
close to your sample without touching it. 
11. Add enough 4% NDS to cover the section. 
12. Place slide into moist chamber and incubate at room temperature for 20 mins. 
13. Tilt the slide and use a pipette to remove and discard the liquid. Do not remove the slides 
from the moist chamber. 
14. Add enough of the selected primary antibody (working stock in 4% NDS) to cover the 
tissue. 
15. Seal the moist chamber with parafilm and incubate at 4°C overnight. 
Secondary Antibody 
16. Tilt the slide and use a pipette to remove and discard the primary antibody. 
17. Add DPBS and incubate at room temperature for 3-5 mins. Add as much PBS as possible 
within the confines of the hydrophobic marker. This will create a large bubble of fluid over 
the tissue section. 
18. Remove liquid. 
19. Repeat steps 17 and 18 at least 4 more times. 
20. Add enough secondary antibody (working stock diluted in 4% NDS) to cover the tissue. 
This step, and all subsequent steps, MUST be completed in the dark to ensure that the 
reporter dyes to not degrade. 
21. Seal the moist chamber with parafilm and incubate at 37°C for 1 hour. Ensure there is 
ample liquid in the tissue paper used in the moist chamber.  
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22. Remove the secondary antibody and then repeat steps 17 and 18 at least five times to 
remove any unbound secondary antibodies. 
23. Tilting the slide and place folded tissue or Kimwipe at the bottom of the sample to soak 
up the remaining PBS. It is important not to touch the tissue section or wipe the liquid. 
24. Add 20 µl of the mounting solution (Vectashield + Hoechst). 
25. Add a coverslip and seal using nail polish. Place one edge of the coverslip to the side of 
the sample, in contact with the mounting solution. Slowly lower the other edge using a 
scalpel blade (or another suitable thin, flat utensil), allowing the solution to spread along 
the coverslip. This method minimises the introduction of bubbles. 
26. Store slide(s) at RT in the dark until the slide is dry (~30 minutes). 
27. Examine slide(s) using a fluorescent microscope. 
28. Place the slide(s) at 4°C for long-term storage. 
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Appendix L: Flow Cytometry Cell Death 
Analysis SOP 
Reagents: 
1) Sterile 15 ml Falcon tubes 
2) Ethanol (70%) for disinfection 
3) Accutase (Merk Millipore) 
4) CMRL media + 10% FCS (Gibco) 
5) Dulbecco’s phosphate buffered saline (DPBS) (Gibco) 
6) P10, P20, P200 and P1000 autoclaved tips 
7) P1000 autoclaved tips with the end cut off (to transfer islets only) 
8) 10 ml serology pipette tips 
9) FACS tubes 
10) Cell strainer (70 µm) 
11) Hypotonic buffer – see step 1. 
 
Equipment 
1) Water bath set at 37°C 
2) Centrifuge with 15ml swing-bucket rotor 
3) Well calibrated micropipettes designated for cell culture 
4) Electronic serological pipette 
5) Flow-cytometer (turned on >20 mins before use) 
 
Reagent Setup 
1) Set water bath to 37°C 
a. Place PBS and CMRL + 10% FCS into the water bath for >15 mins 
2) Clean gloves, and anything else entering the biosafety cabinet, with 70% ethanol 
prior to use 
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Procedure 
1. Create the hypotonic buffer. 
Reagent Original Conc. Final Conc. Amount (for 2ml) 
Sodium Citrate 1% 0.1% 200 ul 
Triton-X 100 10% 0.1% 20 ul 
Propidium Idodide 1 mg/ml 500 ug/ml 100 ul 
Nuclease-free Water - - 1680 ul 
 
2. Transfer cells and media into a 15 ml tube. It is recommended to gently mix the cells prior to 
transfer. 
3. Centrifuge at 1500 rpm for 2 mins. 
4. Remove media. 
5. Resuspend islets in 5 ml warm DPBS. 
6. Repeat washing steps 3-4. 
7. Remove DPBS. 
8. Add 200 µl of Accutase and incubate in a 37°C water bath for 10 mins. 
9. Gently pipette to break the cells apart. 
10. Add 5 ml of CMRL + 10% FCS 
11. Centrifuge at 1500 rpm for 2 mins. 
12. Remove supernatant. 
13. Add 5 ml of CMRL + 10% FCS. 
14. Incubate for 30-60 mins at 37°C with 5% CO2. This will allow the cells to recover 
15.  Centrifuge at 1500 rpm for 2 mins. 
16. Remove media 
17. Add 250 µl of hypotonic buffer. 
  Appendices 
282 
 
18. Add to FACS tubes. If any clumps can still be seen, pass the liquid through a cell filter as it is added 
to the FACS tubes. 
19. Set up and run FACSCalibur. Read at least 10,000 events.  
 
